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Summary 
 
P-glycoprotein (P-gp) is an exceptional membrane transporter because of its 
ability to carry a large variety of compounds across the plasma membrane. Thanks to 
this substrate promiscuity, P-gp over-expression is responsible for multidrug 
resistance (MDR) in a variety of cells from microorganisms to humans. The cellular 
MDR is responsible for failure of treatment in over 90% of patients with metastatic 
cancer, as well as in yeast and bacteria infections and in life-threatening human 
parasites such as Plasmodium causing malaria. P-gp is not only expressed in 
multidrug resistant cells but also in non-resistant cells at basal levels, but its 
physiological functions in the absence of drug pressure are not well understood. So far 
P-gp was proposed to be involved in several important cellular processes ranging 
from immunological functions to membrane lipid remodelling. Given the importance 
of P-gp in human and microbial MDR, there was an important need to identify the 
substrates and transport activities of this protein and to understand its physiological 
functions as a basis for the rational design of new drugs and MDR inhibitors.  P-gp is 
localized mainly in the plasma membrane. Because the plasma membrane is the first 
barrier that intracellular pathogens need to cross to infect the host cell, we wanted to 
investigate whether P-gp plays a role in this first line host-pathogen interaction. As a 
model pathogen we used the human parasite Toxoplasma gondii, which causes 
toxoplasmosis, a potentially life-threatening disease in individuals with 
immunodeficiency. As both host cell and parasite have a P-gp localized in the plasma 
membrane, we hypothesised that both P-gps could be involved in events during 
parasite infection and replication. Our project had two goals: i) to characterize the 
physiological functions of host cell P-gp and its contribution to host-parasite 
interactions and ii) to characterize the T. gondii P-gp and its function in host-parasite 
interactions.   
To investigate the physiological functions of host cell P-gp and its contribution to 
host-parasite interactions, we compared three mouse embryonic fibroblast cell lines 
with different P-gp expression: wild type cells (WT) and P-gp knockout (P-gp KO) 
cells, as well as P-gp complemented P-gp KO (P-gp KO/P-gp) cells. We used these 
cell lines to analyse the role of host P-gp in parasite invasion, replication and 
cholesterol transport, processes that are crucial for successful T. gondii propagation 
and survival. We showed that host P-gp is essential for normal T. gondii replication 
and specifically required for cholesterol transport from host endo-lysosomes to the 
parasite. Importantly, using cholesterol auxotrophic T. gondii replication as a bio-
indicator of cholesterol homeostasis in the host cell, we found that P-gp is involved in 
host cholesterol trafficking from endo-lysosomes to the plasma membrane.  
To characterize the T. gondii P-gp and its function in host-parasite interactions, we 
pharmacologically inhibited parasite P-gp (TgP-gp) with the P-gp specific inhibitor 
GF120918 (GF) and we used P-gp KO host cells to avoid the contribution of host P-
gp to the observed phenotype. We analysed the role of parasite P-gp in invasion, 
replication and lipid metabolism. We showed that T. gondii P-gp is crucial for parasite 
Ca2+-depended attachment and invasion. Moreover, we propose that TgP-gp is 
involved in Ca2+ signalling which is important for the regulation of these processes 
and essential for T. gondii survival. Importantly, TgP-gp functionality is required for 
successful T. gondii replication and involved in the parasite lipid synthesis and 
transport. In summary, in this study we showed for the first time that both host cell 
and parasite P-gp have an important role in host-parasite interactions. 
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I was also involved in a joint project focusing on the epigenetic regulation of stage 
conversion of Giardia lamblia. G. lamblia is an intestinal pathogen which infects 
millions of people all over the world causing the disease giardiasis. G. lamblia resides 
in the upper small intestine of humans and other vertebrates which become infected 
by ingestion of cysts from contaminated water or food. Giardia is characterized by 
two different developmental stages: the motile, proliferating trophozoites responsible 
for the clinical manifestation of the disease such as diarrhoea and malabsorption, and 
the cyst forms, the infective stage of the parasite. Infectious cysts are environmentally 
resistant and protected by a rigid extracellular matrix, the cyst wall. Stage conversion 
of G. lamblia is essential for transmission and survival of this human pathogen, but 
the understanding of the molecular mechanism which regulates this fundamental 
process still remains poorly understood.  In this project we aimed to analyse the effect 
of histone deacetylase inhibitor FR235222 on gene regulation of stage conversion in 
G. lamblia. We showed for the first time that inhibition of a histone deacetylase 
activity in Giardia with FR235222 induced transcriptional changes in proliferating 
and differentiating stages and potently blocked formation of cysts. We propose that G. 
lamblia stage conversion is under the control of epigenetic regulation and dependent 
on the acetylation state of histones. In addition, histone deacetylase activity could be a 
promising target for developing new anti-Giardia drugs since the inhibition of histone 
deacetylase activity is blocking G. lamblia cyst formation and thus has potential to 
reduce disease transmission.   
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Zusammenfassung 
 
Das P-Glykoprotein (P-gp) ist ein außergewöhnlicher Membrantransporter, vor 
allem wegen seiner Eigenschaft, eine Vielzahl verschiedener Stoffe über die 
Plasmamembran befördern zu können. Aufgrund der geringen Substratpräferenz  führt 
das Überexprimieren von P-gp zu einer gesteigerten Antibiotikaresistenz in einer 
Vielzahl von Zellen sowohl in Mikroorganismen als auch beim Menschen. Diese 
zelluläre Antibiotikaresistenz, auch „multidrug resistance“ (MDR) genannt, ist 
verantwortlich für einen Misserfolg bei mehr als 90% der klinischen Behandlungen 
von Patienten mit metastatischem Krebs aber auch bei der Behandlung von 
pathogenen Pilzen oder Bakterien und lebensbedrohlichen menschlichen Parasiten 
wie dem Malariaerreger Plasmodium.  Da P-gp nicht nur in Antibiotika-resistenten, 
sondern auch in nicht-resistenten Zellen exprimiert wird, ist es von großem Interesse 
die allgemeine physiologische Funktion dieses Proteins zu verstehen. Nach dem 
heutigen Wissensstand wird vermutet, dass P-gp in mehreren wichtigen zellulären 
Prozessen involviert ist und sowohl immunologische Funktionen übernimmt als auch 
bei der Modellierung von Membranlipiden mitwirkt. Aufgrund der Bedeutung von P-
gp bei der mikrobiellen und humanen MDR ist es von großer Wichtigkeit, die 
Substratspezifität, Transportaktivität und physiologische Funktion des Proteins zu 
verstehen – letztlich, um bei der Entwicklung von neuen Antibiotka- oder MDR-
Inhibitoren zu helfen. P-gp ist vor allem in der Plasmamembran lokalisiert. Da die 
Plasmamembran für pathogene Organismen die erste Barriere darstellt, die für die 
Infektion der Wirtszelle überwunden werden muss, untersuchten wir zunächst, ob P-
gp eine Funktion bei der Interaktion zwischen Wirt und Pathogen übernimmt. Dabei 
diente der den Menschen infizierende Parasit Toxoplasma gondii, der in 
immunsupprimierten Individuen eine lebensbedrohliche Toxoplasmose hervorrufen 
kann, als Modellorganismus. Unser Projekt besaß zwei Zielsetzungen: i) die 
Erforschung der physiologischen Funktion von Wirtszellen P-gp und dessen Beitrag 
zur Wirt-Parasit-Interaktion und ii) die Charakterisierung von T. gondii P-gp und 
dessen Aufgabe bei der Wirt-Parasit-Interaktion.  
Zur Bestimmung der physiologischen Funktion von Wirtszellen P-gp und dessen 
Interaktion mit dem Parasiten verglichen wir drei Zelllinien mit verschiedener P-gp 
Expression: embryonale Mausfibroblasten vom Wildtyp (WT), P-gp „knockout“ (P-
gp KO) und P-gp komplementierten (P-gp KO/P-gp) Zellen. Wir untersuchten die 
Rolle von P-gp bei der Parasiteninvasion, der Replikation und des 
Cholesteroltransports, entscheidende Prozesse für die erfolgreiche Prolongation und 
das Bestehen von T. gondii. Wir konnten zeigen, dass P-gp essentiell für die reguläre 
Replikation in T. gondii ist, da das Protein für den Cholesterintransport vom 
Endolysosomen des Wirtes in T. gondii gebraucht wird. Bei der Analyse einer 
Cholesterol-auxotrophen Replikation in T. gondii, ein Bioindikator für die 
Cholesterol-Homeostase in der Wirtszelle, zeigten wir insbesondere, dass P-gp 
eingebunden ist in den Cholesteroltransport des Wirtes vom Endolysosomen zur 
Plasmamembran.  
Zur Charakterisierung des T. gondii P-gp und dessen Funktion bei der Wirt-
Parasit-Interaktion inhibierten wir pharmakologisch das P-gp des Parasiten (TgPgp) 
mit dem P-gp spezifischen Inhibitor GF120918 (GF). Dabei nutzen wir P-gp KO 
Wirtszellen, um einen Einfluss vom P-gp des Wirtes auf den Phänotyp 
auszuschließen. Wir analysierten die Funktion von P-gp bei der Invasion, der 
Replikation und beim Lipidmetabolismus des Parasiten. Es gelang aufzuzeigen, dass 
das Vorhandensein von P-gp in T. gondii ausschlaggebend für die Ca2+-abhängige 
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Anheftung sowie die Invasion des Parasiten ist. Des Weiteren vermuten wir, dass 
TgPgp involviert ist in eine Ca2+-abhängige Signalkaskade, die wichtige Prozesse für 
das Überleben von T. gondii steuert. Interessanterweise ist die Funktionalität von 
TgPgp erforderlich für die Replikation von T. gondii und beeinflusst zudem die 
Lipidsynthese und den Transport des Parasiten.  
Zusammenfassend konnten wir in dieser Arbeit zum ersten Mal zeigen, dass 
sowohl das P-gp der Wirtszelle als auch das P-gp des Parasiten einen wesentlichen 
Einfluss auf die Wirt-Parasit-Interaktion ausübt.  
Der Schwerpunkt des zweiten Teils meiner Arbeit beinhaltete Untersuchungen zur 
epigenetischen Regulation der Entwicklungsstadien von Giardia lamblia. G. lamblia 
ist ein Darmparasit, der in tausenden von Menschen weltweit das Krankheitsbild der 
Giardiasis hervorruft. G. lamblia besiedelt den oberen Dünndarm im Menschen und 
anderen Vertebraten, die im Allgemeinen durch die Aufnahme von kontaminiertem 
Trinkwasser oder verunreinigter Nahrung mit Zysten infiziert werden. Giardia 
durchläuft zwei charakteristische Entwicklungsstadien: eine Lebensphase mit 
beweglichen, begeißelten Trophozoiten, welche für die Proliferation und die klinische 
Manifestation der Krankheit, wie einer Diarrhoe oder Malabsorption, entscheidend 
sind. Die Zysten, die infektiösen Stadien des Parasiten, bestehen aus den 
Trophozoiten, welche umgeben sind von einer rigiden, schützenden Zystenwand, die 
das Überleben und die Übertragung des Parasiten auf neue Empfänger bei externen 
Umweltbedingungen sichert. Die Umwandlung in verschiedene Entwicklungsstadien 
ist essentiell für die Übertragung und das Überleben dieses menschlichen Pathogens, 
dennoch wirft der molekulare Mechanismus, der diesen fundamentalen Prozess regelt, 
bis heute viele Fragen auf.  In diesem Projekt untersuchten wir den Einfluss des 
Histon-Deacetylase-Inhibitors FR235222 auf die Genregulation der 
Stadienumwandlung im extrazellulären G. lamblia-Parasiten. Zum ersten Mal konnten 
wir zeigen, dass die die Inhibition der Histon-Deacetylase mit FR235222 
transkriptionelle Veränderungen in beiden Entwicklungsstadien von G. lamblia 
induzierte und interessanterweise auch die Zystenbildung blockierte. Wir vermuten, 
dass die Stadienumwandlung in G. lamblia unter Kontrolle der epigenetischen 
Regulation und der Histon-Acetylierung steht. Hinzukommend scheint die Aktivität 
der Histon-Deacetylase ein hoffnungsvoller Ansatz für die Entwicklung neuer Anti-
Gardia-Wirkstoffe, da die Inhibierung der Histon-Deacetylase-Aktivität die 
Zystenbildung in G. lamblia blockiert und daher Potential besitzt, die Übertragung der 
Krankheit zu reduzieren.    
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1 P-glycoprotein (P-gp, ABCB1, MDR) 
 
1.1 Localization and function 
 
P-glycoprotein is an ATP-driven efflux pump which is a member of one of the largest families 
of proteins found in both prokaryotes and eukaryotes, so called ATP-Binding Cassette (ABC) 
transporters. ABC transporters use energy from ATP hydrolysis to transport a wide range of 
substrates across membranes of organisms from bacteria to humans (6). P-gp is one of the most 
extensively studied ABC transporters because of its central role in the development of multidrug 
resistance (MDR) in cancers and pathogenic microorganisms. 
P-gp is predominantly localized in the plasma membrane of cells with barrier function, 
including epithelia of the liver, kidney, small and large intestine and capillary endothelial cells in 
brain, ovary and testis. Moreover, P-gp was found to be partially localized in intracellular 
compartments such as the Golgi apparatus (8,9), early endosomes and lysosomes (10).  
P-gp is known to bind and to transport a large variety of hydrophobic and cationic organic 
compounds across the plasma membrane. P-gp substrates include many of the commonly used 
anticancer drugs and other pharmaceuticals ranging from antiarrhythmics and antihistamines to 
cholesterol-lowering statins (11) and HIV protease inhibitors (12). Moreover, P-gp also transports 
hydrophobic peptides (13), cytokines (14) and some lipids, such as steroid metabolites and 
phospholipids (15,16). The complete understanding of P-pg transport mechanism is important for 
the rational design of anticancer drugs and MDR inhibitors. 
 
1.2 Structure 
 
P-gp consists of 2 nucleotide-binding domains (NBD) and 12 transmembrane domains (TM 1-
12) which form an inner channel in the plasma membrane (Figure 1A). Importantly, the structural 
composition of transmembrane helices results in the formation of substrate-binding internal cavity 
which is opened to the cytoplasm and the inner leaflet of the plasma membrane lipid bilayer (7). 
The P-gp substrates incorporate from outside of the cell into the plasma membrane inner leaflet and 
enter the internal substrate-binding pocket through an open cavity. Binding of the substrate is 
subsequently followed by activation of one of the ATP-binding domains, and the hydrolysis of ATP 
causes a large conformational change of P-gp, which results in the release of the substrate into the 
outer leaflet and the extracellular space (17). Hydrolysis of a second molecule of ATP is needed to 
restore the transporter to its original state so that it can repeat the cycle of substrate binding and 
release (18,19) (Figure 1B). The NBD are located on the cytoplasmic face of the protein and are 
characterized by Walker A and Walker B motifs, also found in many other nucleotide-binding 
proteins, and by a signature C motif unique to the ABC superfamily. The internal substrate-binding 
cavity contains 73 solvent-accessible residues, 15 are polar and only two are charged or potentially 
charged (7). The volume of the internal cavity within the lipid bilayer is extensive and could 
accommodate at least two transported compounds simultaneously (20). This detailed description of 
protein structure has helped to understand P-gp substrate promiscuity.   
 
 
  
 
 
 
 
 
 
 
 
NBD1NBD2
TM 1-12
PM
substrate
ATP ATP
P-gp
substrate-binding 
pocket
BINDING RELEASE
Figure 1: A) P-gp structure (4) B) Model of P-gp ATP-driven efflux (7) 
A B
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1.3 P-glycoprotein and multidrug resistance 
 
Ordinarily, drug resistance is specific to a single class of compounds. Cancer cells as well as 
microorganisms may also exhibit a cross-resistant phenotype against several unrelated drugs. This 
phenomenon has been termed multidrug resistance (MDR) and it is the major reason for failure of 
chemotherapeutical and pharmacological treatment. The principal mechanism of MDR is the active 
transport of drugs out of the cell which is responsible for failure of treatment in over 90% of 
patients with metastatic cancer (21). The P-gp efflux pump plays an important role in the multidrug 
export and this transporter is highly over-expressed in drug resistant tumour cells (22,23). The over-
expression of P-gp is also responsible for drug resistance in the pathogenic yeast and bacteria and in 
the important human parasites Plasmodium,  Leishmania and Trypanosoma (24).  
P-gp is intensively studied in the human parasite Plasmodium faciparum. This parasite causes 
malaria and is responsible for over one million deaths each year also because traditional 
antimalarial drugs have recently become ineffective in many parts of the world due to the 
development of drug resistance. The P. falciparum P-gp homologue PfABCB1 (Pgh1, PfMDR1) is 
constitutively expressed and its over-expression and/or mutations have been implicated in decreased 
susceptibility to several antimalarial drugs (25,26).  
Given the importance of P-gp in human and microbial MDR, it became urgent to identify the 
substrates and transport activities of this protein and its physiological function for the rational 
design of new drugs and MDR inhibitors. 
 
1.4 P-glycoprotein inhibition  
 
P-gp inhibition as a way of reversing MDR has been extensively studied for more than two decades. 
Many drugs have been investigated which modulate P-gp transport including calcium channel 
blocker such as verapamil, immunosuppressant such as cyclosporine A and the antisteroid 
tamoxifen (27). These compounds were not specifically developed to block P-gp, however, have 
low affinity for P-gp. Because many of them are substrates for other transporters and enzymes, their 
off-label use as MDR inhibitors entails a significant potential for side effects (28). To overcome the 
limitations of these first-generation inhibitors, several novel analogues of these P-gp modulators 
were developed with the aim of finding P-gp modulators with less toxicity and greater potency (29). 
These second-generation P-gp modulators include dexverapamil, valspodar (PSC 833) and biricodar 
(VX-710). They have an improved pharmacological profile, but they also retain some 
characteristics that limit their clinical usefulness. They also function as inhibitors for other 
transporters, particularly those of the ABC transporter family, whose inhibition reduces the ability 
of normal cells and tissues to protect themselves against cytotoxic agents (29). Recently, a new 
generation of inhibitors has reached clinical testing. These third-generation inhibitors are nontoxic, 
more specific, and more potent than the earlier inhibitors used in trials of P-gp modulation. These 
compounds include tariquidar, R101933, LY335979 and GF120918 which we used in our study. 
These modulators inhibit the ATPase activity of P-gp (30).  
 
1.5 Physiological function of P-glycoprotein 
 
It is well-established that P-gp mediates efflux of chemotherapeutic agents out of cancer cells 
and thereby its over-expression contributes to drug resistance. However, P-gp is also expressed at 
basal levels in non-malignant cells. The physiological function and the substrates of this protein in 
normal cells remain poorly characterized, however, there have been several attempts to define the 
physiological function of P-gp and so far a number of different roles have been proposed for P-gp:  
  
1.5.1 Cellular detoxification 
P-gp is present in a range of classical pharmacological barriers and excretory tissues like 
liver, intestine, kidney and blood-tissue barriers. Since the tissue distribution of a protein can yield 
II Introduction 
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important clues to its function, it was hypothesised that this protein might be involved in protecting 
the organism against naturally occurring xenotoxins.  
The analyses of the knockout mice lacking P-gp support the proposed role of P-gp in the 
protection against xenotoxins exposure. P-gp knockout mice do not show reduced viability, nor 
haematological parameters compared with the wild type in the absence of drug pressure (31). 
Importantly, in the presence of drug pressure the lack of P-gp significantly increased the uptake of 
these toxic compounds from the gastrointestinal tract and made the blood-brain barrier and other 
blood-tissue barriers strongly susceptible to the exposure of toxins that have entered the 
bloodstream compared with the wild type mice (31).  
 
1.5.2 Immunological functions 
P-gp was shown to be present in several sub-classes of bone marrow, peripheral leukocytes 
and also in human hematopoietic stem cells, which are precursors of all the blood cell types (32). 
This observation raised the hypothesis that P-gp might be involved in the hematopoietic 
development or function.   
It has been shown that inhibition of P-gp efflux function using either specific monoclonal 
antibodies or pharmacological inhibitors reduced cytolytic activity of natural killer cells and CD8+ 
T-cells, possibly by mediating the release of the cytolytic protein perforin (33,34). Moreover, 
blocking P-gp inhibited the migration of antigen-presenting dendritic cells and T-cells during an 
immune response (35). P-gp is capable to transport peptides (13), thus it was proposed that this 
protein transports the polypeptide cytokine interleukin 2 and possibly other cytokines required for 
the migration of dendritic cells and T-cells (14,36).  
 
1.5.3 Ion transport activity 
P-gp is structurally similar to cAMP-activated chloride channels such as cystic fibrosis 
transmembrane conductance regulator (CFTR) (37). Thus it was speculated that P-gp might also 
function as an ion channel. It was shown that P-gp does not have basic ion channel activity but it 
can regulate a thus far unidentified endogenous chloride channel and like this it indirectly 
modulates channel activity (38,39). Recently, it was suggested that P-gp mediates H+- Na+- Cl- 
symport as was shown using P-gp analogue LmrA from bacterium Lactococcus lactis (40). This 
protein can functionally substitute for P-gp function in human lung fibroblasts, and exhibits a 
substrate specificity similar to that of the human protein (41). 
 
1.5.4 Lipid transport and intracellular cholesterol trafficking 
 
Several ABC transporters act as flippases which transport lipids from the inner to the outer 
leaflet of plasma membrane (Figure 2) (42). Lipids are the main structural component of biological 
membranes and the key factors in variety of cellular processes including signalling. Therefore there 
has been a strong interest to define the role of ABC proteins in the lipid transport. One of the ABC 
transporters involved in lipid transport is ABCB4 which functions as a phosphatidylcholine (PC)-
specific transporter (43). Given that P-gp is closely related to this PC-transporter (78% sequence 
similarity), it has been proposed that P-gp plays a role in the lipid transport by acting as a lipid 
flippase.  
In support to this hypothesis, P-gp has been reported to act as a flippase for short-chain 
fluorescent analogs of plasma membrane lipids of very different structure such as PC, 
phosphatidylethanolamine (PE) (16), glucosylceramide (GlcCer) and sphingomyelin (SM) from the 
inner to the outer leaflet of the plasma membrane (15). In addition, it was shown that 
pharmacological inhibition of P-gp could limit SM movement from the inner to the outer leaflet of 
the plasma membrane, leading to an increase of hydrolysable SM pool (hydrolysis: SM→Ceramide) 
(44). The role of P-gp in lipid flipping has been also suggested in connection with cholesterol 
transport from the inner to the outer leaflet of plasma membrane using native membrane vesicles 
model (45). Moreover, some studies using second-generation of P-gp inhibitors have demonstrated 
that P-gp can modulate esterification of plasma membrane cholesterol (46,47). This observation was 
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confirmed in P-gp deficient mice where the lack of P-gp decreased hepatic accumulation and 
enhanced esterification of cholesterol (48). Recently, P-gp have been proposed to have a role in the 
secretion of lipid-based signalling molecules: platelet-activating factors (PAFs) from the inner to 
the outer membrane leaflet, from which they may diffuse into the extracellular environment (49). So 
far PAFs are the only natural lipids that have been shown to be transported by P-gp. Thus, the main 
question, whether natural unlabelled membrane lipids with two long acyl chains are transported by 
P-gp acting as plasma membrane lipid flippase, still remains open.  
 
 
 
 
 
 
 
 
 
 
 
1.6 P-gp in host-pathogen interaction 
 
The interactions between a pathogen and its host are complex and dynamic. The outcome of 
such interactions is a manifestation of the pathogen capability to exploit its host and the ability of 
the host to respond to the infection. This outcome may range from disease to asymptomatic 
transmission or even pathogen elimination. The understanding of the mechanisms of such 
interactions is essential for the targeted development of effective prevention and control strategies. 
P-gp seems to be involved in several important metabolic processes including membrane lipid 
remodelling and transport of signalling molecules. It is localized in the plasma membrane of a 
number of human cells types and since the plasma membrane is the first barrier that an intracellular 
pathogen has to cross for entry into the host cell, it is conceivable that P-gp plays role in host-
pathogen interaction.  
P-gp was proposed to be involved in essential biological processes of the medically relevant 
human parasite Toxoplasma gondii (50). It was shown that fundamental processes of this parasite 
such as intracellular replication and host cell invasion could be inhibited by second-generation P-gp 
modulators (50). These investigations have pointed out for the first time a possible role of P-gp in 
host-parasite interaction, and raised the major question about the physiological role of P-gp in the 
biology of T. gondii.  
 
2 Toxolpasma gondii 
 
Toxoplasma belongs to the phylum Apicomplexa, which consists of protozoan parasites that 
have a characteristically polarized cell structure and a complex cytoskeletal and organellar 
arrangement at their apical end (51) (Figure 3A). Other members of this phylum are the human and 
animal pathogens Plasmodium and Cryptosporidium, Neospora and Sarcocystis. T. gondii is an 
obligate intracellular parasite, which infects a broad range of vertebrate hosts, including humans. T. 
gondii causes toxoplasmosis, a potentially life-threatening disease in immunocompomised 
individuals such as AIDS patients and organ transplant recipients, and in congenitally infected 
foetuses. Currently existing chemotherapeutic regimens, while effective at controlling the 
proliferating parasite, cause severe side effects during the treatment and therefore there is a need for 
developing new improved drugs against toxoplasmosis.   
Importantly, T. gondii is the most experimentally tractable of the Apicomplexa because of its 
feasible genetic and cell culture manipulations allowing easy in vitro propagation of the parasite 
ATP
IN
OUT
ADP
+Pi
P-gp
lipid
PM
Figure 2: Model of P-gp acting as lipid flippase; PM-plasma membrane 
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pathogenic stages and well-established mouse model. Thus, T. gondii has emerged as a major model 
for the study of apicomplexan biology (52), intracellular parasitism and host-parasite interactions.  
 
2.1 Life cycle   
 
The life cycle of T. gondii has two phases: a sexual and an asexual (Figure 3B). The sexual part 
of the life cycle takes place exclusively in members of the Felidae family, the definitive T. gondii 
host. The production of gametes and fertilized zygotes occur within feline intestinal enterocytes, 
giving rise to diploid oocysts, which undergo meiosis (53). Excreted oocysts undergo sporulation 
and can survive in soil for several months. The asexual part of the life cycle can take place in any 
warm-blooded animal like mammals and birds, the intermediate T. gondii host. Interestingly, T. 
gondii are less infective and less pathogenic in the definitive host compared with intermediate hosts 
(54).  
Our study focuses on asexual life cycle. Asexual life cycle is composed of three stages: the 
rapidly replicating tachyzoites, the slowly replicating bradyzoites contained in tissue cysts, and the 
sporozoites formed in oocysts during the sexual phase of the cycle. The two major ways of human 
infection with the parasite are by ingestion of tissue cysts in under-cooked meat or by ingestion of 
food or water contaminated with oocysts. After ingestion, both bradyzoites from tissue cysts and 
sporozoites from oocysts infect the intestinal epithelium and convert to tachyzoites, observed during 
the acute stage of infection. Tachyzoites invade a variety of cell types, where they rapidly multiply. 
Tachyzoite replication eventually leads to lysis of host cells and release of parasites, which then 
start a new cycle of the infection by invading a new host cell. In the chronic stage of toxoplasmosis, 
tachyzoites convert to the slowly replicating bradyzoites, which form cysts in several tissues, 
including the brain. Since bradyzoite cysts are not detected by the host immune system, they persist 
in the tissues for the life span of the host (54). 
 
 
 
 
 
  
 
 
 
 
 
 
 
2.2 Lytic cycle 
 
 
 
 
 
2.2 Lytic cycle 
 
The lytic cycle of toxoplasmosis starts with invasion of the host cell. The tachyzoite first 
attaches via its apical pole to the host cell (55,56), and by using contractile proteins, including actin 
and myosin, the parasite penetrates the host cell (57,58). This active process of parasite invasion 
leads to the formation of a specialized parasitophorous vacuole (PV). The PV is derived from the 
host cell membrane and modified by the parasite to avoid fusion with host cell lysosomes (59). The 
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PV segregation from the host vesicular traffic provides the parasite with a unique niche where 
parasites successfully replicate and then egress to infect neighbouring cells (60) (Figure 4).  
 T. gondii has a number of secretory organelles that include the apical micronemes, rhoptries and 
dense granules (Figure 3A). Each compartment contains its own pool of proteins whose function is 
consistent with the timing of their release during the lytic cycle (61): micronemes release their 
contents (adhesins) early during 
the attachment-invasion process 
to initiate apical attachment and 
penetration of the host cell. 
Rhoptry proteins are released as 
invasion proceeds to assists in the 
formation of the developing PV 
and its interaction with host 
organelles. Finally dense granules 
discharge their contents when 
invasion is essentially completed 
to prepare the PV for intracellular 
replication and for survival of the 
parasite. T. gondii has been 
extensively studied and crucial 
factors involved in invasion, PV 
formation and replication have 
been identified, but relatively few 
have been thoroughly 
characterised yet.  
   
2.2.1 Motility and Invasion   
 
T. gondii motility and cell invasion are essential elements of the infection process ensuring 
the propagation and survival of the parasite, and therefore they are an important focus of research 
investigations. It is expected that a detailed understanding of these processes will help with the 
identification of novel therapeutic targets.   
To gain the entry into a host cell, the parasite must first make a direct contact with the plasma 
membrane of the host cell. Subsequently, T. gondii uses a substrate-dependent locomotion termed 
gliding motility for tissue migration and cell invasion (2,62). The gliding motility relies on a 
complicated linear motor system sandwiched between the parasite’s plasma membrane and the 
inner membrane complex (IMC) of the parasite (Figure 3A). Motive force is generated by the 
myosin that is anchored to the inner membrane complex by two gliding-associated proteins (GAP) 
(63), and short actin microfilaments. The actin microfilaments associate with the enzyme aldolase 
(64), which links the complex to the transmembrane adhesive proteins (microneme proteins) that 
bridge over the parasite’s plasma membrane (Figure 5A). The secretion of transmembrane adhesion 
proteins from the apical end, and a unidirectional orientation of the actin microfilaments support 
forward motion with the apical pole leading the way.   
The actino-myosin motor that drives the motility is intracellular, thus at least one transmembrane 
bridge is required for the parasite to link it to an extracellular host cell ligand for locomotion. 
Consistent with the model for motility T. gondii invasion is highly polarized, with the parasite 
exclusively using its apical end and conoid extrusion (56) to initiate penetration into the target cell. 
Figure 4: T. gondii tachyzoite lytic cycle (1); 1) Attachment of tachyzoite to its host cell, 2) The tachyzoite 
reorientates to its apical end and initiates invasion, 3) The newly formed parasitophorous vacuole (PV) recruits 
host mitochondria and ER, 4) The tachyzoite undergoes several rounds of replication 5) which results in host cell 
lysis and parasite exit. 
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Several adhesins are released from apical secretory organelles called micronemes to allow parasite 
attachment to the host cell. For example, microneme proteins MIC1 contains two adhesive 
sequences related to a domain of thrombospondin (involved in blood colagulation), and it is capable 
of binding host cells in vitro (65). Similarly, MIC2 includes several thrombospondin-like repeat 
sequences and an integrin- like adhesive domain  (66) and recently it was demonstrated that this 
microneme protein is responsible for the parasite host cell binding activity later forming a tight 
connection between the parasite and host plasma membrane: MIC2-host receptor conjugates known 
as the moving junction (61,67) (Figure 5A, B).  
The process of invasion involves two Ca2+-dependent events: extrusion of the apical conoid and 
the induction of secretion of MIC proteins from the micronemes. It has been shown that addition of 
calcium ionophores, such as ionomycin and A23187 activated both conoid extrusion and 
microneme secretion (68-70).Conversely, loading of T. gondii tachyzoites with the intracellular 
Ca2+-chelator BAPTA-AM prevented calcium ionophore-induced conoid extrusion, MIC secretion 
and inhibited invasion (68-70). Furthermore, the gliding motility of T. gondii is also activated by 
elevated cytosolic Ca2+ levels (68). The largest store of Ca2+ in apicomplexan protozoa is found in 
the acidocalcisomes (71), acidic organelles which are present in a diverse range of microorganisms, 
but absent in mammalian cells (72,73). These studies revealed the importance of the intracellular 
Ca2+ in the process of parasite–host cell interaction, but the stimulus for these Ca2+ changes remains 
unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2 Vacuole formation and parasite replication  
  
The vacuole formed by the parasite after invasion is atypical because it does not acidify (74) and 
does not fuse with any vesicles of the endocytic pathway including lysosome (75,76). To prevent 
parasitophorous vacuole (PV) acidification and endocytic processing, the PV must either exclude or 
rapidly eliminate surface proteins which guarantee vesicular fusion. Such displacement of host 
membrane proteins from PV membrane was demonstrated for Na+/K+ ATPase, β1-integrin and 
CD44 and was proposed to be accomplished by the moving junction (77), however the complete 
mechanism of this sorting remains undefined. 
After the PV is formed, a third set of secretory organelles, called dense granules, release their 
contents from both the anterior and posterior poles of the parasite (61). Dense granule proteins are 
A
Figure 5: A) T. gondii gliding motility sandwich (modified from (2)). Plasma membrane (PM), gliding-associated 
proteins (GAP), microneme protein (MIC2), inner membrane complex (IMC);  B) T. gondii model of invasion 
(modified from (2)).  
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responsible for the construction of the tubulovesicular network that extends from the T. gondii cell 
surface into the lumen of the PV (78) (Figure 6A). The PV recruits host mitochondria and 
endoplasmic reticulum (ER) immediately following invasion (79). These organelles form a close 
interaction with the PV membrane and they are suggested to provide lipids for the PV (80) which 
could be transported to intra-vacuolar parasites through a tubulovesicular network established 
within the PV (79).   
Following entry, T. gondii rapidly divides by a special manner termed endodyogeny, where two 
daughter cells are formed within a mother cell. Once the resources of the host cell cytoplasm are 
exhausted, the parasites actively exit the dying cell to find another host. This lytic cycle involved 
tissue damage and one round of invasion and lysis typically takes 24–48 h and results in production 
of 16 to 128 tachyzoites that originate from a single invaded parasite. 
The investigation of T. gondii-infected cells demonstrated that the PV imports Ca2+ from the 
host cytoplasm and after 48 h of intracellular replication, a significant decrease in the level of host 
cytosolic Ca2+ was observed compared to that in uninfected cells. This could suggest that the 
increase of [Ca2+]i in the PV may act as a signal that triggers the egress of the parasite (81). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3 Parasite egress 
 
As with the process of invasion, intracellular parasites have evolved a mechanism for egress 
and transmission to neighbouring cells. The T. gondii egress is a rapid process and results in the 
lyses of the host cell and release of motile parasites (Figure 6B). The mechanism of this event 
remains poorly understood. 
During natural egress T. gondii mechanically ruptures the host cell with escalating tension on 
the host cell membrane due to increased parasite burden (82,83). However the exact mechanism by 
which the parasites rupture the membrane is not completely understood. Recently, it was shown that 
micronemal perforin-like protein 1 facilitates parasite egress by compromising the integrity of the 
PV (84). Determination of factors required during natural egress is difficult to asses because of the 
fact that natural egress is highly variable in the timing and it is asynchronous between parasites in 
different host cells (82). Conversely, the egress induced by the artificial host cell permeabilization 
or by Ca2+ ionophore such as A23187 (85) allows easy manipulation of the timing and 
synchronization (85-87). Consequently, induced egress has become an important model for the 
study how the egress may occur under natural conditions (88).  
Similar to invasion, T. gondii egress from host cells is affected by Ca2+ flux. The Ca2+ 
ionophore-stimulated egress can occur even when extraparasitic (vacuolar and host cell) Ca2+ has 
been removed with Ca2+chelators (85-87), indicating that the parasite uses its own Ca2+ stores. 
tubular 
network 
Figure 6: A) T. gondii intracellular parasitophorus vacuole (PV) (modified from (3)); B) Calcium ionophore induced 
egress (5).  
Intracellular PV T.gondii egress
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These observations suggest that activation of motility and induction of calcium fluxes are sufficient 
to cause egress in the intracellular parasites. Consistent with this concept, chelation of [Ca2+]i in 
intracellular parasites using BAPTA-AM severely inhibited natural egress (86). 
 
2.3 Exploitation of the host cell 
 
T. gondii resides and replicates inside a nonfusogenic PV during the entire intracellular cycle. 
Such a safe niche guarantees resistance to host cell defences but significantly limits the access of 
parasites to host metabolites. The intracellular parasite adopted the strategy to remodel the PV 
membrane (PVM) to make it accessible to nutrients. The newly formed PVM of T. gondii is 
immediately modified and contains the pore that allows free diffusion of small molecules such as 
simple sugars, amino acids, nucleobases and cofactors (89). The pore allows the passage of small 
molecules into the PV in the absence of transporters, while their subsequent uptake by the parasite 
is mediated via substrate-specific transporters or endocytosis. This molecular filter plays a critical 
role in the context of the multiple parasite auxotrophies.  
T. gondii depends on host-derived glucose for energy and as a carbon source for fatty acid 
biosynthesis (90), and it is auxotrophic for amino acids such as arginine (91) and tryptophan (92). T. 
gondii salvages purines and pyrimidines (93,94) despite its ability to synthesize pyrimidines de 
novo (95). Because T. gondii lacks the mitochondrial genes required for de novo synthesis of lipoic 
acid, a cofactor for many biosynthetic pathways, the host mitochondria are likely the source of this 
compound for the parasite (96).  
Importantly, the segregation of the PV from host cell vesicular transport pathways limits also 
the possibility of the acquisition of exogenous lipids whose trafficking is restricted to those 
pathways. The acquisition of essential lipids is fundamental for membrane biogenesis to support 
successful parasite replication. T. gondii has the autonomous capacity to synthesize phospholipids, 
but it also readily scavenges precursors from its environment for the construction of more complex 
lipids (97,98). Conversely, T. gondii lacks enzymes to synthesize steryl molecules and needs to 
acquire these lipids intact from the host cell (99). A recent study has proposed a novel mechanism 
established by the parasite to acquire low density lipoprotein (LDL)-derived cholesterol from the 
host cell. It was suggested that T. gondii sequesters host lysosomes to the PV lumen by recruiting 
host microtubules and forming H.O.S.T (host organelle sequestering tubulo-structures) (Figure 6A) 
(100). However, the exact molecular mechanism of cholesterol delivery to the parasite is still 
unknown. Since cholesterol is required for parasite membrane biogenesis and cholesterol import is 
necessary for T. gondii replication (99), it is essential to define the mechanism of cholesterol 
transport from the host to the PV. The elucidation of the cholesterol import mechanism would 
improve our understanding of host-parasite interaction and could lead to the identification of new 
drug targets in T. gondii. 
 
2.4 T. gondii P-gp 
 
Recently, it was demonstrated that efflux of xenobiotics could be modulated in extracellular T. 
gondii using the first generation of P-gp inhibitors: verapamil and cyclosporine A, thus providing 
indirect evidence for the existence of T. gondii P-gp homologue (101). Subsequently, it was shown 
that T. gondii contains two P-gp homologues termed TgABCB1 (TgP-gp) and TgABCB2, which 
share about 50% amino acid identity and sequence similarity with the P. falciparum PfABCB1 and 
human HuABCB4, respectively. TgP-gp is constitutively expressed in the three major T. gondii 
genotypes and the intracellular localization analysis revealed a plasma membrane-association of this 
protein. The highest TgP-gp expression was demonstrated in the most virulent T. gondii RH strain, 
at both the transcriptional and translational levels (102,103). The role of T. gondii P-gp homologue 
in parasite biological processes remains unsolved.  
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Figure 7: Histone acetylation. histone 
acetylase (HAT), histone deacetylase 
(HDAC) inhibited by FR235222. 
3 The aim of the project 
 
It has been already well established that P-gp over-expression is responsible for multidrug 
resistance in a variety of cells, but the physiological functions of P-gp in absence of drug pressure 
are still not completely understood, neither in human cells nor in parasitic protozoa. The aim of our 
project was to characterize the role of P-gp in host-pathogen interaction using T. gondii as a model 
parasite. Specifically, our aims were:  
1) To define the precise role of host P-gp in the host cells and in biological processes of the 
parasite. To perform this study we used mouse embryonic fibroblasts (MEF) lacking P-gp (mouse 
double knockout in mdr1a and mdr1b genes; DKO; P-gp KO) as model system but also P-gp 
complemented P-gp knockout MEF (DKO/P-gp) and the wild type MEF (WT) as well.  
2) To characterize the P-gp homologue in T. gondii and its function. To study T. gondii P-gp, 
we used specific pharmacological inhibition of the parasite protein by third-generation P-gp 
modulators: GF120918 in a host cell background of DKO cells to study the function of the parasite 
protein in isolation to avoid contribution of host cell P-gp to the final effect.  
 
4 Additional project: Regulation of the parasite stage conversion 
 
During infection in mammals, intracellular T. gondii undergoes stage conversion between the 
rapidly replicating tachyzoites that are responsible for acute toxoplasmosis and the dormant non-
replicating bradyzoites that cause the chronic infection (Figure 3B). The bradyzoites survive within 
a cyst limited by a cyst-wall in several tissues such as brain and muscle during the lifetime of the 
host. Stage conversion is an important step for parasite 
transmission because bradyzoites within tissue cysts act as 
a source of infection for transmission via carnivorism. 
Moreover, in immunocompromised individuals, the 
majority of cases of fatal toxoplasmosis is the result of 
reactivation of encysted bradyzoites into actively 
replicating tachyzoites (104).   
Recently, it has been proposed that histone 
modifications, particularly acetylation, could be the key 
epigenetic regulators of parasite stage conversion. Histone 
acetylation regulates DNA packaging, and therefore 
influences gene expression (Figure 7). Histone 
hyperacetylation is usually linked with chromatin 
decondensation, because it neutralizes the basic charge of 
target lysine residues on histones (105). It was shown, 
using histone deacetylase inhibitor FR235222, that a histone deacetylase (HDAC3) plays a role in 
expression of stage-specific genes, stage conversion, and cell-cycle control of T. gondii. Moreover, 
FR235222 strongly inhibits T. gondii and Plasmodium replication (106).  
In the project that I contributed to, we analysed the effect of histone deacetylase inhibitor 
FR235222 on the epigenetic regulation of the stage conversion in extracellular parasite Giardia 
lamblia.  
G. lamblia (also called G. intestinalis or G. duodenalis), is a simple eukaryote causing the 
disease giardiasis.  G. lamblia resides in the upper small intestine of humans and several other 
vertebrates usually infected by ingestion of cysts from contaminated water or food (107). The 
parasite is non-invasive, and neither toxins nor virulence factors have been clearly defined (107). 
Giardia is characterized by two different developmental stages: the motile, flagellate trophozoites 
that are responsible for the proliferation and the clinical manifestation of the disease such as 
diarrhoea and malabsorption, and the cyst forms which are shed into the environment (Figure 8). 
The cysts are the infective stage of the parasite, in which trophozoites are surrounded by a rigid, 
protective cyst wall that allows the parasite to survive in the environment and permits transmission 
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silent non 
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of the infection to susceptible hosts (108). The stage 
conversion process of G. lamblia is essential for 
transmission and survival of this human pathogen, but 
the understanding of the molecular mechanism which 
regulates this fundamental process still remains poorly 
understood. Importantly for our study, the inhibitor 
FR235222 gave us the tool to investigate for the first 
time the role of histone deacetylase in the epigenetic 
regulation of the stage conversion of G. lamblia.  
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P-glycoprotein (P-gp) is amembrane-bound efflux pump that
actively exports a wide range of compounds from the cell and is
associated with the phenomenon of multidrug resistance. How-
ever, the role of P-gp in normal physiological processes remains
elusive. Using P-gp-deficient fibroblasts, we showed that P-gp
was critical for the replication of the intracellular parasite Tox-
oplasma gondii but was not involved in invasion of host cells by
theparasite. Importantly,we found that theproteinparticipated
in the transport of host-derived cholesterol to the intracellular
parasite. T. gondii replication in P-gp-deficient host cells not
only resulted in reduced cholesterol content in the parasite but
also altered its sphingolipid metabolism. In addition, we found
that different levels of P-gp expressionmodified the cholesterol
metabolism in uninfected fibroblasts. Collectively our findings
reveal a key and previously undocumented role of P-gp in host-
parasite interaction and suggest a physiological role for P-gp in
cholesterol trafficking in mammalian cells.
P-glycoprotein (P-gp, ABCB1, MDR1)2 is one of the most
intensively studiedmembers of the ABC transporter superfam-
ily. With remarkably broad substrate recognition, P-gp drives
the ATP-dependent efflux of toxic metabolites and xenobiotics
from the cell (1) and is thus a central mediator of drug bioavail-
ability. Importantly, P-gp overexpression following drug treat-
ment is responsible for themultidrug resistance (MDR) pheno-
type, a major reason for chemotherapy failure not only in
cancer cells (2) but also in pathogenic microorganisms (3, 4).
Aside from its well known role in drug efflux, P-gp is also
expressed at basal levels in many different tissues, yet the nor-
mal physiological functions of the protein remain poorly
understood.
The possibility that physiological levels of host P-gp play a
role in host-pathogen interaction, other than mediating drug
resistance, has not been investigated so far. We addressed this
question using Toxoplasma gondii as a model pathogenic par-
asite. T. gondii is the causative agent of toxoplasmosis, a poten-
tially fatal disease not only for immunocompromised patients
and fetuses but according to recent insights also emerging as a
life threatening infection in immunocompetent individuals (5).
T. gondii infects virtually all nucleated host cells and resides in a
highly specialized vacuole, called the parasitophorous vacuole
(PV), which is formed by invaginating the host cell membrane
at the time of invasion. The PV is not competent for lysosome
fusion, thus avoiding acidification (6), but it is closely associated
with host organelles, including lysosomes, mitochondria, and
endoplasmic reticulum (reviewed in Ref. 7). Even though the
PV does not intersect directly with host vesicular traffic,T. gon-
dii remains dependent on host cells for a number of critical
nutrients. Significant progress has beenmade in our understand-
ingof themechanismsT. gondiiuses to scavengenutrients fromits
host, especially in the case of lipidmolecules. An important recent
examplewas the identificationofH.O.S.T. (host organelle-seques-
tering tubulo-structures), a unique system of tubular structures
formed by the parasite to sequester cholesterol-containing endo-
lysosomes from the host cytoplasm into the PV (8). However, the
molecular mechanisms of the traffic from the host cell to the PV
are not completely elucidated, and the existence of transporters
has been proposed frequently.
To analyze whether the P-gp transporter plays a role in T.
gondii biology we compared parasite replication in wild type
(WT) mouse embryonic fibroblasts with double knock-out
(DKO) fibroblasts in which neither of the two murine P-gp
isoforms are expressed (9). In parallel, we also analyzed DKO
cells complemented with the human P-gp homologue (DKO/
P-gp) (10), which restored P-gp functionality to DKO cells and
allowed P-gp expression levels higher than those found in WT
cells (supplemental Fig. S1). In this way, our model did not
depend on either drug-selected P-gp-overexpressing cells,
whichmay acquire adaptationmechanisms different fromP-gp
overexpression during the development of the MDR pheno-
type, or P-gp inhibitors, several of which are known to have side
effects on host metabolism.
EXPERIMENTAL PROCEDURES
Biochemical Reagents—Unless otherwise stated, all chemi-
cals were purchased from Sigma, cell culture reagents were
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from Invitrogen, and radiolabeled lipids were from Amersham
Biosciences. Anti-P-gp monoclonal antibody C219 was pur-
chased from Alexis Biochemicals; anti-Lamp1 1D4B antibody
was obtained through the Developmental Studies Hybridoma
Bank (University of Iowa, Iowa City, IA); anti-giantin and anti-
tubulin were a kind gift from J. Rohrer and M. A. Hakimi,
respectively. Conjugated secondary antibodies were from
Invitrogen. Reconstituted high density lipoproteins and apoli-
poprotein A-I (apoA-I) were a kind gift from P. Lerch (CSL
Behring, Bern, Switzerland). NDB-cholesterol was fromAvanti
Polar Lipids.
Mammalian Cell and Parasite Culture—Mouse embryonic
fibroblasts double knocked out for P-gp (77.1, Mdr1a//
Mdr1b/) (9), triple knocked out for P-gp and MRP1 (3.8,
Mdr1a//Mdr1b//Mrp1/) (11) and parental cells were
kindly provided by A. Schinkel (The Netherlands Cancer Insti-
tute, Amsterdam, The Netherlands). Mdr1 transfected 77.1
(10) and G185 NIH 3T3 fibroblasts (12) were a generous gift
from M. M. Gottesman (National Cancer Institute, National
Institutes of Health, Bethesda, MD).
The cells were routinely cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum, 2 mM
glutamine, 50 units of penicillin/ml, and 50 g of streptomy-
cin/ml at 37 °C with 5% CO2. Mdr1 transfected 77.1 and G185
cells were maintained in 20 and 60 ng/ml colchicine, respec-
tively. Colchicine was removed from the culture medium dur-
ing parasite infection.
-Galactosidase expressing T. gondii andNeospora caninum
were a kind gift from J. Boothroyd and D. Sibley, respectively.
The parasites were maintained by serial passages in mouse
embryonic fibroblasts, harvested from infected host cells by
passage through a 26-gauge needle, and purified by separation
on Sephadex-G25 columns (Amersham Biosciences) as
described (13). Purified parasites were counted in a hemocy-
tometer chamber and used for a new cycle of host cell invasion
at the multiplicity of infection of 1. Parasite burden was quan-
tified after 24 h by direct parasite counting or after 48 or 72 h by
colorimetric detection of parasite-galactosidase using chloro-
phenol red--D-galactopyranoside as substrate, as described
(14). In some experiments, parasite quantification in infected
host cells was performed by flow cytometry analysis on a FACS-
Calibur flow cytometer (Becton Dickinson), after staining per-
meabilized cells with a rabbit polyclonal anti-T. gondii
tachyzoite antiserum (15) at 1:2000 dilution, followed by fluo-
rescein-conjugated anti-rabbit secondary antibody at 1:300
dilution. Parasite invasionwas determined by dual color immu-
nostaining with the described anti-T. gondii antiserum to dif-
ferentiate intracellular and extracellular parasites, as described
(16).
Lipid Analyses—For cholesterol transport to intracellular T.
gondii, infected host cells were labeled with 0.5 Ci/ml
[3H]cholesterol for 5 h. After extensive washing with PBS and
0.05% fat-free bovine serum albumin in PBS, parasites were
isolated as previously described and counted, and the associ-
ated radioactivity was measured by liquid scintillation. Back-
ground radioactivity resulting from host cell debris was deter-
mined using similarly processed uninfected host cells and
subtracted from parasite samples.
For cholesterol uptake analysis, host cells were incubated
with 0.5Ci/ml [3H]cholesterol for 5 h and extensively washed,
and cell-associated radioactivity was measured by liquid scin-
tillation. Steady state cholesterol mass was assessed using the
Amplex Red kit (Invitrogen) or by lipid extraction according to
Bligh and Dyer (17) and high performance thin layer chroma-
tography separation of aliquots corresponding to equal protein
content on Silica Gel 60 plates in benzene/2-propanol/water
(100:10:0.25). The bandswere visualizedwith 10%CuSO4 in 8%
aqueous phosphoric acid and quantified by densitometry.
Liquid chromatography-mass spectrometry analysis of lipids
from T. gondii grown in WT or DKO host cells was performed
as described (18) in aWatersAquityUPLC systemconnected to
a Waters LCT Premier orthogonal accelerated time of flight
mass spectrometer (Waters, Millford, MA), operated in posi-
tive electrospray ionization mode.
For analysis of sphingolipid synthesis in T. gondii, purified
parasiteswere labeledwith 0.5Ci/ml [3H]palmitic acid for 3 h,
lipids were extracted as before and aliquots corresponding to
equal protein content were separated by high performance thin
layer chromatography using chloroform/methanol/25%
NH4OH (65:25:4.5). Radiolabeled bands were visualized by use
of a tritium-sensitive screen (PerkinElmer Life Sciences) in a
Personal Molecular PhosphoImager FX (Bio-Rad), identified
according to co-migrating standards visualized by iodine
vapors and quantified using ImageQuant software (Amersham
Biosciences).
For kinetic of cholesterol esterification, host cells were
labeled with 0.5 Ci/ml [3H]cholesterol for 5, 24, and 48 h, and
lipids were extracted as before and separated by high perform-
ance thin layer chromatography using benzene/2-propanol/
water (100:10:0.25) as a solvent system. After iodine vapor visu-
alization, bands co-migrating with cholesterol and cholesteryl
ester standards were cut out of the plates, and the associated
radioactivity was measured by liquid scintillation. The data for
cholesterol esterification are reported as a percentage of
[3H]cholesteryl esters from total cellular [3H]cholesterol.
For cholesterol extraction with methyl--cyclodextrin (CD)
and efflux to reconstituted high density lipoproteins (HDL) or
apoA-I, the cells were labeled with 0.5 Ci/ml [3H]cholesterol
for 24 h, extensively washed, and incubated with 2 mM CD, 20
g/ml reconstituted HDL, or 10 g/ml apoA-I in medium
without fetal calf serum. Medium aliquots were measured by
liquid scintillation at the time points indicated in the figures.
Residual cell radioactivitywasmeasured after cell solubilization
in 0.1 NNaOH. Total radioactivity was calculated asmedium
cell-associated radioactivity. Background efflux to medium
alone was measured at the same time points and subtracted
from the values obtained with the cholesterol acceptors CD,
reconstituted HDL, and apoA-I.
Cholesterol Visualization and Immunofluorescence Analysis—
To visualize intracellular transport of fluorescent cholesterol,
host cells were seeded on glass slides and infectedwithT. gondii
for 24 h. The cells were incubated with 5 M NBD-cholesterol
inDulbecco’smodified Eagle’smediumwithout fetal calf serum
for 1 h at 37 °C, fixed in 3% formaldehyde, mounted in Vectash-
ield antifade agent (Vector Laboratories, Inc., Burlingame, CA),
and imaged employing an excitation filter of 450–500 nm.
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For visualization of unesterified cholesterol, the cells were
seeded as before, fixed, and incubatedwith 0.05mg/ml filipin in
PBS, 10% fetal calf serum for 1 h at room temperature. The
images were collected using an excitation filter of 350–410 nm.
For visualization of esterified cholesterol in intracellular lipid
droplets, the cells were fixed with 3% formaldehyde, blocked,
and stainedwithNile red at a concentration of 0.5g/ml in PBS
for 20 min. The cells were extensively washed in PBS and
mounted, and lipid fluorescence was analyzed employing an
excitation filter of 450–500 nm.
For P-gp localization, DKO/Pgp host cells grown on glass
slides were infected with T. gondii for 24 h, prior to fixation in
acetone at20 °C for 10 min. Anti-P-gp monoclonal antibody
C219 was used at 1:10 dilution according to the manufacturer’s
instruction, followed by fluorescein-conjugated secondary
antibody at 1: 200 dilution. T. gondii was stained with a rabbit
polyclonal anti-T. gondii tachyzoite antiserum (15) at 1:2000
dilution, followed byTexas Red-conjugated anti-rabbit second-
ary antibody at 1:300 dilution. The nuclei were visualized with
4,6-diamidino-2-phenylindole.
For endo-lysosome localization, host cells grown on glass
slides were infected with T. gondii or N. caninum for 24 h,
incubated with 6g/ml fluorescein-conjugated cholera toxin B
subunit for 60 min at 37 °C, and analyzed after fixation. For
lysosome and Golgi localization, cells were seeded as before,
fixed, and stained with anti-Lamp1 (1:50) or anti-giantin
(1:750) antibodies followed by fluorescein-conjugated second-
ary antibody.
Microscopy analyses were performed on a Leica DM IRBE
fluorescence microscope or on a Leica SP2 AOBS confocal
laser-scanningmicroscope (LeicaMicrosystems,Wetzlar, Ger-
many), using the appropriate settings. Image stacks of optical
sections were further processed using the Huygens deconvolu-
tion software package version 2.7 (Scientific Volume Imaging,
Hilversum, NL).
Transmission Electron Microscopy Analysis—Host cells
grown on sapphire disks were infected with T. gondii and incu-
bated at 37 °C for 24 h, prior to fixation with 0.25% glutaralde-
hyde and freezing in a high pressure freezing machine (HPM
010, BAL-TEC) as described by Monaghan et al. (19). Frozen
cells were transferred into a freeze substitution unit (FS 7500,
Boeckeler Instruments, Tucson, AZ) precooled to 88 °C for
substitution with acetone and subsequent fixation with 0.25%
glutaraldehyde and 0.5% osmium tetraoxide at temperatures
between 30 °C and 2 °C as described in detail (20) and
embedded in Epon. 50–60-nm-thick sections were stained
with uranyl-acetate and lead-citrate and analyzed in a transmis-
sion electron microscope (CM12; Philips, Eindhoven, The
Netherlands) equipped with a CCD camera (Ultrascan 1000;
Gatan, Pleasanton, CA) at an acceleration voltage of 100 kV.
Cell Viability Following Cholesterol Loading—Host cells
were loaded with cyclodextrin-cholesterol complexes (Sigma)
for 24 h at the concentrations indicated in the figure legend,
washed in medium, and incubated at 37 °C for additional 24 h.
Cell viability was tested by using the AlamarBlue assay (BIO-
SOURCE, Camarillo, CA), according to the manufacturer’s
instructions.
P-glycoprotein Functional Assay—P-gp activity was assessed
by cellular retention of the P-gp substrate rhodamine 123
(Rho). Briefly, the cells were incubated with 0.5 g/ml Rho in
PBS for 30 min at 37 °C, washed in PBS, and incubated in
medium at 37 °C for the time points indicated in the figure
legend. The kinetic of rhodamine retention was quantified by
flow cytometry.
Western Blot Analysis—Cell lysates for immunoblots were
prepared by sonicating cells at 107/ml in 50 mM Tris-HCl (pH
6.8), 10% glycerol, 2% SDS, 5 mM dithiothreitol, 0.5 mM phen-
ylmethylsulfonyl fluoride, and complete protease inhibitor
mixture (Calbiochem). Samples corresponding to 40 g pro-
teins weremixedwith SDS-PAGE loading buffer and incubated
10 min at room temperature to prevent P-gp aggregation. The
samples were separated on 7.5% SDS-PAGE gels, transferred to
nitrocellulose membranes, and probed using anti-P-gp C219
(1:50) and anti-tubulin (1:2000)monoclonal antibodies. Immu-
noreactive bands were visualized with horseradish peroxidase-
conjugated secondary antibodies and ECL.
Determination of Protein Concentration—Protein content
was determined using the Bio-Rad Protein Assay according to
the instructions provided by the manufacturer. Bovine serum
albumin was used for the standard curve.
Statistical Analyses—The data are expressed as the means
S.E. One-way analysis of variance was performed (GraphPad
Prism 4.0c; GraphPad Software, Inc.), and a probability value
0.05 was considered statistically significant. When the overall
probability value was  0.05, the Dunnett multiple-compari-
sons testwas used as a post-test to determinewhether therewas
a significant difference between values of control (reference
sample) and samples of interest.
RESULTS
Host Cell P-gp Is Essential for Normal Parasite Replication—
To determine whether the activity of host P-gp plays a role in
parasite replication, host cells expressing different levels of the
protein (supplemental Fig. S1) were infected with T. gondii
expressing -galactosidase, which allows parasite quantifica-
tion by colorimetric reaction (21). Direct parasite count at 24 h
post-infection (p.i.) revealed the presence of smaller vacuoles
containing fewer parasites in P-gp-deficient host cells (Fig. 1A).
Importantly, complementation of P-gp-deficient cells with the
human P-gp homologue fully restored parasite replication.
Analysis of parasite burden by visualization of parasite vacuoles
at 48 h p.i. (Fig. 1B) and colorimetric reaction at 48 and 72 h p.i.
(Fig. 1C) confirmed that T. gondii replication was strongly
inhibited in the absence of host P-gp. In addition, P-gp-com-
plemented host cells generated a higher T. gondii burden than
that found in WT cells. To further confirm that P-gp activity
confers a replication advantage for the parasite, we used WT
3T3 fibroblasts transfected to overexpress P-gp as host cells
(12). Parasite quantificationwas performed either at the level of
single host cells using flow cytometry or as parasite burden of
thewhole host cellmonolayer by colorimetric reaction (supple-
mental Fig. S2). Both analyses indicated a positive correlation
between P-gp expression levels and parasite replication.
Absence of the multidrug transporter MRP1, in addition to the
two P-gp isoforms (triple KO cells) (11), did not further
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decrease parasite replication (data not shown). Collectively,
these data unambiguously show that the presence of an active
P-gp in the host is directly involved in a process controlling T.
gondii replication.
Host Cell P-gp Is Not Involved in Parasite Invasion—The
reduction in parasite number seen in P-gp-deficient cells could
have resulted from either decreased parasite replication or
decreased invasion efficiency. To assess whether the absence of
P-gp on the host plasma membrane compromises the ability of
T. gondii to enter host cells, an invasion assay was performed
using parasites harvested from WT host cells and allowed to
infect cells expressing different levels of P-gp. The number of
intracellular parasites was comparable in all tested cell lines at
2 h post-infection (Fig. 1D), indicating that host P-gp is not
required for parasite invasion and that the reduced parasite
burden observed in DKO cells is not due to a defect in host cell
entry.
Host Cell P-gp Deficiency Inhibits Cholesterol Transport to T.
gondii—The reduced parasite replication observed in P-gp-de-
ficient host cells led us to hypothesize that the absence of P-gp
may disturb the supply of lipid components necessary for
assembly of new parasite membranes. To test this hypothesis,
we evaluated cholesterol trafficking andmetabolism in the par-
asite, because T. gondii is auxotrophic for cholesterol and
depends solely on the host for its supply (22). When we tested
the transport of exogenous radiola-
beled cholesterol to the parasite, we
found that in the absence of host
P-gp, cholesterol delivery was
strongly reduced (Fig. 2A). Impor-
tantly, P-gp DKO cells showed nor-
mal uptake of exogenous choles-
terol (supplemental Fig. S3),
indicating that the reduced choles-
terol transport to the parasite is not
caused by a compromised uptake of
this lipid by the host cells. In addi-
tion, the increased T. gondii replica-
tion in P-gp-complemented host
cells coincided with enhanced cho-
lesterol delivery to the parasites,
suggesting that the level of choles-
terol transport was regulating para-
site replication rate.
In addition, we monitored the
cholesterol transport in vivo by
using the fluorescently labeled ana-
logue NBD-cholesterol (Fig. 2B).
Similar to the observations during
the radiolabeled cholesterol incuba-
tion, transport of NBD-cholesterol
to parasites grown in DKO cells was
reduced compared with WT cells
and a pattern of punctuated struc-
tures, reminiscent of endocytic ves-
icles, accumulated around the para-
site vacuoles. Conversely, parasites
infecting P-gp-complemented cells
showed high level of fluorescence, indicating a robust traffick-
ing of cholesterol to the vacuole.
To test whether decreased cholesterol availability in the
absence of host P-gpwas directly responsible for the reducedT.
gondii replication, we evaluated the parasite burden in DKO
cells loaded with exogenous cholesterol following infection.
This treatment improved parasite replication in a dose-
dependent manner (Fig. 2C), confirming that insufficient cho-
lesterol availability was indeed the limiting factor for parasite
replication.
To investigate the mechanism of P-gp involvement in the
cholesterol trafficking to T. gondii, we inhibited the vesicular
transport of host cholesterol from lysosomes to both plasma
membrane and endoplasmic reticulum with the class 2 amphi-
phile U-18666A (23). Treatment with U-18666A has been
shown to decrease the cholesterol delivery to intracellular par-
asites (22). This broad inhibition of cholesterol trafficking
severely affected T. gondii replication in WT host cells, with
higher levels of inhibition than the ones observed in P-gp defec-
tive cells (Fig. 2D). On the other hand, parasite replication in
DKO cells was further inhibited by only 10% upon U-18666A
treatment. The absence of a significant cumulative effect
between the lack of P-gp and inhibitor treatment indicates that
P-gpmay operate, directly or indirectly, on a similar pathway of
cholesterol trafficking that is essential for parasite replication.
FIGURE 1. Host cell P-gp modulates parasite replication. A, WT, P-gp-deficient (DKO) and P-gp-comple-
mented (DKO/P-gp) host cells were infected with T. gondii at multiplicity of infection 1. After 24 h p.i., intracel-
lular parasites were quantified by direct counting. The distribution of the parasite number in single vacuoles is
expressed as percentage of total vacuoles examined (n 30). B, immunofluorescence analysis of intracellular
vacuoles containing parasites at 48 h p.i. using anti-T. gondii serum, followed by fluorescein-conjugated sec-
ondary antibodies.C, quantificationof parasite burden at 48 and72hp.i. by a colorimetric assaymeasuring the
amount of parasite-expressed-galactosidase. The results are expressed as percentages of parasite number in
WT host cells S.E. (n 6). *, p 0.05; **, p 0.01. D, host cell monolayers were incubated with T. gondii at a
multiplicity of infection of 1. After 2 h of incubation, 20 fields of infected cells were examined, and the number
of intracellular invaded parasites was determined as described under “Experimental Procedures.” The data are
expressed as percentages of total parasite number S.E. (n 20).
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P-gp Associates with the Parasite Vacuole—Our previous
results suggest that P-gp may be involved in the cholesterol
trafficking to the parasite via the endocytic pathway. To inves-
tigate this possibility, we localized host P-gp in infected cells.
P-gp is mainly present in the plasmamembrane of the cells, but
a minority also localizes in intracellular compartments, includ-
ing endo-lysosomes (24, 25). Because endo-lysosomes have
been shown to be recruited to the PV in T. gondii infected cells
(8), we reasoned that P-gp also associates with the parasite vac-
uole. To test this hypothesis, we infected P-gp-complemented
host cells, whose level of P-gp expression allows analysis by
immunofluorescence using the P-gp specific monoclonal anti-
body C219 (supplemental Fig. S1). This analysis showed that
P-gpwas predominantly present on the host plasmamembrane
as expected. In addition, P-gp was also found closely associated
with the PV (Fig. 3, A and B).
HostOrganelles Are Recruited to the PV in theAbsence ofHost
P-gp—T. gondii scavenges cholesterol from host endo-lysoso-
mal compartments (22), and these organelles are actively
recruited by the parasite to the PV in a time-dependentmanner
after infection (8). To test whether the decreased cholesterol
delivery to the parasite in P-gp-deficient cells was due to a fail-
ure in recruiting the cholesterol rich endo-lysosomes, we
probed the localization of these
organelles in infected cells (Fig. 3C).
First we analyzed the labeling of
endocytic vesicles using cholera
toxin B-subunit, which binds to the
raft-associated sphingolipid GM1
and enters the cell by retrograde
transport in the secretory pathway
(26). Cholera toxin-positive struc-
tures were equally found around the
PV of parasites infectingWT, DKO,
and P-gp-complemented host cells.
Moreover, Lamp1 (lysosome-asso-
ciated membrane protein 1) stain-
ing further confirmed that lyso-
somes are recruited to the PV in
DKO cells. Finally, host Golgi,
which was previously shown to
redistribute at the PV (8), was also
found close to the PV surface in all
tested cell lines. Collectively, our
results show that the absence of host
P-gp does not inhibit the parasite-
mediated recruitment of host
organelles to the PV.
Cholesterol Accumulates outside
the PV in the Absence of Host P-gp—
Despite the normal recruitment of
lysosomes around the PV in DKO
host cells, the accumulation of
NBD-cholesterol observed in this
cell type (Fig. 2B) prompted us to
analyze whether the intracellular
distribution of endogenous choles-
terol is altered in absence of host
P-gp. Staining of unesterified cholesterol with the poliene anti-
biotic filipin (27) in infectedWT cells showed labeling of para-
sitemembranes and perinuclear vesicular structures, previously
reported to be endo-lysosomal compartments (Fig. 4A). On the
contrary, inDKOcells the filipin-positivevesicular structureswere
bigger and more intensely labeled and accumulated outside the
PV. Importantly, P-gp complementation prevented the choles-
terol accumulation, indicating that thecholesterol accumulation is
P-gp-dependent.
Inhibition of Cholesterol Transport to the Parasite Vacuole
Does Not Depend on H.O.S.T. Formation—Next we assessed
whether the defective transport of cholesterol to the parasite
resulted from a faulty formation of the H.O.S.T. system, a
recently described structure that can supply the parasite with
cholesterol contained in host endo-lysosomes (8). Analysis by
electron microscopy found normal recruitment of host
organelles to the PV, including mitochondria, both in WT and
DKO host cells (Fig. 4B, arrowheads). Importantly, parasites
grown in DKO host cells were able to form H.O.S.T. structures
with clearly visible tubules and vesicles (Fig. 4B, arrows and
magnified images). Thus, host P-gp is not required for the for-
mation of structurally normal parasite vacuoles. In this respect,
the observed inhibition of cholesterol transport despite the for-
FIGURE2.Host cell P-gpdeficiency inhibits cholesterol transport toT. gondii.A, T. gondii-infectedhost cells
were labeled for 5 h with 0.5 Ci/ml [3H]cholesterol. The parasites were isolated, and [3H]cholesterol incorpo-
ration was measured by liquid scintillation. The data are expressed as percentages of cholesterol in parasites
(dpm/106 parasites) isolated from WT host cells  S.E. (n  6). B, host cell monolayers were infected with T.
gondii for 24 h followed by incubation with NBD-cholesterol and observed by fluorescence microscopy. The
asterisks indicate parasite vacuoles. C, after T. gondii invasion, DKO host cells were loaded with the indicated
concentrations of cyclodextrin-cholesterol complexes, and parasite replication was monitored at 48 h p.i. as
described in the legend to Fig. 1. The data are averages S.E. (n 3). D, after T. gondii infection, WT and DKO
host cells were treated with the class 2 amphiphile U-18666A at the indicated concentrations, and parasite
replicationwas quantified at 48 hp.i. The results are expressed as percentages of parasite number in untreated
(Cntl) WT cells. The data are averages S.E. (n 6).
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mation of H.O.S.T. suggests that either P-gp acts at a later stage
than the development of these structures, or it affects a
H.O.S.T.-independent mechanism of cholesterol delivery. To
test the latter hypothesis, we analyzed the replication ofN. cani-
num, an apicomplexan parasite related toT. gondiiwhose intra-
cellular vacuoles recruit host endo-lysosomes (supplemental
Fig. S4) but are devoid of H.O.S.T (8). As with T. gondii, N.
caninum replication was inhibited in absence of host P-gp and
could be rescued by P-gp complementation (Fig. 4C). In addi-
tion, N. caninum growth in DKO host cells resulted in
decreased free cholesterol content and cholesteryl ester storage
in lipid droplets (Fig. 4D), suggesting that P-gp-mediated cho-
lesterol supply to the parasite operates via a mechanism inde-
pendent of the H.O.S.T. system found in the PV.
Host Cell P-gp Deficiency Affects T. gondii Sphingolipid
Metabolism—Our previous results showed that cholesterol
transport to the parasite is defective in P-gp-deficient host cells.
We then investigated whether this impaired transport affected
the lipid content of the parasite. Lipid analyses of T. gondii
maintained in DKO host cells revealed that the steady state of
cholesterol content was comparable with WT after one lysis
passage (23  1.6 g/mg protein) but decreased after pro-
longed growth in these cells (four lysis passages) (Fig. 5A). Sim-
ilar to the observations in N. caninum, a marked decrease in
cholesteryl esters stored in lipid droplets was observed in par-
asites isolated from DKO cells (supplemental Fig. S5).
Because cholesterol is an important regulator of membrane
fluidity, membrane domains and signaling processes (reviewed
in Ref. 28), we investigated whether the reduced cholesterol
content observed in T. gondii grown in DKO host cells affected
the lipid profile of the parasite membranes. Unexpectedly, liq-
uid chromatography-mass spectrometry analysis of parasite
sphingolipids revealed a considerably higher amount of cera-
mide, ceramide phosphatidylethanolamine, sphingomyelin,
and lactosylceramide, whereas the levels of glucosylceramide
did not change (Fig. 5B). Given the crucial role of ceramide in
cell physiology both as a precursor of complex sphingolipids
and as a second messenger regulating a variety of cellular pro-
cesses (reviewed in Ref. 29), we analyzed whether neosynthesis
of this lipid was up-regulated in T. gondii grown in DKO host
cells. Metabolic labeling of extracellular parasites revealed that
ceramide synthesis was higher in T. gondii isolated from DKO
host cells after four lysis passages than in WT cells (Fig. 5C),
supporting the hypothesis that the higher ceramide levels
observed are indeed an active response of the parasite. These
results suggest that reduced cholesterol availability triggers
compensatorymechanisms inT. gondii, presumably to adapt to
the intracellular environment of DKO cells and/or to adjust the
lipid composition of its membranes.
Absence of P-gp Alters Normal Cholesterol Metabolism in
Uninfected Fibroblasts—The observed inhibition of choles-
terol transport to the parasite and the accumulation of cho-
lesterol-loaded organelles around the PV in P-gp-deficient
host cells prompted us to analyze whether P-gp is also
involved in cholesterol trafficking in uninfected host cells.
To test this hypothesis, we investigated whether P-gp
expression levels correlated with alterations in cholesterol
metabolism in fibroblasts. Analysis of intracellular choles-
terol distribution visualized with filipin revealed that P-gp
DKO cells accumulated cholesterol in perinuclear vesicles
compared with WT and P-gp-complemented cells (Fig. 6A).
In addition, despite comparable uptake of radiolabeled cho-
lesterol (supplemental Fig. S3), DKO cells showed a time-de-
pendent increase in cholesterol esterification compared with
WT cells (Fig. 6B). On the other hand, P-gp complementa-
tion of DKO cells lowered the levels of cholesterol esterifi-
cation. This correlation between the absence of P-gp and
increased cholesterol esterification was evident not only in
the kinetics of the process, but also in the steady state cho-
lesteryl ester content (supplemental Fig. S6). Next we evalu-
ated cholesterol levels in the plasma membrane by extrac-
tion with CD or efflux to the extracellular acceptors
FIGURE 3. Host P-gp associates with the parasite vacuole. A, confocal
microscopy of P-gp localization in P-gp-complemented (DKO/Pgp) cells
infected for 24 hwith T. gondii. Nuclear DNAwas stainedwith 4,6-diamidino-
2-phenylindole (DAPI). PV, parasitophorous vacuole.DIC, differential interfer-
ence contrast image. B, confocal microscopy of infected cells as described for
A, showing P-gp (green) and parasite (red) staining. C, fluorescence micros-
copy of infected WT, P-gp-deficient (DKO) and P-gp-complemented (DKO/P-
gp) host cells showing that T. gondii PV associated with labeled host endo-
lysosomes (cholera toxin (CTX)), lysosomes (Lamp1), and Golgi (giantin). The
asterisks indicate parasite vacuoles.
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reconstituted HDL (30) and
apoA-I. We found that less choles-
terol couldbeextractedwithCDfrom
the plasma membrane of DKO cells
and that P-gp complementation
increased the level of cholesterol
extraction (Fig. 6C). Furthermore,
P-gp complementation also en-
hanced the ABCA1-mediated efflux
of cholesterol to its natural acceptor
HDL (Fig. 6D) and apoA-I (Fig. 6E).
These data reveal that cells defi-
cient in P-gp accumulated free and
esterified cholesterol in perinu-
clear vesicular structures and
cytosolic lipid droplets, respec-
tively. On the other hand, cells
expressing high levels of P-gp
showed increased amounts of cho-
lesterol in the plasma membrane,
which then resulted in increased
efflux to extracellular acceptors.
To further test whether WT cells
were more prone to accumulate
free cholesterol in the plasma
membrane than DKO cells, we
exploited the toxicity induced by
destabilizing the plasma mem-
brane via exogenous cholesterol
loading. Analysis of cell viability
showed that DKO cells were min-
imally affected by exogenous cho-
lesterol loading, whereas viability
decreased with increasing levels of
P-gp expression in WT and P-gp-
complemented cells (Fig. 6F). As
previously reported in cholester-
ol-loaded macrophages (31),
blocking cholesterol transport
from lysosomes to the plasma
membrane using the hydrophobic
amine U-18666A (23) prevented
the cholesterol toxicity in P-gp-
expressing cells but did not alter
the viability of DKO cells (data not
shown). Thus, these data suggest
that inhibition of intracellular
cholesterol transport mimics the
increased survival of DKO cells
during cholesterol loading.
DISCUSSION
P-gp is a unique transporter
because of its broad substrate spec-
ificity, and its expression constitutes
a major obstacle in the fight against
multidrug-resistant tumor cells and
pathogens. Yet P-gp also plays a key
P-glycoprotein and Host-Parasite Interaction
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role in normal physiological processes, including preventing
cellular toxicity at the blood brain barrier, as shown in vivo by
the extremely high sensitivity of P-gp KO mice to toxic com-
pounds (32).
Our aim was to investigate whether host P-gp plays a role in
host-pathogen interaction that is distinct from multidrug
resistance. Previous studies using P-gp inhibitors suggested
that T. gondii may require a functional P-gp to survive in the
host cell (33). In the present work more detailed investigation
found that host P-gp is in fact a crucial modulator of T. gondii
and N. caninum replication. In addition, we found that host
P-gp is not a receptor for the parasite, and its absence does not
affect parasite invasion or the formation of structurally normal
parasite vacuoles. Importantly, we found that transport of cho-
lesterol from the host cell to the parasites, a process onwhichT.
gondii is completely dependent, was impaired in absence of
FIGURE 4. Cholesterol accumulates outside the parasite vacuole in absence of host P-gp. A, WT, P-gp-deficient (DKO), and P-gp-complemented (DKO/P-
gp) host cell monolayers were infected with T. gondii for 24 h. After fixation, the intracellular distribution of unesterified cholesterol was visualized with filipin
andobservedby fluorescencemicroscopy. Thearrows indicate parasite vacuoles.B, electronmicroscopyof T. gondii infectedWTandP-gp-deficient (DKO) host
cells at 24hp.i., showingPV-associatedmitochondria (arrowheads) andH.O.S.T. structures (arrows).Right panels,magnificationofH.O.S.T. structures. Scale bars,
2 m. C, host cells monolayers were infected with N. caninum and parasite replication quantified at 72 h p.i., as described. The results are expressed as
percentages of parasite number in WT host cells  S.E. (n  3). D, lipids were extracted from N. caninum isolated from WT or DKO host cells after four lysis
passages. A representative TLC of lipids corresponding to equal protein amount is shown. Free cholesterol (FC) and cholesteryl esters (CE) were visualizedwith
CuSO4. Inset, Nile red staining of cholesteryl esters-containing lipid droplets in parasites isolated fromWT or DKO host cells after four lysis passages.
FIGURE 5. Host cell P-gp deficiency affects T. gondii lipid metabolism. A, quantification of free cholesterol (FC) and cholesteryl esters (CE) by enzymatic
reaction (Amplex red) inT. gondii isolated fromWTorDKOhost cells after four lysis passages. Thedata areexpressedaspercentagesof lipid content in T. gondii
fromWTcells S.E. (n5).B, liquid chromatography-mass spectrometry analysis of sphingolipids of T. gondii isolated fromWTorDKOhost cells after four lysis
passages. The data are averages S.E. (n 3) of a representative from two experiments done in triplicate. Cer, ceramide; GlcCer, glucosylceramide; LacCer,
lactosylceramide; CerPE, ceramide phosphoethanolamine. The predominantly detected C16 species are plotted. SM, sphingomyelin. C, left panel, TLC separa-
tion of de novo synthesized lipids labeled with [3H]palmitic acid in T. gondii isolated from WT (1) or DKO (2) cells. Right panel, newly synthesized ceramide is
expressed as a percentage of ceramide in T. gondii isolated fromWT host cells. The data are averages S.E. (n 3).
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host P-gp. Biochemical analyses revealed that the lipid compo-
sition of the parasite was altered when grown in P-gp-deficient
host cells. Specifically, both free and esterified cholesterol levels
were reduced, as expected from a decreased uptake of choles-
terol from the host; interestingly, the content of selected sphin-
golipids also changed compared with T. gondii grown in WT
cells. In particular, the level of sphingomyelin, a major struc-
tural sphingolipid mainly found on the plasma membrane, was
increased 2-fold. Sphingomyelin has a high affinity for and
closely associates with cholesterol and both lipids contribute to
the ordered state of plasma membrane domains. Although it is
well accepted that cholesterol
homeostasis is modulated by sphin-
gomyelin content, studies on the
regulation of sphingomyelinmetab-
olism by varying the cellular choles-
terol levels produced contradictory
results in different cell types ana-
lyzed (reviewed in Ref. 34). How-
ever, cholesterol depletion was
shown to stimulate sphingomyelin
synthesis in fibroblasts (35), and
high levels of sphingolipids can
retain the ordered state of model
membranes (36), suggesting that in
conditions of cholesterol depletion,
increased sphingomyelin content
could still contribute to the mainte-
nance of an ordered plasma mem-
brane structure. Thus, it is possible
that the increased sphingomyelin
content detected in parasites with
limited cholesterol levels plays a
role in conserving the structural
properties of parasite membranes.
Also noteworthy was the increased
ceramide content in parasites from
P-gp-deficient host cells. It is tempt-
ing to speculate that this elevation is
a compensatory mechanism for the
decreased cholesterol in the mem-
branes, because ceramide-choles-
terol replacement has been shown
to occur in vitro (37). However, the
ceramide increase observed does
not justify this hypothesis, because
similarly for mammalian cells, cera-
mide in the parasite is about 10
times less abundant than choles-
terol. On the other hand, ceramide
plays a well known role of second
messenger in a variety of cellular
processes, including stress response
(reviewed in Ref. 38); thus it seems
more likely that the enlarged cera-
mide pool helps to fulfill the signal-
ing needs of T. gondii in a host cell
environment not optimal for para-
site survival. The increased ceramide synthesis observed in
labeled parasites isolated from P-gp-deficient host cells sup-
ports the idea that the content of this lipid is modulated at least
in part by an active synthetic process in the parasite. Scavenging
of sphingolipids from the host cell cannot be excluded at this
stage, although it has not been demonstrated to date in this
parasite.
Although our results clearly indicate that cholesterol trans-
port from the host to the parasite is defective in absence of host
P-gp, the data regarding the modality of this transport were
quite surprising. So far, T. gondii has been shown to depend on
FIGURE 6. P-gp expression alters cholesterol metabolism in fibroblasts. A, filipin labeling of WT, P-gp-
deficient (DKO), and P-gp-complemented (DKO/P-gp) host cells monolayers to visualize the intracellular dis-
tribution of unesterified cholesterol. B, host cells were labeled with [3H]cholesterol, and the time course of
[3H]cholesterol esterification wasmeasured at the indicated time points. The data are percentages of [3H]cho-
lesteryl esters (CE) of total cellular [3H]cholesterol. C, cells were labeled with [3H]cholesterol for 24 h, washed,
and incubatedwith 2mMmethyl--cyclodextrin.Mediumaliquotswere takenat the indicated timepoints, and
extracted [3H]cholesterol wasmeasured by liquid scintillation. Extracted cholesterol is expressed as a percent-
age of total [3H]cholesterol (medium cell associated radioactivity). D and E, the cells were similarly labeled
and incubatedwith 20g/ml reconstituted HDL (D) or 10g/ml apoA-I (E). Cholesterol efflux is expressed as a
percentage of total [3H]cholesterol as before. F, cells were loaded with the indicated concentrations of cyclo-
dextrin-cholesterol complexes for 24 h, and viability was measured by AlamarBlue assay. Results are
expressed as percentage of untreated (cntl) cell viability. All of the data are averages S.E. (n 3).
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two forms of host-derived cholesterol: free cholesterol con-
tained in endo-lysosomes (22) and esterified cholesterol pres-
ent in cytosolic lipid bodies (14). The former requires func-
tional host vesicular trafficking (22, 39) and relies on the
recruitment of host endo-lysosomes around the PV and their
diversion to the PV interior via the formation ofH.O.S.T. struc-
tures (8). Our data show that P-gp-deficient cells were compe-
tent for cholesterol esterification, endo-lysosome recruitment
to the PV, and H.O.S.T. formation; thus, the inhibition of cho-
lesterol trafficking to the parasite cannot be attributed to lack of
these processes. However, the observed accumulation of cho-
lesterol in endo-lysosomes in P-gp-deficient cells raised the
possibility that P-gp contributes to the cholesterolmobilization
from lysosomes, a crucial process for cholesterol trafficking to
the PV (8, 22). Thus, P-gp in endocytic compartments (25)
could help to mobilize cholesterol from endo-lysosomes either
juxtaposed to or internalized in the PV via the H.O.S.T. system.
This scenario is also in agreement with the reduced cholesterol
content in N. caninum when grown in P-gp-deficient cells,
because the PV of this parasite does not contain H.O.S.T. but is
in close proximity with host endo-lysosomes.
Collectively, these results show that host P-gp plays an
important role in cholesterol transport to the parasite vacuole.
However, there are several observations implying that P-gp
does not control all cholesterol transport to the parasite and
that P-gp-independent transport pathways must also exist,
namely (i) the slight (10%) additional inhibition of parasite rep-
lication in DKO cells following U-18666A drug treatment, (ii)
the increased parasite replication upon cholesterol loading of
DKO cells, and (iii) the ability of the parasite to replicate in
DKO cells for several lysis passages.
Considering these results, it seems that the mechanism
underlying P-gp-mediated cholesterol transport to the parasite
is most likely to fall within one of two general scenarios, namely
(i) P-gp does not transport cholesterol directly but is critical in
another yet unidentified cellular process essential for choles-
terol transport and parasite replication or (ii) P-gp plays a direct
but seemingly not exclusive role in cholesterol transport and/or
metabolism. The role of P-gp as a transporter of cellular cho-
lesterol has been the subject of considerable debate. Although
the presence of cholesterol in the membrane surrounding P-gp
is crucial for the ATPase activity of the protein (40), results of
studies addressing the role of P-gp in cholesterol trafficking
have been contradictory. P-gp has been proposed to translocate
cholesterol between the plasmamembrane leaflets in vitro (40).
In addition, several reports using chemically selected cell lines
or inhibitors associated P-gp overexpression with increased
cholesterol transport to the endoplasmic reticulum and conse-
quent esterification (reviewed in Ref. 41). However, from these
studies it is not clear whether the enhanced cholesterol traffick-
ing observed is due to a direct role of the protein or to an ele-
vated turnover of the cholesterol-rich membranes where P-gp
is located (42). Our understanding of P-gp-mediated choles-
terol transport is further compromised by the contradictory
results obtained through the use of P-gp inhibitors with poten-
tial side effects and cell type-specific outcome of P-gp expres-
sion (41). In our work using P-gp-deficient cells, we found that
free cholesterol accumulated in vesicular structures located in
the perinuclear region and that this accumulation was absent
once P-gp activity was restored. In addition, contrary to previ-
ous reports using P-gp inhibitors (43, 44) or selected MDR cell
lines (45), cholesteryl esters accumulated in the absence of
P-gp. Interestingly, a similar increase in cholesterol esterifica-
tionwas observed in vivo in the liver of P-gp-deficientmice (46).
Furthermore, we found a positive correlation between choles-
terol extractability/efflux from the plasmamembrane and P-gp
expression. Taken together, our results suggest that P-gp does
play a significant role in cholesterol transport in both host-
parasite interaction and in normal metabolism of fibroblasts.
Thus, although an indirect effect on cholesterol transport in
the absence of P-gp cannot be completely excluded, we
observed a number of indications consistent with a model in
which P-gp resident in the endo-lysosomes is involved in cho-
lesterol mobilization from these compartments to the PV in
case of parasite infection. These indications include: the endo-
lysosome recruitment around the PV in infected cells, the cho-
lesterol accumulation outside the PV, the reduced cholesterol
supply to the parasite in the absence of host P-gp, and the obser-
vation that P-gp-mediated parasite inhibition depends on
vesicular trafficking of cholesterol. In addition, several alter-
ations in cholesterol metabolism observed in DKO host cells
also suggest that P-gp plays a role in cholesterol trafficking from
endo-lysosomes to the plasma membrane in uninfected cells.
Such observations include the accumulation of free cholesterol
in endo-lysosome like structures in the absence of P-gp, the
decreased recycling of exogenous cholesterol to the plasma
membrane, and the increase in cholesterol esterification. On
the other hand, increased P-gp expression in host cells corre-
lates with increased cholesterol content in the plasma mem-
brane and efflux and increased sensitivity to cholesterol loading
toxicity.
In summary, our studies using the intracellular parasites T.
gondii and N. caninum provide evidence that host cell P-gp
plays a previously unidentified role in host-parasite interaction.
Our results reveal that host P-gp is required for cholesterol
transport to the parasite vacuole via a mechanism independent
of H.O.S.T. formation and is also involved in normal choles-
terol metabolism in uninfected mammalian fibroblasts.
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Abstract 
Up-regulation of the membrane-bound efflux 
pump P-glycoprotein (P-gp) is associated 
with the phenomenon of multidrug-resistance 
in pathogenic organisms, including protozoan 
parasites. In addition, P-gp plays a role in 
normal physiological processes, however our 
understanding of these P-gp functions 
remains limited. In this study we investigated 
the effects of the P-gp inhibitor GF120918 in 
Toxoplasma gondii, a model apicomplexan 
parasite and an important human pathogen. 
We found that GF120918 treatment severely 
inhibited parasite invasion and replication. 
Further analyses of the molecular 
mechanisms involved revealed that the P-gp 
inhibitor modulated parasite motility, 
microneme secretion and egress from the host 
cell, all cellular processes known to depend 
on Ca2+ signaling in the parasite. In support of 
a potential role of P-gp in Ca2+-mediated 
processes, immunoelectron and fluorescence 
microscopy showed that T. gondii P-gp was 
localized in acidocalcisomes, the major Ca2+ 
storage in the parasite, at the plasma 
membrane, and in the intravacuolar tubular 
network. In addition, metabolic labeling of 
extracellular parasites revealed that inhibition 
or down-regulation of T. gondii P-gp resulted 
in aberrant lipid synthesis. These results 
suggest a crucial role of T. gondii P-gp in 
essential processes of the parasite biology and 
further validate the potential of P-gp activity 
as a target for drug development.  
 
Abbreviations 
P-gp, P-glycoprotein; P-gp DKO, murine 
embryonic fibroblast knocked out for the two 
mouse P-gp isoforms; TLC, thin layer 
chromatography. 
 
Introduction  
The integral membrane protein P-
glycoprotein (P-gp, MDR1, ABCB1) is one 
of the most studied cellular transporters of the 
ATP-binding cassette (ABC) transporter 
superfamily [1]. The clinical importance of P-
gp derives from the fact that over-expression 
of this transporter is commonly associated 
with the phenomenon of multidrug resistance 
[2], a major public health problem associated 
with drug-resistant cancer cells and microbial 
pathogens. The main function of P-gp is the 
export of xenobiotics from the cell, as 
corroborated by the findings that P-gp 
deficient mice are viable but show strikingly 
altered pharmacokinetics and increased 
sensitivity to a variety of drugs [3]. In 
addition to this well known role, an increasing 
amount of evidence now suggests that P-gp 
also participates in normal physiological 
processes, including the transport of steroid 
hormones [4] and lipid translocation (rev. in 
[5]).  
Here we investigated the effects of the potent 
P-gp inhibitor GF120918 in the biology of 
Toxoplasma gondii, a model intracellular 
parasite and an important human pathogen, 
causing toxoplasmosis. Previous studies 
III Manuscripts                                                                                                            Manuscript 2 
 
 
37
based on efflux analyses in the presence of P-
gp inhibitors suggested that an active P-gp 
homologue is present in T. gondii [6,7]. 
Recently, two P-gp homologues with the 
typical P-gp structure have been identified in 
the genome of the parasite (TgABC.B1 and 
TgABC.B2) and found to be constitutively 
expressed in both the vegetative and quiescent 
stages of T. gondii’s life cycle [8]. Further 
molecular characterization revealed that 
TgABC.B1 is coded by a single copy gene, 
expressed as a membrane-associated protein 
of ~150 kDa, and constitutively present in 
different parasite strains [9]. Indications that 
T. gondii P-gp may be involved in key 
biological processes, such as replication and 
host cell invasion were provided by early 
works using P-gp inhibitors [6,10]. However, 
given that these studies used host cells 
containing P-gp, it was not possible to 
discriminate between the contribution of T. 
gondii and host cell P-gp. Indeed, we recently 
showed that host cell P-gp plays a crucial role 
in T. gondii replication by facilitating the 
transport of host cholesterol to the parasite 
vacuole [11]. In this study we used P-gp 
deficient host cells [3] in parallel with 
pharmacological inhibition of P-gp, thereby 
enabling more selective insights into the 
specific role of T. gondii P-gp. Inhibition of 
parasite P-gp was achieved with the 
acridonecarboxamide derivative GF120918, a 
potent competitive P-gp inhibitor of the latest 
generation [12,13], whose use  has been 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: GF120918 treatment inhibits parasite invasion. A. Functionality assay of P-gp in isolated T. gondii treated with the 
indicated inhibitor concentrations as measured by time course analysis of intracellular rhodamine 123 (Rho 123) retention. 
Retention is expressed as percentage of mean fluorescence of intracellular Rho 123 at time 0. B. Invasion assay in presence of 10 
μM GF120918 (GF) or solvent (cntl). T. gondii were pre-treated with GF120918 for 30 min and allowed to infect wild type (WT) or 
P-gp deficient (DKO) host cell monolayers in presence of GF120918 (pre-treatment and invasion, white bars). Alternatively, 
parasites were pre-treated with 10 μM GF120918 for 4 h, washed to remove the drug and incubated with host cells in absence of 
GF120918 (only pre-treatment, gray bars). Invasion was quantified by enumerating the parasite vacuoles at 24 h post infection. 
Data are average of vacuoles per field ± SE (n=15). C. Adhesion/invasion assay in presence of 10 μM GF120918 (GF) or solvent 
(cntl). Parasites were pre-treated with GF120918 for 30 min at 37°C and allowed to infect DKO host cell monolayers for 2 h in 
presence of the drug. Alternatively, drug pre-treatment was omitted and GF120918 added at the time of invasion. Adherent 
(intracellular + extracellular) and invaded (intracellular) parasites were counted after dual color immunostaining. Data are average 
of parasites per field ± SE (n=15) and expressed as percentage of cntl adhesion. Numbers above the bars represent the invasion 
index (percentage of intracellular parasites out of the total parasite number). 
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widely published both in vitro [14] and in 
vivo [15,16]. Importantly, GF120918 does not 
inhibit the P-gp-related multidrug transporters 
MRP1 and MRP2 [17] nor cytochrome P450 
3A, a key enzyme  in drug metabolism [18],  
and achieves adequate P-gp inhibition in vivo 
without significant side effects [13,19] 
Results 
 
GF120918 inhibits parasite invasion. As an 
obligate intracellular parasite, T. gondii 
depends completely on host cells for its 
survival and propagation; thus host cell 
invasion is an essential process in the 
parasite’s biology. To block the function of T. 
gondii P-gp, isolated parasites were treated 
with GF120918, a potent P-gp inhibitor of the 
latest generation [13]. GF120918 was found 
to strongly hamper P-gp function in the 
parasite at low micromolar concentrations, as 
assessed by efflux analysis of the specific P-
gp substrate rhodamine 123 (Fig. 1A). To 
analyze whether GF120918 inhibits parasite 
invasion, parasites were pre-treated for 30 
min with the inhibitor, then allowed to infect 
host cells wild type (WT) or deficient in the 
two mouse P-gp isoforms (P-gp DKO) [3] for 
4 h in presence of the inhibitor.  The drug was 
then removed and the infection was 
determined by counting the parasite vacuoles 
after 24 h incubation. GF120918 treatment 
reduced the number of intracellular vacuoles 
by 50% in both host cell types, indicating that 
host P-gp is not involved in parasite invasion 
(Fig.1B, white bars). Importantly, the 
invasion inhibition was not caused by parasite 
lethality following compound treatment, as 
GF120918 did not significantly compromise 
parasite viability at the concentration 
inhibitory for invasion (data not shown). To 
analyse whether the presence of GF120918 at 
the time of infection was necessary for the 
inhibitory effect, parasites were pre-treated 
with GF120918, washed and incubated with 
host cells in absence of the drug. Also in these 
experimental conditions, parasite invasion 
was reduced by ~50% (Fig. 1B, grey bars), 
confirming that the drug inhibited parasite 
invasion by acting solely on the parasite. 
These results also showed that the invasion 
inhibition is not reversed by removal of the 
drug from the medium, suggesting that 
GF120918 stably inhibited the parasite target. 
Having shown that GF120918 inhibited 
parasite invasion, we then further dissected 
the inhibitory effect using a sequential 
staining method, which allows discrimination 
between the processes of adhesion to a host 
cell and active invasion. GF120918 treatment 
reduced the number of both adherent and 
invaded parasites by ~ 50% compared with 
control cells (Fig. 1C, pre-treatment). This 
dual inhibition is indicative of an effect on 
parasite attachment, since attachment is 
required for invasion [20]. Consistently, we 
found that the invasion index, namely the 
percentage of invaded parasites calculated out 
of the total number of parasites present, 
decreased by less than 20% in presence of 
GF120918. Interestingly, in absence of 
parasite pre-treatment, the inhibitory effect of 
GF120918 on parasite adhesion and invasion 
was less pronounced and did not decrease the 
invasion index (Fig. 1C, no pre-treatment), 
suggesting that a time delay after adding the 
compound is necessary for the inhibitory 
effect to take place. 
 
GF120918 treatment increases T. gondii 
motility. From the above experiments we 
established that GF120918 inhibited parasite 
invasion. As parasite invasion is an active 
process which depends on parasite motility 
(reviewed in [21]), we next examined whether 
the  GF120918-mediated  inhibition of 
invasion was a consequence of defective T. 
gondii motility. Parasite motility was 
analyzed by allowing parasites to glide on a 
substratum in presence or absence of 
GF120918 whilst visualizing the trails  
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Figure 2: GF120918 treatment increases parasite motility. A. Parasites were treated with 10 μM GF120918 
(GF, white bars), 1 μM Ca2+ ionophore A23187 (CaI, gray bars) or the respective solvents (cntl) and the trails 
deposited during gliding enumerated. Data are average of trail number per field ± SE (n=10) and expressed as 
percentage of cntl. B. Indirect immunofluorescence microscopy demonstrating that the average length of trails 
increased with GF120918 (GF) treatment. C. Adhesion/invasion assay in presence of  1 μM of the  Ca2+ 
ionophore  A23187 (CaI) or solvent (cntl). Adherent and invaded parasites were counted after dual color 
immunostaining. Data are average of parasites per field ± SE (n=10) and expressed as percentage of cntl 
adhesion. D. Parasites were treated with 10 μM GF120918 (GF) in presence or absence of 100 μM BAPTA 
and trail deposition was quantified as before. Data are average of trail number per field ± SE (n=10) and 
expressed as percentage of GF120918-treated parasites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
produced by parasite movement by 
immunofluorescence [22]. Surprisingly, 
GF120918 treatment did not reduce parasite 
motility, as assessed by the number of trails 
generated. On the contrary, the trails 
produced by GF120918-treated cells were 
more numerous (Fig. 2A, white bars) and 
longer (Fig. 2B) compared with control cells. 
Parasite motility is known to be regulated by 
intracellular Ca2+ fluxes [23,24]. To test 
whether the alteration of parasite motility 
induced by GF120918 treatment correlates 
with the effects of Ca2+ deregulation, we 
increased intracellular calcium levels using 
the Ca2+ ionophore A23187. In our 
experimental conditions, both P-gp inhibitor 
and A23187 incubations increased parasite 
motility in a comparable manner (Fig. 2A, 
gray bars). Similarly to what was observed 
during GF120918 treatment, incubation with 
A23187 reduced parasite adhesion and 
invasion as well (Fig. 2C). In addition, when 
parasites were co-treated with GF120918 
together with the Ca2+ chelator BAPTA, the 
increase in motility was reduced compared 
with parasites solely treated with GF120918 
(Fig. 2D). Collectively, these findings 
indicated that GF120918 treatment increases 
parasite motility and that this increase is 
likely to depend on alterations in parasite’s 
Ca2+ fluxes. 
 
GF120918 treatment induces microneme 
secretion. Secretion of micronemes, secretory 
organelles located at the apical end of the 
parasite, depends on Ca2+ fluxes in the 
parasite and it is essential for T. gondii  
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motility [24]. To analyse whether GF120918 
affected microneme secretion, we examined 
the discharge of the microneme protein 
MIC2, which is secreted on the parasite 
surface and then shed after proteolytic 
processing [25]. Parasites treated for 5 and 30 
min with GF120918 showed a time dependent 
increase in MIC2 surface staining compared 
with control cells (Fig. 3A). Population-wide 
quantification by flow cytometry revealed 
that MIC2 surface staining in non-
permeabilized cells increased following 
GF120918 treatment in ~25% of the cells 
(Fig. 3B, thick lines). The staining was not 
due to cell permeabilization induced by 
inhibitor treatment, as detergent-
permeabilized cells showed a much stronger 
signal (Fig. 3B, thin lines). In addition, 
analysis of permeabilized cells revealed that 
in control samples 64.44% of the total cell 
number (n=10’000) showed high MIC2 
signal, while GF120918 treatment decreased 
this number to 48.47%, suggesting a loss of 
cell associated MIC2 following secretion. 
Collectively, these data indicate that 
GF120918 treatment induced microneme 
secretion without increasing the permeability 
of parasite plasma membrane.  
 
GF120918 treatment induces parasite egress. 
As we observed that GF120918 treatment of 
extracellular T. gondii enhanced parasite 
motility, we reasoned that if GF120918 could 
activate motility also in intracellular parasites, 
it would promote active egress of T. gondii 
from the host cells, a process which depends 
on parasite motility and is triggered by 
changes in the host cells ionic environment 
[26]. When infected cultures were treated for 
4 h with GF120918, a two fold increase in 
parasite egress was observed compared with 
untreated cells (Fig. 4A, w/o CaI).  
Contrary to the natural egress which occurs at 
the end of the parasite lytic cycle and does not 
require parasite motility [27], the motility- 
Figure 3: GF120918 treatment increases 
MIC2 secretion. A. Isolated parasites were 
treated with 10 μM  GF120918 (GF) or 
solvent (cntl) for 5 or 30 min, fixed and 
stained with anti-MIC2 antibody without cell 
permeabilization. Central panel, 
magnification of T. gondii treated with 
GF120918 for 30 min showing MIC2 surface 
staining. Insets, differential interference 
contrast images. B. Isolated parasites treated 
with 10 μM GF120918 (GF) or solvent (cntl) 
for 30 min were stained with anti-MIC2 
antibody without (thick lines) or with (thin 
lines) cell permeabilization and quantified by 
flow cytometry. Overlay histogram showing 
cells treated with solvent (cntl, yellow lines) 
or GF120918 (GF, black lines). U, unstained 
cells. 
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dependent active egress is thought to be 
employed by the parasite as an escape 
mechanism from a dying host cell [28]. To 
determine whether the GF120918-mediated 
egress was caused by host cell lethality, we 
analyzed the viability of host cells treated 
with the inhibitor. Incubation with GF120918 
for 24 h did not reduce host cell viability, 
indicating that the increased egress induced 
by GF120918 was not a response to inhibitor-
mediated host cell toxicity (Fig. 4B). 
Next we analyzed the effect of GF120918 
during experimental induction of active 
egress. As with microneme secretion, active 
egress can also be induced by adding the Ca2+ 
ionophore A23187 [29], which raises 
intracellular calcium levels and activates 
parasite motility (rev. in [30]). When parasite 
egress was induced with A23187 incubation, 
a similar increase in egress was observed in 
presence or absence of GF120918, indicating 
that GF120918 treatment was not able to 
further increase egress when used in 
combination with the Ca2+ ionophore (Fig. 
4A, w CaI).  
 
Intracellular localization of T. gondii P-gp. 
We showed that treatment of T. gondii with 
the P-gp inhibitor GF120918 strongly 
correlated with alterations in Ca2+-dependent 
processes; thus, it is possible that P-gp plays a 
role in Ca2+ regulation in this parasite. To 
investigate this hypothesis, we analyzed 
whether P-gp localized in parasite organelles 
involved in Ca2+ homeostasis. For this aim we 
used the P-gp-specific monoclonal antibody 
C219, which recognizes a conserved epitope 
also present in the T. gondii orthologue (Fig. 
S1B). Western blot analysis confirmed that 
the antibody reacts with a parasite protein 
corresponding to the predicted mass of P-gp 
(Fig. S1A).  Immunoelectron microscopy of 
infected cells showed a distinct staining 
concentrated in conspicuous membrane bound 
electron-lucent vesicles of 100-400 nm  
Figure 4: GF120918 treatment increases T. 
gondii egress. A. T. gondii was allowed to 
replicate in P-gp DKO host cells for 30 h, 
treated with 10 μM GF120918 (GF) or solvent 
(cntl) for 4 h and egress quantified after 
parasite immunolabeling. For Ca2+ ionophore 
(CaI)-induced egress, infected monolayers were 
treated with GF120918 as before and 
additionally incubated with 1 μM A23187 for 
10 min. Data are average of egressed parasites 
per field ± SE (n=20) expressed as percentage 
of cntl without CaI. Right panels, examples of 
intravacuolar and egressed parasites. B. 
Metabolic activity of P-gp DKO host cells 
treated for 24 h with solvent (cntl) or 
GF120918 (GF) at the indicated concentrations 
was assessed by measuring AlamarBlue 
reduction (Biosource). Results are average ± SE 
(n = 6). 
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diameter, which morphologically resembled 
acidocalcisomes, the largest intracellular store 
of Ca2+ in the parasite [31] (Fig. 5A). Co-
immunostaining with antibodies against the 
acidocalcisome marker VP1 [32] revealed 
that both proteins are indeed present in 
morphologically similar structures (Fig. 5B). 
In addition, P-gp labeling was found in the 
tubulovesicular network within the parasite 
vacuole. The plasma membrane of theparasite 
was less intensely 
labeled with this 
antibody, and no 
staining of other 
vesicular 
structures, such as 
rhoptries and 
dense granules 
was observed. 
Strikingly, P-gp 
staining 
drastically 
increased in the 
rare vacuoles 
which contained 
dying parasites, 
characterized by 
high intracellular 
vacuolization, 
plasma membrane 
rupture and 
release of 
cytosolic content 
in the parasite 
vacuolar space (Fig. 5C).  
Next, we investigated the localization of P-gp 
by immunofluorescence analysis. As the 
monoclonal antibody C219 is suitable for this 
technique only in case of P-gp 
overexpression, we engineered a P-gp 
minigene composed of three sequences of the 
parasite protein showing low degree of 
similarity with the mammalian P-gp (Fig 
S1B), and which encompassed the peptide 
sequence used in a previous study to raise 
anti-T. gondii P-gp antibodies [9]. Similar to 
the C219 antibody, the immune serum against 
P-gp minigene reacted with a band of mass 
expected for P-gp (Fig. S1A). As previously 
reported [9], lower molecular weight bands 
were also detected; it is currently not known 
if they constitute protein degradation or 
processing products. Immunofluorescence 
analysis of T. gondii infected cells using the  
Figure 5: Ultrastructural localization of T. gondii 
P-gp. A. T. gondii was allowed to replicate in P-gp 
DKO host cells for 24 h and immunoelectron 
microscopy performed with anti-Pgp antibody C219. 
PVN, parasitophorous network. DG, dense granules. 
N, nucleus. Scale bars, 0.5 μm. B. Co-localization of 
C219 (15 nm gold, arrows) and anti-VP1 (5 nm gold, 
arrowheads). Scale bars, 0.5 μm. C. Examples of P-
gp localization in damaged parasite vacuoles. Scale 
bars, 1 μm. 
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P-gp minigene antibody showed a strong 
labeling of distinct intracellular structures 
distributed throughout the cell and, less 
intensely, of plasma membrane (Fig. 6A). 
Similar to the observations with electron 
microscopy, these intracellular structures 
partially co-localized with VP1, strongly 
suggesting that P-gp is indeed localized in 
acidocalcisomes (Fig. 6B).  
Interestingly, when extracellular T. gondii 
were probed with the P-gp minigene 
antibody, a subgroup of parasites showed P-
gp labeling exclusively on the plasma 
membrane and labeling of the internal 
structures was no longer evident. In addition, 
the staining concentrated at the apical end of 
the parasite and formed a collar around the 
conoid, which in turn remained unlabeled 
(Fig. 6C). These results suggest that P-gp 
transiently re-localized in extracellular 
parasites. 
 
GF120918 treatment inhibits T. gondii 
replication and lipid synthesis. To determine 
whether GF120918 treatment affected 
parasite replication, P-gp DKO host cells 
were infected with T. gondii and subsequently 
treated with different concentrations of the 
inhibitor. Analysis of parasite burden 48 h 
post infection revealed a marked dose-
dependent inhibition of parasite replication 
(Fig. 7A). Immunofluorescence analysis did 
not show any cells positive for the bradyzoite-
specific antigen BAG1 (data not shown), 
indicating that GF120918 treatment reduced 
parasite replication without triggering parasite 
stage conversion to the quiescent bradyzoite 
form. Treatment with verapamil, an earlier 
generation P-gp inhibitor reported to be less 
potent than GF120918 [33], was less effective 
in blocking parasite replication. However, 
longer incubation times with verapamil 
strongly inhibited T. gondii replication as well 
(Fig. 7B), without affecting host cell viability 
(data not shown). In addition, GF120918-
mediated inhibition of parasite replication 
was not reversed following removal of the  
Figure 6: Intracellular localization of T. gondii P-
gp. A. Fluorescence microscopy of intracellular T. 
gondii at 24 h post infection using anti-P-gp minigene 
antibody. Nuclear DNA was stained with DAPI. B. 
Dual staining of isolated T.gondii using anti-P-gp 
minigene (green) and anti-VP1 (red) antibodies, 
showing partial co-localization of the two proteins. C. 
Fluorescence (left panels) and confocal (right panels) 
microscopy showing differential P-gp distribution in 
extracellular parasites stained with anti-P-gp minigene 
antibody (green). The arrow indicates the absence of 
P-gp staining in the conoid area labeled with anti- T. 
gondii antibody (red). Nuclear DNA was stained with 
DAPI (blue). 
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Figure 7: GF120918 treatment inhibits parasite replication and lipid synthesis. A. T. gondii were allowed to 
infect P-gp DKO host cells and subsequently treated with the indicated concentrations of GF120918 (GF) and 
verapamil (Ver). Parasite burden was quantified 48 h post infection by a colorimetric assay measuring the amount of 
parasite-expressed β-galactosidase. Results are expressed as percentage of parasite number in control untreated cells 
± SE (n=5). B. Time course of parasite replication inhibition by verapamil. T. gondii infected host cells were treated 
with the indicated concentrations of verapamil or solvent (cntl). Parasite burden was quantified at the indicated 
times post infection as described above. Results are expressed as percentage of parasite number in control untreated 
cells ± SE (n=3). C. T. gondii were treated with 10 μM GF120918 (GF) or solvent (cntl) for 4 h, washed and 
incubated with P-gp DKO host cells for 24 h in absence of the drug. Intracellular parasites were quantified by direct 
counting after immunostaining. The distribution of the parasite number in single vacuoles is expressed as percentage 
of total vacuoles examined (n>100). D. Isolated parasites were labeled with 0.5 µCi/mL of [3H]palmitic acid for 3 h 
in presence of 10 μM GF120918 (GF) or solvent (cntl) and lipid were extracted. Left panel, TLC separation of de 
novo synthesized lipids. Lipid standard used: ceramide (Cer), glucosylceramide (GC), phosphatidylcholine (PC), 
sphingomyelin (SM). Right panel, quantification of the relative amount of newly synthesized lipid species expressed 
as percentage of total lipids. Data are average ± SE (n=3). E. Isolated parasites were labeled with 0.5 µCi/mL of 
[3H]palmitic acid or 4 µCi/mL [3H]choline for 3 h in presence of 10 μM GF120918 (GF) or solvent (cntl). [3H] 
incorporation was measured in both whole cell (TOT) and lipid extracts by liquid scintillation and normalized by 
protein content. Data are average ± SE (n=6). 
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drug: parasites treated with the inhibitor prior 
to contact with host cells not only showed 
defective invasion (Fig. 1B), but also formed 
smaller vacuoles containing fewer parasites 
than control cells after 24 h incubation in the 
absence of the drug (Fig. 7C). 
As we previously showed that host P-gp is 
involved in cholesterol transport from the host 
cell to the parasite vacuoles, a critical process 
for proper parasite replication [11], we 
hypothesized that the defective parasite 
replication observed during T. gondii 
treatment with the P-gp inhibitor GF120918  
may derive from impaired lipid transport 
and/or synthesis. To test this, we treated 
isolated parasites with the inhibitor and 
monitored lipid synthesis after metabolic 
labeling. The fatty acid precursor [3H]palmitic 
acid was readily incorporated in phospho- and 
sphingolipid species of control parasites (Fig. 
7D). However, incubation with GF120918 
induced a general decrease in parasite lipid 
synthesis. Interestingly, the inhibitor did not 
reduce the synthesis of all labeled lipids in a 
similar manner, but differently affected the 
relative amount of the lipid species, with PC 
synthesis being the most down-regulated 
while ceramide synthesis was increased 
compared with control cells. Next, we 
determined whether GF120918 affected not 
only lipid synthesis but also lipid precursor 
uptake. Liquid scintillation analysis revealed 
that inhibitor treatment strongly inhibited the 
incorporation of [3H]palmitic acid in both 
total cell extracts and lipid fraction (Fig. 7E). 
This reduced incorporation was specific for 
[3H]palmitic acid as incorporation of 
[3H]choline was not affected by GF120918 
treatment. Collectively, these data show that 
GF120918-induced inhibition of T. gondii 
replication was likely mediated by a reduction 
in parasite lipid uptake and synthesis. 
 
Down-regulation of T. gondii P-gp correlates 
with reduced parasite replication and lipid 
synthesis. While T. gondii is able to grow in 
P-gp DKO host cells, its replication rate is 
reduced due to defective cholesterol 
trafficking to the parasite vacuole [11]. When 
we analyzed T. gondii maintained for more 
than 4 lysis cycles in P-gp DKO host cells, we 
found that the sub-optimal growth conditions 
did not trigger parasite stage conversion to the 
quiescent bradyzoite form (Fig. 8A). In 
addition, parasites isolated from P-gp DKO 
host cells after more than 4 passages were 
able to infect (Fig. 8B) and to egress from 
(Fig. 8C) new host cells as efficiently as 
parasites maintained in WT host cells. These 
finding suggest that the lower parasite burden 
observed was not caused by compromised 
infection or exit from host cells, but by a 
specific defect in replication, consistent with 
the limited access to host cholesterol 
demonstrated previously [11]. However, 
when parasites isolated from P-gp DKO host 
cells were allowed to infect WT host cells 
with a normal cholesterol trafficking, their 
replication rate remained slower compared 
with parasites isolated from WT host cells, as 
monitored up to 72 h post infection (Fig. 8D 
and not shown). While it is conceivable that 
cholesterol storage still depleted in the 
parasite after prolonged growth in P-gp DKO 
host cells affected T. gondii replication, it is 
also possible that lipid transport and/or 
synthesis are altered in these parasites. To test 
this hypothesis, we monitored the lipid 
synthesis in T. gondii isolated from P-gp 
DKO host cells after more than 4 lysis cycles. 
Surprisingly, [3H]palmitic acid labeled cells 
showed an overall decrease in lipid synthesis 
with a profile similar to what was observed 
during P-gp inhibition with GF120918 (Fig. 
8E). To investigate whether the inhibition of 
lipid synthesis correlated with inhibition of T. 
gondii P-gp, we performed real-time PCR 
(Fig. 8F) and P-gp functionality assay (Fig. 
8G) on parasites isolated from WT or P-gp  
 
III Manuscripts                                                                                                            Manuscript 2 
 
 
46
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Down-regulation of T. gondii P-gp correlates with decreased lipid synthesis. A. Immunoflorescence 
analysis using antibodies against the bradyzoite-specific antigen BAG1 showing the absence of parasite stage 
conversion into bradyzoites after more than 4 lysis cycles in P-gp DKO host cells (upper panels). Lower panels, 
positive control of parasites induced to differentiate by alkaline treatment as described in the Materials and Methods 
section. Arrows, parasite vacuoles. DIC, differential interference contrast images. B. Adhesion/invasion assay in WT 
host cells of T. gondii isolated from P-gp WT or DKO host cells after more than 4 lysis cycles. Adherent and invaded 
parasites were counted after dual color immunostaining. Data are average of parasites per field ± SE (n=10) and 
expressed as percentage of cntl adhesion of T. gondii maintained in WT host cells. C. The same isolated parasites 
were allowed to replicate in WT host cells for 30 h, following induction of egress with 1 μM A23187 for 10 min. Data 
are average of egressed parasites per field ± SE (n=15) expressed as percentage of the total (egressed  + intravacuolar) 
parasites. D. Parasites isolated from P-gp WT or DKO host cells after more than 4 lysis cycles were incubated with 
WT host cells for 24 h. Intracellular parasites were quantified by direct counting after immunostaining. The 
distribution of the parasite number in single vacuoles is expressed as percentage of total vacuoles examined (n>100). 
E. Parasites isolated from P-gp WT or DKO host cells after more than 4 lysis cycles were labeled with 0.5 µCi/mL of 
[3H]palmitic acid for 3 h and lipid were extracted. Left panel, TLC separation of de novo synthesized lipids. Lipid 
standard used: ceramide (Cer), glucosylceramide (GC), phosphatidylcholine (PC), sphingomyelin (SM). Right panel, 
quantification of the relative amount of newly synthesized lipid species expressed as percentage of total lipids. Data 
are average ± SE (n=3). F. Semi-quantitative real time PCR of P-gp expression levels in parasites isolated from P-gp 
WT or DKO host cells after more than 4 lysis cycles. Gene expression levels were given as values in arbitrary units 
relative to the amount of the constitutively expressed house-keeping gene tubulin. Data are average ± SE (n =5). G. 
Functionality assay of P-gp in T. gondii isolated from P-gp WT or DKO host cells after more than 4 lysis cycles. 
Parasites from WT host cells were treated with 5 μM  GF120918 (GF) as positive control for inhibition of P-gp 
functionality. Intracellular rhodamine 123 (Rho 123) retention is expressed as percentage of mean fluorescence of 
intracellular Rho 123 at time 0. 
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DKO host cells. Both approaches indicated 
that P-gp expression and activity were  
reduced in parasites grown in P-gp DKO host 
cells, supporting the correlation between lipid 
synthesis and P-gp activity revealed by 
pharmacological P-gp inhibition. 
 
Discussion 
P-gp has been shown to be a major 
mechanism of multidrug resistance in 
pathogenic organisms, including protozoan 
parasites (rev. in [34]). However, the 
physiological roles of P-gp in the absence of 
drug pressure remain poorly understood. In 
the present study we investigated the effects 
of the potent, third generation P-gp inhibitor 
GF120918 in the pathogenic parasite T. 
gondii. We found a dual role of GF120918 in 
the parasite physiology, namely in Ca2+-
dependent processes and lipid synthesis.  
GF120918 treatment and Ca2+-regulated 
processes. Ca2+ fluxes have been shown to 
play a key role in T. gondii invasion by 
regulating the secretion of microneme 
proteins, which serve as a bridge between the 
internal actin-myosin motor system and 
external substrates, and thus mediate both T. 
gondii adhesion and movement [35]. 
However, the molecular mechanisms 
regulating Ca2+ homeostasis in the parasite 
are not completely elucidated [36]. Here we 
showed that GF120918 treatment induced the 
secretion of the microneme protein MIC2 in 
absence of contact with host cells. In addition, 
increased MIC2 secretion correlated with 
increased parasite motility, in terms of 
number and length of trails left by the parasite 
while gliding on a substrate. Increased 
motility was not reported in a previous study 
using an early generation P-gp inhibitor [6]. 
While the different methods used by the 
authors to quantify parasite movement could 
account for this discrepancy, another 
explanation derives from different potency 
and binding capacity of the inhibitors to P-gp, 
which is also suggested by the different 
reversibility of the compounds observed in 
replication and invasion assays. Consistent 
with a role in promoting Ca2+-mediated 
motility, GF120918 treatment induced T. 
gondii egress from infected host cells, a 
process known to depend on parasite motility 
and Ca2+ fluxes [26]. 
Increased T. gondii motility has been reported 
only rarely, and is generally characterized by 
fast and unregulated movement not resulting 
in productive locomotion. Examples are 
treatments with jasplakinolide, an actin 
filament stabilizer [37], or selected small 
molecules identified in a screen for parasite 
invasion inhibitors [38]. However treatment 
with calmidazolium, which increased 
intracellular Ca2+ levels in the parasite, 
induced both microneme secretion and 
productive motility [39]. The mechanism of 
calmidazolium-mediated increase of Ca2+ 
levels has not been identified in the parasite 
as yet; however the fact that chelation of 
extracellular Ca2+  decreased the 
calmidazolium-induced parasite motility led 
to the hypothesis that the compound may 
promote the  influx of extracellular Ca2+ by 
modulating a Ca2+ transporter localized on the 
parasite plasma membrane [39]. Importantly, 
in our experimental conditions, extracellular 
Ca2+chelation decreased the GF120918-
induced parasite motility as well. The striking 
similarity of the calmidazolium and 
GF120918 effect on parasite motility strongly 
suggests that the two compounds operate on a 
similar molecular mechanism and reveal a 
possible involvement of P-gp in Ca2+ 
signaling in the parasite. In addition, it is 
possible that calmidazolium, which is 
marketed as a calmodulin inhibitor, induced 
the T. gondii phenotype by interfering with P-
gp function, as Pgp is inactivated by 
calmodulin antagonists [40]. Conversely, 
GF120918 has not been reported thus far to 
interfere with Ca2+ transport or Ca2+-
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dependent processes. Analysis of P-gp-
dependent Ca2+ fluxes is limited by the fact 
that commonly used Ca2+ indicators are 
known P-gp substrates and are actively 
exported from the cell interior [41]. However 
studies performed with radiolabeled Ca2+ in 
mammalian cells indicated that this ion 
accumulated more in P-gp over-expressing 
than in control cells [42-44].  Two P-type 
Ca2+ transporters, the plasma membrane Ca2+-
ATPase (PMCA) and the sarcoplasmic 
reticulum Ca2+-ATPase (SERCA), play a 
crucial role in maintaining Ca2+ homeostasis. 
Both proteins counter-transport protons and 
alteration of intracellular pH has been shown 
to produce changes in Ca2+ levels (Rev. in 
[45]). Interestingly, P-gp expression has been 
associated with outward proton movement 
and intracellular alkalinization as a 
consequence of increased  Cl-/H+ antiport 
[46]; similar data were also obtained in the 
analysis of human P-gp over-expression in 
yeast cells [47] and in the characterization of 
a bacterial P-gp homologue [48]. While the 
direct mechanism regulating the P-gp-
mediated ion transport is not known, it is 
conceivable that P-gp may play a role in Ca2+ 
homeostasis by regulating cellular 
concentration of protons and pH-dependent 
Ca2+ transporters. Ca2+ regulation via PMCA 
and SERCA homologues is operational in T. 
gondii (rev. in [36,49]). Importantly, a 
PMCA-type Ca2+-ATPase  (TgA1) involved 
in Ca2+ influx, is localized to 
acidocalcisomes, the largest Ca2+ storage in T. 
gondii (rev. in [31]). TgA1 deficiency 
reduced T. gondii invasion and decreased 
parasite virulence [32], confirming that these 
organelles play an essential role in Ca2+ 
homeostasis and cellular processes in the 
parasite. Surprisingly, our localization data 
revealed that P-gp was found not only on the 
plasma membrane of the parasite, but also in 
acidocalcisomes, further supporting a P-gp 
involvement in Ca2+ regulation. Similarly to 
the observations with the acidocalcisome 
marker type I vacuolar-type H+-
pyrophosphatase [50], P-gp transiently re-
localized in a collar-like structure at the apical 
end of extracellular parasites. Thus, we can 
propose a model where P-gp may participate 
in the Ca2+ homeostasis via facilitating Ca2+ 
uptake in acidocalcisomes by contributing to 
the establishment of the proton gradient in the 
organelles and, in addition, via promoting the 
function of TgA1. In addition, P-gp may also 
facilitate the activity of PMCA and its 
inhibition would promote the entry of 
extracellular Ca2+ and increase parasite 
motility. In support of this hypothesis, 
chelation of extracellular Ca2+ reduced 
GF120918-stimulated parasite motility. 
P-gp has also been proposed as a regulator for 
Cl- selective channels with a role in cell 
volume regulation [51]. As acidocalcisomes 
have been implicated in maintaining ionic 
homeostasis and regulating cell volume in 
Leishmania parasites [52], it is tempting to 
speculate that T. gondii P-gp present in these 
organelles may contribute to this regulatory 
function as well. 
 
One intriguing finding of T. gondii treatment 
with GF120918 was the inhibition of host cell 
invasion despite increased microneme 
secretion. Microneme secretion is necessary 
for a successful host cell invasion; however 
several results suggest that it is not sufficient 
to promote this process. Strong stimulation of 
micronemes via prolonged Ca2+ increase 
inhibits parasite invasion ([24,53] and our 
study), presumably due to the exhaustion of 
required invasion factors. The increased 
inhibition of T. gondii invasion we observed 
following prolongation of the GF120918 
incubation time suggested that a similar 
mechanism is responsible for the observed 
time dependent inhibition. In addition, T. 
gondii deficient for the acidocalcisome Ca2+ 
transporter AP1 also showed increased and 
III Manuscripts                                                                                                            Manuscript 2 
 
 
49
disregulated microneme secretion and 
invasion inhibition [32]. Interestingly, no 
invasion defect was observed in T. gondii 
with down-regulated P-gp expression, 
suggesting either that the reduced P-gp 
activity may still be sufficient to guarantee a 
normal infection rate, or that compensatory 
mechanisms are in place to maintain proper 
Ca2+ regulation.  
 
GF120918 treatment and parasite 
replication. Our previous work demonstrated 
that functional host cell P-gp is required for 
normal parasite replication [11]. In contrast 
with mammalian cells where P-gp inhibition 
or absence does not affect cell replication, in 
this study we showed that GF120918 
treatment inhibits parasite replication. Our 
analyses also indicated that the replication 
inhibition was likely caused by defective lipid 
synthesis, as GF120918 treatment selectively 
reduced palmitic acid incorporation in both 
total cell and lipid extracts. Conversely the 
normal choline incorporation in presence of 
GF120918 treatment suggested that the 
observed defect in palmitic acid incorporation 
is likely to occur also at the level of fatty acid 
uptake.  The role of P-gp as a lipid 
transporter/flippase has been confirmed using 
labeled short chain lipid analogues [5]. In 
addition, the recently resolved X-ray structure 
of P-gp revealed the presence of portals open 
to both the cytoplasm and the inner leaflet of 
the plasma membrane, consistent with a 
function as a lipid flippase [54]. However, 
experiments with naturally occurring lipids 
are scarce and the physiological role of P-gp 
in endogenous lipid transport is still 
uncharacterized, with the only exception of 
platelet-activating factor (PAF) [55]. T. 
gondii has been shown to scavenge not only 
cholesterol [56], but also a variety of lipids 
from the host cells [57]. While the 
mechanisms by which host–derived lipids 
reach the parasite are not completely 
elucidated, the formation of H.O.S.T., a 
unique system of tubular structures, has been 
proposed to be a key event to sequester endo-
lysosomes from the host cytoplasm into the 
parasite vacuole, thus providing T. gondii 
with cholesterol and possibly other lipids 
[58]. As our analyses showed that P-gp 
localized in the tubular structures forming the 
intravacuolar network, it is tempting to 
speculate that parasite P-gp is involved in the 
uptake of host–derived lipids, either directly 
or via modulation of other transporters. A 
broad analysis of lipid transport by T. gondii 
P-gp and related transporters will be an 
important area for future investigation. 
Quite surprisingly, our localization studies 
also revealed an increased P-gp labeling in 
damaged parasite vacuoles, thus raising the 
question of a possible role of P-gp during 
cellular stress in the parasite. In support of 
this hypothesis, increased P-gp expression 
was observed in mammalian cells after 
radiation exposure and was associated with 
resistance to apoptotic signals and 
radioprotection [59], indicating that P-gp 
plays a role not only in cell protection during 
xenobiotic exposure, but also in cell survival 
during cell damage.  
Finally, we found unexpectedly that parasites 
grown in P-gp deficient host cells had 
reduced P-gp expression. The molecular 
mechanisms leading to P-gp down-regulation 
remain to be determined. One possibility is 
that the reduced cholesterol content found in 
these parasites [11] affected P-gp expression, 
as cholesterol depletion has been shown to 
down-regulate P-gp expression [60]. 
Alternatively, the slower T. gondii replication 
rate observed during infection of P-gp 
deficient host cells may result in reduced P-gp 
expression. Consistent with this hypothesis, 
less virulent T. gondii strains which are 
characterized by a slower replication rate 
showed a reduced P-gp expression compared 
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with the virulent and fast replicating RH 
strain [9]. 
 
In summary, this study demonstrated that 
GF120918 treatment potently inhibits parasite 
invasion and replication, thus validating the 
potential of P-gp inhibitors as a therapeutic 
strategy against T. gondii. In addition, we also 
showed that GF120918 affected Ca2+-
dependent processes and lipid metabolism in 
the parasite. Finally, our results indicated that 
GF120918 can be used to specifically 
uncouple parasite motility and host cell 
invasion, thus providing a useful tool to study 
these processes. While our data on P-gp 
localization and expression are in support for 
a direct involvement of P-gp in these events, 
additional investigations using genetic 
approaches will be required to further our 
understanding of the function of P-gp and 
possibly other ABC transporters in the 
biology of T. gondii. 
 
Materials and Methods 
Biochemical reagents. Unless otherwise 
stated, all chemicals were purchased from 
Sigma and cell culture reagents from Gibco-
BRL. GF120918 was a kind gift of 
GlaxoSmithKline. Reagents stock solutions 
were prepared at the following 
concentrations:  2 mM GF120918 in DMSO, 
10 mM BAPTA (1,2-bis (2-aminophenoxy) 
ethane-N, N, N’, N’ tetracetic acid) in 0.3 M 
NaHCO3, 1 mM A23187 in DMSO, 1 mg/mL 
rhodamine 123 in EtOH, 4.1 mM verapamil 
in PBS. Reagents were freshly diluted to the 
concentrations required for the individual 
experiment.  Radiolabeled palmitic acid and 
choline were purchased from Amersham 
Pharmacia Biotech. Anti-P-gp monoclonal 
antibody C219 was purchased from Alexis 
Biochemicals; anti-T. gondii MIC2 and VP1 
were a kind gift from J.F. Dubremetz 
(Université de Montpellier 2, Montpellier, 
France) and S. Moreno (University of 
Georgia, Athens, GA), respectively. 
Conjugated secondary antibodies were from 
Invitrogen. Lipid standards were from Avanti 
Polar Lipids, Alabaster, Alabama.   
Mammalian cell and parasite culture. Mouse 
embryonic fibroblasts (MEF) double knocked 
out (DKO) for P-gp, (77.1 , Mdr1a-/-/Mdr1b-/-) 
[3]  and parental cells were kindly provided 
by A. Schinkel (The Netherlands Cancer 
Institute, Amsterdam, The Nederlands). Cells 
were routinely cultured in Dulbecco’s 
modified Eagle medium (DMEM) 
supplemented with 10% fetal calf serum 
(FCS), 2 mM glutamine, 50 U of 
penicillin/mL, and 50 µg of streptomycin/mL 
at 37°C with 5% CO2. β-galactosidase 
expressing T. gondii were a kind gift from J. 
Boothroyd (Stanford University School of 
Medicine, Stanford, CA). T. gondii 
tachyzoites of the RH strain expressing 
Escherichia coli β-galactosidase [61] were 
used in this study. Parasites were maintained 
by serial passages in MEF, harvested from 
infected host cells by passage through a 26-
gauge needle and purified by separation on 
Sephadex-G25 columns (Amersham) as 
described [62]. Purified parasites were 
counted in a hemocytometer chamber and 
used for a new cycle of host cell invasion. 
For determination of parasite invasion, 
parasite were pre-treated with 10 μM 
GF120918 for 30 min at 37°C and allowed to 
infect for 4 h host cell monolayers at a 
multiplicity of infection (MOI) of 3 in 
presence of the drug. Alternatively, parasites 
were pre-treated with 10 μM GF120918 for 4 
h, washed, and allowed to infect host cell 
monolayers in absence of the drug. After 
removal of residual extracellular parasites, 
infected cells were incubated for 20 h in 
absence of the drug and invasion was 
quantified by enumerating the parasite 
vacuoles per field.  
For adhesion/invasion assay, parasites were 
pre-treated with 10 μM GF120918 for 30 min 
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at 37°C and allowed to infect host cell 
monolayers at MOI 3 for 2 h in presence of 
the drug. Alternatively, drug pre-treatment 
was omitted and 10 μM GF120918 added at 
the time of invasion. Parasites were analyzed 
by dual color immunostaining with anti-T. 
gondii antiserum to differentiate adherent 
(extracellular + intracellular) and invaded 
(intracellular) parasites, as described [63]. 
For determination of parasite replication, host 
cell monolyers were infected at a MOI of 3; 
and parasite burden was quantified after 24 
hrs by direct parasite counting or after 48 or 
72 hrs by colorimetric detection of parasite β-
galactosidase using chlorophenol red-β-D 
galactopyranoside as substrate, as described 
[64]. During inhibitor analyses, GF120918 
was added 2 h after infection at the 
concentration indicated in the figure legends. 
Bradyzoite differentiation was induced in 
vitro by alkaline treatment as described [65]. 
Briefly, T. gondii tachyzoites were allowed to 
infect a host cell monolayer for 2 h and then 
the medium was replaced with RPMI-1640 
containing 1g/L NaHCO3 and 50mM tricine 
that had been adjusted to pH 8.1 with NaOH. 
Cultures were incubated at 37°C and ambient 
CO2 for 4 days. 
Cell viability of parasites was tested by trypan 
blue exclusion; metabolic activity of host 
cells was tested by using the AlamarBlueTM 
assay (BioSource, Camarillo, CA), according 
to the manufacturer instructions. 
P-glycoprotein functional assay. P-gp activity 
was assessed by cellular retention of the P-gp 
substrate rhodamine 123 (Rho). Briefly, cells 
were incubated with 0.5 mg/mL Rho in PBS 
for 30 min at 37˚C in presence or absence of 
GF120918, at the concentrations indicated in 
the figure legends. After washing in PBS, 
cells were incubated in medium at 37˚C in 
absence or presence of the inhibitor for the 
time points indicated in the figure legend. The 
kinetic of rhodamine retention was quantified 
using a FACSCalibur flow cytometer (Becton 
& Dickinson, Basel, Switzerland).  
Motility assay. Motility was assayed by trail 
deposition visualization, as described [38] 
with the following modifications. Freshly 
harvested parasites were resuspended in 
HBSS containing 1% FCS and 10 mM Hepes, 
pre-treated with 10 μM GF120918 or DMSO 
for 15 min at 4°C, then added to poly-lysine 
coated slides (Thermo Fisher, Portsmouth, 
NH) for 15 min at room temperature and 
allowed to glide for 30 min at 37°C. After 
buffer removal, parasite trails were fixed in 
PBS containing 3.6% formaldehyde, blocked 
and stained with anti-T. gondii antiserum, 1: 
400 dilution,   followed by Alexa 488-
conjugated goat anti-rabbit IgG, 1:200 
dilution. 
Egress. Egress was assayed as described [66], 
with the following modifications. P-gp DKO 
MEF monolayers were grown on 10-well 
glass slides (Thermo Fisher, Portsmouth, 
NH), infected with T. gondii at an MOI of 3 
and parasites were allowed to replicate for 30 
h at 37°C. 10 μM GF120918 was added in the 
last 4 h of replication, then cells were fixed 
with 3.6% formaldehyde, blocked and stained 
with anti-T. gondii antiserum, 1: 2000 
dilution,   followed by Alexa 488-conjugated 
goat anti-rabbit IgG,1:200 dilution. For 
induced egress, infected monolayers were 
treated with 10 μM GF120918 as before, 
washed, incubated with 1 μM A23187 in 
warm HBSS buffer for 10 min at 37°C and 
stained as described before. Lysed and intact 
vacuoles were quantified and egress was 
expressed as percentage of lysed vacuoles out 
of the total vacuoles present in a given field. 
Antibody production.  T. gondii P-gp 
minigene was obtained by fusing three 
sequences of the parasite protein (aa 1-52, 
295-331, 625-755) showing low degree of 
similarity with the mammalian P-gp.  
Oligonucleotides (5'-3' orientation) used in 
this study were: 
III Manuscripts                                                                                                            Manuscript 2 
 
 
52
s1 BamHI  
CGGGATCCATGGCCACCTCAGACGACT
CATC, as1 XbaI GCTCTAGA TTCT 
GTTCCAGAGACGAAGTGGAAC, s2 XbaI 
GCTCTAGAGGACAAGTGATCTCCGAC
GGA 
TTG, as2 EcoRI CGGAATTC 
AGCGTCGCCACCCTGAAACTCCAG, s3 
EcoRI 
CGGAATTCATGAAAGACGAGAGCGGT
CTG, as3 HindIII 
CCCAAGCTTAGGCCAGTAG 
CGGAGAGCGAG. 
The P-gp minigene was inserted downstream 
of the maltose binding protein (MBP) in the 
plasmid vector pMal-2Cx (New England 
Biolabs, MA). The fusion protein was 
produced in transgenic Escherichia coli by 
induction with 0.3 mM IPTG (isopropyl-β-D-
thiogalactopyranoside) for 2 h at 37°C. 
Following protein isolation by affinity 
purification on amylose resin according to the 
manufacturers protocol (New England 
Biolabs, MA), P-gp minigene was dialyzed, 
lyophilized and 150 µg used to immunize 
intraperitoneally with RIBI adjuvant (Corixa, 
Hamilton MT, USA) NMRI mice on days 0, 
15, and 30 and 50.  
Immunofluorescence analysis. Host cells 
infected with T. gondii or extracellular 
parasites were fixed in 3.6 % formaldehyde, 
permeabilized with 0.2% Triton X-100 in 
PBS for 20 min, when indicated in the figure 
legends, blocked and incubated with primary 
antibodies for 1 h. The primary antibodies 
used in this study were: anti-T. gondii 
tachyzoite rabbit antiserum [67], 1:2000 
dilution, anti-T. gondii MIC2 monoclonal 
antiserum, 1:1000 dilution; anti-T. gondii 
VP1 rabbit antiserum, 1:2000 dilution; anti-T. 
gondii BAG1 rabbit antiserum [68], 1: 250 
dilution; anti-T. gondii P-gp minigene mouse 
antiserum, 1:250 dilution. Fluorophore-
conjugated secondary antibodies were used at 
1: 200 dilution. Nuclei were visualized with 
4', 6-diamidino-2-phenylindole (DAPI). 
Microscopy analyses were performed on a 
Leica DM IRBE fluorescence microscope or 
on a Leica SP2 AOBS confocal laser-
scanning microscope (Leica Microsystems, 
Wetzlar, Germany), using the appropriate 
settings. Image stacks of optical sections were 
further processed using the Huygens 
deconvolution software package version 2.7 
(Scientific Volume Imaging, Hilversum, NL). 
Transmission electron microscopy analysis. 
P-gp DKO host cells were grown in 75 cm2 
flasks, infected with T. gondii tachyzoites at 
MOI 1 and incubated at 37°C for 24 h prior to 
fixation with 3% paraformaldehyde and 0.5% 
glutaraldehyde. Ultrathin sections were 
stained with anti-P-gp C219, 1:2 dilution, 
followed by 10 nm gold conjugated anti-
mouse antibodies, or double labeled with anti-
P-gp C219, followed by 15 nm gold 
conjugated anti-mouse antibodies, and anti-
VP1, 1:250 dilution, followed by 5 nm gold 
conjugated anti-rabbit antibodies. Sections 
were counterstained with uranyl acetate and 
lead citrate and analyzed in a transmission 
electron microscope (CM12, Philips, 
Eindhoven, The Netherlands) equipped with a 
CCD camera (Ultrascan 1000; Gatan, 
Pleasanton, CA) at an acceleration voltage of 
100 kV. 
Lipid analyses. For analysis of T. gondii lipid 
synthesis, purified parasites were labeled with 
0.5 μCi/mL [3H]palmitic acid  or 4 μCi/mL 
[3H]choline for 3 h in DMEM supplemented 
with 10% FCS. After extensive washing with 
PBS and 0.05% fat free BSA in PBS, lipids 
were extracted according to [69] and aliquots 
corresponding to equal protein content were 
separated by high performance thin layer 
chromatography (HPTLC) on Silica Gel 60 
plates using chloroform/methanol/25% 
NH4OH (65:25:4.5). Radiolabeled bands were 
visualized by use of a tritium-sensitive screen 
(Perkin-Elmer, Boston, MA) in a Personal 
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Molecular PhosphoImager FX (Biorad), 
identified according to co-migrating standards 
(Avanti Polar Lipids, Alabaster, Alabama) 
visualized by iodine vapors and quantified 
using ImageQuant software (Amersham, 
Otelfingen, Switzerland). For determination 
of radioactivity associated with total cell 
extract or lipid fraction, labeled cells aliquots 
were solubilized in 0.1N NaOH or lipid 
extracted as described above and radioactivity 
measured by liquid scintillation. 
Semi-quantitative real time-PCR (RT-PCR). 
RNA was isolated from 107 parasites isolated 
from WT or P-gp DKO host cells after five 
lysis cycles using an RNAeasy kit (Qiagen, 
Stanford, CA) following the “Animal Cells 
Spin” protocol. Residual genomic DNA was 
removed with DNase I digestion according to 
the manufacturer’s protocol. First strand 
cDNA synthesis was performed using ~250 
ng RNA and Omniscript reverse transcriptase 
(Qiagen), according to manufacturer’s 
protocol. Amplification was performed in an 
iCycler iQ (Biorad, Hercules, CA) Primer 
pairs (5'-3' orientation) used for amplification 
of parasite tubulin (TUB), and P-gp were: 
T.gTUB s CCAGGAGATGTTCAAG, 
T.gTUB as 
ACTCGGACACCAGGTCGTTC, T.gPgp s 
AAGGACAGCCGAAGGAAGAC, T.gPgp 
as GATGATGTCCGTCTGTGAC.  Control 
PCR showed absence of contamination from 
host cell RNA or parasite genomic DNA. To 
assess the efficiency of the amplification 
reactions, standard curves for every primer 
pair and cDNA were generated from six-fold 
serial dilutions in duplicate, using the iQ5 
software. Expression levels of the genes were 
given as values in arbitrary units relative to 
the amount of the constitutively expressed 
house-keeping gene tubulin. 
Western blot analysis.  Cell lysates for 
immunoblots were prepared by sonicating 
cells at 107/ml in 50 mM Tris-HCl (pH 6.8), 
10% glycerol, 2% SDS, 5 mM DTT, 0.5 mM 
phenylmethylsulfonylfluoride and complete 
protease inhibitor mixture (Calbiochem). 
Samples corresponding to 40 μg proteins 
were mixed with SDS-PAGE loading buffer 
and incubated 10 min at room temperature to 
prevent P-gp aggregation. Samples were 
separated on 7.5% SDS-PAGE gels, 
transferred to nitrocellulose membranes, and 
probed using anti-P-gp C219 (1: 50), anti-T. 
gondii P-gp  minigene (1:1000) and anti-
tubulin (1:2000) antibodies. Immunoreactive 
bands were visualized with horseradish 
peroxidase-conjugated secondary antibodies 
and enhanced chemiluminescence (ECL). 
Determination of protein concentration. 
Protein content was determined using the Bio-
Rad Protein Assay according to the 
instructions provided by the manufacturer. 
Bovine serum albumin was used for the 
standard curve. 
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Figure S1: Detection of P-gp in T. gondii. A. Immunoblot analysis of T. gondii extracts probed with the 
P-gp specific monoclonal antibody C219 or with the anti-T. gondii P-gp minigene antibody. Tubulin 
staining was used as a loading control. Due to the low levels of P-gp expression compared with tubulin, 
probed membranes were exposed for different times to record unsaturated signal for both proteins. B. 
Protein sequence alignment of T. gondii P-gp (Tgmdr1) with the two mouse homologues. Highlighted in 
yellow are the sequences used to create the P-gp minigene fusion protein. Red box, sequence used in a 
previous study [1] to raise antibodies specific for T. gondii P-gp. Green box, epitope recognized by the P-
gp specific monoclonal antibody C219. Gene bank accession numbers: T.g mdr1, DQ094188; Mmdr1a, 
NP_035206; Mmdr1b, NP_035205. 
1. Schmid A, Sauvage V, Escotte-Binet S, Aubert D, Terryn C, et al. (2009) Molecular characterization 
and expression analysis of a P-glycoprotein homologue in Toxoplasma gondii. Mol Biochem Parasitol 
163: 54-60. 
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SUMMARY 
Histone modification is an important mechanism regulating both gene expression and the establishment 
and maintenance of cellular phenotypes during development. Regulation of histone acetylation via histone 
acetylases (HAT) and deacetylases (HDAC) appears to be particularly crucial in determining gene 
expression patterns. In this study we explored the effect of HDAC inhibition on the life cycle of the 
human pathogen Giardia lamblia, a highly reduced parasitic protozoan characterized by minimized 
cellular processes. We found that the HDAC inhibitor FR235222 increased the level of histone 
acetylation and induced transcriptional regulation of ~2% of genes in proliferating and encysting 
parasites. In addition, our analyses showed that the levels of histone acetylation decreased during 
differentiation into cysts, the infective stage of the parasite. Importantly, FR235222 treatment during 
encystation reversed this histone hypo-acetylation and potently blocked the formation of cysts. These 
results provide the first direct evidence for epigenetic regulation of gene expression in this simple 
eukaryote. This suggests that regulation of histone acetylation is involved in the control of Giardia stage 
differentiation, and identifies epigenetic mechanisms as a promising target to prevent Giardia 
transmission. 
INTRODUCTION 
Regulation of gene expression is a complex process controlled by several molecular mechanisms 
including modification of chromatin structure, activity of sequence-specific DNA binding proteins, and 
post-transcriptional modulation of mRNA levels. Epigenetic histone modifications result in alteration of  
chromatin structure, which in turn induces changes in gene expression (reviewed in (Jenuwein and Allis, 
2001; Kouzarides, 2007)). In general terms, the process of covalent histone acetylation regulates gene 
expression by modifying DNA packaging, with histone hyperacetylation leading to chromatin 
decondensation and activation of transcription. Conversely, histone hypoacetylation leads to a tighter 
DNA-histone binding, with consequent chromatin condensation and gene silencing. The level of histone 
acetylation is strictly controlled by the concerted activity of histone acetylases (HAT) and deacetylases 
(HDACs), which act as central organizers of chromatin remodeling and gene transcription. The correct 
regulation of HDACs is critical for cellular homeostasis. The importance of a tight control of HDAC 
activity is exemplified by its up-regulation associated with uncontrolled cell growth at the onset of cancer 
(Glozak and Seto, 2007). In this context, considerable efforts have been invested to develop inhibitors of 
HDAC activity (HDACi) as anti-cancer drugs, as HDACi were shown to counteract aberrant cell cycle 
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regulation in cancer cells both in vitro and in vivo (Bolden et al., 2006). In addition, recent studies 
revealed that the activity of HDACs is crucial not only for cell cycle regulation but also for the 
orchestration of development and cell differentiation in different mammalian organs (Haumaitre et al., 
2009; Margueron et al., 2005). Despite these recent advances, our understanding of the roles HDACs play 
remains limited.  
In this study we investigated whether HDAC activity also plays a role in the differentiation process of the 
intestinal pathogenic parasite Giardia lamblia, a protozoan characterized by a highly reduced genome and 
significant minimization of most cellular systems due to secondary reduction (Morrison et al., 2007). In 
this respect, the parasite is a useful model organism to study basic biological processes of other higher 
eukaryotes. The G. lamblia life cycle is comprised of highly motile flagellated trophozoites and quiescent 
cyst surrounded by a protective cyst wall (Gerwig et al., 2002). Differentiation from the trophozoite to the 
cyst stage is critical for the parasite survival in the environment and disease transmission. 
G. lamblia encystation is a complex process that involves both expression of specific proteins and also 
changes in the parasite’s metabolism (Adam, 2001). The encystation process begins with an early phase 
where cyst wall components, including CWPs1-3, are synthesized and accumulated in encystation-
specific secretory vesicles (ESVs). ESVs are formed transiently only during the time of encystation and 
display Golgi-like characteristics (Hehl and Marti, 2004; Lujan et al., 1998; Marti and Hehl, 2003; 
Stefanic et al., 2009), allowing both maturation and export of the CWPs to the cell exterior to form the 
cyst wall. This late phase is completed with the sequential secretion of two layers of cyst wall material to 
the parasite surface 20-24 h after induction of encystation, where it polymerizes to a rigid extracellular 
matrix, the cyst wall.  
Despite recent discoveries in the field of G. lamblia encystation, our understanding of the molecular 
mechanisms initiating and regulating gene expression during this critical process remains incomplete. 
Several factors have been found to be implicated, including kinase and phosphatase-mediated signal 
transduction (Bazan-Tejeda et al., 2007; Ellis et al., 2003; Lauwaet et al., 2007; Pan et al., 2009), arginine 
deiminase activity (Touz et al., 2008), proteinases (Touz et al., 2002a) and dipeptidyl peptidase IV (Touz 
et al., 2002b). In addition, we recently showed that the synthesis of the sphingolipid glucosylceramide is 
also essential for complete cyst formation in G. lamblia (Štefanić et al., submitted). However, much less 
is known about transcriptional regulation of encystation-specific genes. To date only a few putative 
encystation-related transcription factors have been identified and partially characterized in G. lamblia: a 
Myb2 homolog (Huang et al., 2008; Sun et al., 2002), two members of the GARP family (Sun et al., 
2006), one ARID family member (Wang et al., 2007) and a recently described WRKY protein (Pan et al., 
2009). All these transcription factors, whose expression increases during encystation, bind to the short 
promoter of encystation-induced genes and act as trans-activators of transcription. In addition to trans-
activating factors, mechanisms for negative regulation have also been suggested to control CWP 
expression in vegetative trophozoites, including regulation of mRNA stability via the 3’ untranslated 
region (UTR) (Hehl et al., 2000), the nonsense-mediated mRNA decay (NMD) factor UPF1 (Chen et al., 
2008), and presence of  negative cis-acting elements in the CWP promoters (Davis-Hayman et al., 2003). 
Because G. lamblia encystation is associated with clearly detectable changes in mRNA levels and the 
degree of histone acetylation is critical for transcriptional control, we hypothesized that epigenetic 
chromatin modifications via histone acetylation may participate in the modulation of stage differentiation 
in this parasite. To test this, we analyzed whether modifying histone acetylation levels by inhibiting 
giardial HDAC affected parasite encystation.   
 
RESULTS 
Histone acetylation decreases during G. lamblia stage conversion. G. lamblia encystation is regulated 
at the transcriptional level and results in high levels of transcription of encystation-specific genes during 
the first 7-9 h post induction. To investigate whether epigenetic mechanisms dependent on histone  
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Figure 1: Acetylation levels decrease in G. lamblia upon induction of encystation. Trophozoites (T) and 
parasites induced to encyst for 16 h (E) were probed for acetylated lysine (AcK). A. Immunofluorescence analysis 
showing the staining restricted to the nuclei in both stages of the parasite. DAPI, nuclear staining; DIC, 
differential interference contrast. Scale bar: 3 μm. B. Overlay histogram of the FACS analysis showing 
trophozoites (T) and encysting cells (E) stained for AcK. U, unstained cells. Note the decreased intensity of AcK 
staining in encysting cells compared with trophozoites (logarithmic scale on x-axis). 
 
 
 
 
 
 
 
 
 
 
 
 
acetylation are involved in the stage conversion of G. lamblia, we compared the histone acetylation levels 
in trophozoites and encysting cells. To test this, we incubated isolated parasites with an anti-acetyl lysine 
antibody after chemical fixation and detergent permeabilization. Immunofluorescence analysis revealed 
that the labeling was restricted to the nuclei and that it overlapped with DAPI-stained DNA, as expected 
for labeled histones (Fig. 1A). As previously shown for the labeling of methyl-modified histones 
(Dawson et al., 2007), the two giardial nuclei were similarly stained, indicating that the chromatin of both 
nuclei can be modified by the acetylation mark. Importantly, no cross-reaction was observed with 
cytosolic acetylated proteins, including tubulin (Fig. 4B), indicating that the antibody exclusively 
recognizes acetylated proteins restricted to the nucleus.  
Next we quantified the degree of histone acetylation in trophozoites and encysting cells by flow 
cytometry. Our analysis showed that the staining intensity decreased in differentiating trophozoites (Fig. 
1B), suggesting that the levels of histone acetylation are regulated in the parasite in a stage-specific 
manner.  
Characterization of G. lamblia HDAC. As the cellular levels of histone acetylation are maintained by 
the concerted activity of HAT and HDAC enzymes, we investigated whether these enzymes are present in 
the parasite.  
Analysis of the Giardia Genome Database (www.giardiadb.org) revealed the presence of putative 
enzymes responsible for histone modification, including HDACs (Table 1). In mammalian cells, the 
classical HDAC family consists of the ubiquitously expressed class I (HDAC1-3, 8) and the tissue-
specific classes II (HDAC4-7, 9, 10) and IV (HDAC11), while the structurally unrelated class III is 
composed of sirtuin proteins 1-7. Interestingly, the G. lamblia genome codes for only one predicted 
homologue of the classical HDAC family, and four additional predicted sirtuin type 2 family homologues.  
Multiple sequence alignments showed a high level of similarity between the single giardial HDAC and 
orthologues of protozoan and metazoan species (Fig. 2 and Table 2), indicating that the protein is highly 
conserved in this parasite. Importantly the amino acids  thought to be critical for human HDAC1 activity, 
including the residues in the catalytic pocket  that co-ordinate binding to the co-factor Zn2+, and that are in 
contact with the HDAC inhibitor Trichostatin A (Finnin et al., 1999; Vannini et al., 2004) are also present  
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Table 2. Sequence comparison of Gl HDAC with selected orthologues 
Name Identity (%) Similarity (%) AA overlap 
Tg_ HDAC3 48 68 376 
Eh_ HDAC 46 64 377 
Mm_ 
HDAC1 
50 72 368 
Hs_ HDAC1 50 72 368 
Sc_ RPD3 51 69 372 
Hs _HDAC3 45 66 432 
Hs _HDAC8 41 62 368 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
in the giardial HDAC. Interestingly, the predicted giardial HDAC does not possess an AT insertion which 
is typical of Apicomplexa (Bougdour et al., 2009), but contains a unique four-residue insertion in position 
283-286, which is not found in other species.  
To analyze the localization of giardial HDAC, a recombinant variant fused to a C-terminal HA tag was 
expressed in the parasites. Immunofluorescence analysis of transgenic cells revealed that the protein 
localizes to the parasite nuclei, suggesting that the giardial HDAC is likely to function in this subcellular 
location (Fig. 3A). 
To gain further insights into the structure-function basis of giardial HDAC, a homology model was 
generated using the recently resolved structure of human HDAC8 as a template (Fig. 3B) (Vannini et al., 
2007).  The predicted 3-D structure revealed a striking similarity with the human homologue. In addition, 
position and orientation of the active site residues are essentially identical in the giardial and human 
structures, further supporting the predicted catalytic activity of G. lamblia HDAC. 
 
Table 1. Putative histone modifying enzymes in G. lamblia 
Histone acetylases  
GL50803_10666 Histone acetyltransferase GCN5 
GL50803_2851 Histone acetyltransferase MYST2 
GL50803_16639 Histone acetyltransferase Elp3 
GL50803_14753 Histone acetyltransferase type B subunit 2  
GL50803_17263 Histone acetyltransferase MYST1 
Histone deacetylases  
GL50803_3281 Histone deacetylase  I 
GL50803_10707 NAD-dependent histone deacetylase Sir2 
GL50803_10708 Hypothetical protein, Sir2 domain 
GL50803_16569 Transcriptional regulator, Sir2 family 
GL50803_6942 Sir2 family protein 
GL50803_11676 Sirtuin type 2 
Histone methylases  
GL50803_8921 Set-2, putative 
GL50803_13838 Hypothetical protein 
GL50803_13790 Hypothetical protein 
GL50803_9130 Histone methyltransferase HMT1 
GL50803_17036 Hypothetical protein 
GL50803_221691 Histone methyltransferase HMT2 
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To investigate whether the catalytic pocket of giardial HDAC could accommodate HDAC inhibitors, we 
modeled the structure of the protein in complex with the cyclic tetrapeptide FR235222 (Mori et al., 2003), 
a potent inhibitory that was recently shown to specifically target HDAC3 in the Apicomplexan parasite 
Toxoplasma gondii (Bougdour et al., 2009) (Fig. 3C).  The 3-D structure of FR235222 was built using the 
values of the backbone dihedral angles as they are in the NMR solution conformation (Rodriquez et al., 
2006). Three binding modes of FR235222 in the homology model of G. lamblia HDAC were generated 
by manual docking using the program WITNOTP (Armin Widmer, Novartis Pharma, Basel, Switzerland).  
In all binding modes, the long side chain of FR235222 was positioned in the deep pocket of HDAC with 
the ketone moiety at the tip of the side chain chelating the zinc. The three binding modes differ from each 
other in the orientations of the phenylalanine, isovaline, and 4-methyl-proline side chains on the rim of 
the deep pocket. Each binding mode was energy minimized with rigid protein and zinc atom using the 
TAFF force field (Clark et al., 1989). Upon energy minimization there is good surface complementarity 
in all of the three binding modes.  Furthermore, the binding energy is similar in the three minimized 
structures, which is consistent with the heterogeneity of orientations observed for a set of inhibitors of 
human HDAC 8 (Dowling et al., 2008). 
Figure 2: Multiple sequence alignment of selected deacetylases. Protein sequence alignment of 
giardial HDAC with selected orthologues. Indicated are the residues important for catalytic activity and 
involved in zinc and TSA binding, based on crystal structure of related HDAC (Finnin et al., 1999; 
Vannini et al., 2004). The four residues of the G. lamblia-specific insertion are boxed. Alignments were 
performed with Multalin (http://bioinfo.genopole-toulouse.prd.fr/multalin/). Gene bank accession 
numbers: GlHDAC (AAU89077), TgHDAC3 (AAY53803; ToxoDB accession no. 42.m00014), 
EhHDAC (AAV33348), HsHDAC1 (CAG46518), HsHDAC3 (NP_003874.2), HsHDAC8 (AF245664), 
MsHDAC1 (AAI08372), ScRPD3 (AAB20328). 
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Inhibition of HDAC increases histone acetylation levels in G. lamblia. Because the stage conversion of 
G. lamblia correlated with decreased levels of histone acetylation, we investigated whether reversing the 
decrease in acetylation by inhibiting HDAC could prevent parasite encystation. To this aim, we tested in 
the parasite the inhibitory activity of FR235222, the potent HDAC inhibitor which was predicted to fit in 
the active site of G. lamblia HDAC in our 3-D model. Immunofluorescence and quantitative analysis by 
flow cytometry revealed that treatment with FR235222 increased acetylation levels in encysting parasites 
(Fig. 4A). Selected subtypes of HDACs have been shown to target cytosolic non-histone proteins, 
including tubulin (Schemies et al., 2009). In our experiments, FR235222 treatment did not increase the 
acetylation levels of tubulin (Fig. 4B), implying not only that the inhibitor is not affecting the activity of 
other cellular deacetylases in a non-specific manner, but also that the single giardial HDAC is likely not 
able to accept tubulin as a substrate. In addition, nuclear basic proteins were isolated by acid extraction 
and probed for acetylation (Fig. 4C).  Distinct acetylated proteins were identifiable in the region of 11- 16 
Figure 3: Characterization of G. lamblia HDAC. A. Fluorescence analysis of parasites expressing 
recombinant giardial HDAC fused to a C-terminal HA tag and encysted for 16 h. Cells were co-stained for 
nuclei (DAPI). DIC: differential interference contrast image. Scale bars: 3 μm. B. 3-D homology model of 
GlHDAC (upper panel) built with the SWISS-MODEL program and X-ray structure of HsHDAC8 (lower panel) 
used as a template. Key residues of the active-site are violet (Asp 101, His 142, Phe 152, Phe 208, Tyr 306 in 
HsHDAC8; Asp 94, His 135, Phe 145, Phe 201, Tyr 303 in GlHDAC). The four amino acids of GlHDAC 
insertion are blue. The GlHDAC region not covered by the HsHDAC8 template is red. C. Predicted binding 
mode of FR235222 (sticks) in the homology model of GlHDAC (surface rendering). The energy minimization 
was performed with rigid protein. The atoms of FR235222 are colored according to atomic element with carbon 
in yellow, nitrogen in blue, oxygen in red, and hydrogen in gray.  Hydrogen atoms on the side chains are not 
shown to avoid overcrowding.  The polar surface of HDAC is colored according to atomic element (nitrogen in 
blue and oxygen in red) while the nonpolar surface is green.  The zinc atom is the white sphere that is visible 
only partially at the bottom of the deep pocket close to the center of the image.  The long side chain of 
FR235222 fits nicely in the cavity, and the two oxygen atoms at its tip chelate the zinc atom. Figure prepared 
with the program PyMOL (DeLano Scientific, USA).
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kDa, corresponding with the predicted masses of histone proteins in Giardia (Triana et al., 2001). 
Importantly, their acetylation level specifically increased in the presence of FR235222. Histone identities 
of the bands in the 11- 16 kDa region were further confirmed by mass spectrometry analysis (Fig. S1). 
Collectively, our data provide strong evidence that treatment with the HDAC inhibitor FR235222 induced 
histone hyper-acetylation in the parasite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: FR235222 treatment increases acetylation levels of encysting cells. A. Encysting parasites were 
treated with 2 μM FR235222 (FR) or solvent (cntl), as described. Cells were analyzed by immunofluorescence 
(left panels) after staining with anti-acetylated lysine (AcK) (A) or anti-acetylated tubulin (AcTUB) antibodies 
(B). DAPI, nuclear staining. Scale bar: 3 μm. The level of AcK and AcTUB upon FR235222 treatment was 
quantified by flow cytometry (right panels). Overlay histograms showing cells unstained (U), treated with 
solvent (Cntl) or 2 μM FR235222 (FR). Note the increased AcK signal in presence of the drug. C. Encysting 
cells were treated with 2 μM FR235222 (FR) or solvent. 16 μg of acid-extracted protein were separated by 
SDS-PAGE and probed with anti-acetylated lysine antibody. Note the increased acetylation of proteins with the 
predicted mass of giardial histones (asterisks) in presence of the HDAC inhibitor. 
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FR235222 inhibits expression of cyst wall proteins in encysting G. lamblia. Having shown that 
FR235222 treatment induces histone hyper-acetylation in G. lamblia, we next evaluated whether 
increased acetylation levels prevented parasite stage conversion to cysts. Induction of encystation results 
in high levels of expression of the main structural cyst wall proteins (CWPs). Immunofluorescence 
analysis of CWP1 expression in induced cultures revealed a considerably decreased number of cysts in 
the inhibitor-treated sample compared with control cells (Fig. 5A). In addition, the few cysts produced in 
presence of FR235222 were less viable than the control sample (Fig. 5D). To determine whether the low 
number of cysts was due to a reduced CWP1 expression or a defect of protein secretion and consequent 
accumulation in the cell interior, we quantified the protein expression in detergent-permeabilized cells. 
Population-wide analysis by flow cytometry showed that FR235222 severely impaired expression of 
CWP1 (Fig. 5B). Interestingly, while the maximal inhibition of CWP1 expression was obtained by pre-
treating the cells with FR235222 prior to induction of encystation, a substantial decrease of CWP1 protein 
level was also observed in the absence of drug pre-treatment, indicating a rapid effect of the inhibitor on 
CWP1 synthesis (Fig. S2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: FR235222 treatment inhibits G. lamblia encystation. A. Encysting parasites were treated 
for 24 h with 2 μM FR235222, as described in the experimental procedures section. Cells were stained 
with anti-cyst wall protein 1 (CWP1) antibody without permeabilization and analyzed by 
immunofluorescence. Note the decreased number of cysts in the treated sample. DAPI, nuclear staining. 
B. Encysting parasites were treated as in (A), permeabilized and stained for CWP1 followed by flow 
cytometry quantification. Overlay histogram showing cells unstained (U), treated with solvent (Cntl) or 
2 μM FR235222 (FR).  C. Encysting parasites were treated with the indicated concentrations of 
FR235222 (FR) or solvent (Cntl), stained for CWP1 after permeabilization and analyzed by flow 
cytometry. The amount of cells with M1 fluorescence is expressed as percentage of total cell number 
(TOT). Note the dose-dependent decrease in CWP1 expression upon drug treatment. D. Viability of 
cysts following drug treatment was tested by trypan blue exclusion. Results of a representative 
experiment are presented as percentage of control ± standard errors (n = 3). E. Immunofluorescence 
analysis of treated parasites as in (B). Note the normal morphology of encystation-specific vesicles 
(ESV, arrow) containing CWP1 in both treated and control samples. DAPI, nuclear staining; DIC, 
differential interference contrast. Scale bar: 3 μm. F. Encysting parasites were treated with the indicated 
concentrations of HDAC inhibitors apicidin (API), Trichostatin A (TSA), scripaid (SC) and HC-toxin 
(HC) and CWP1 expression was quantified by flow cytometry after permeabilization. The amount of 
cells with M1 fluorescence is expressed as percentage of total cell number (TOT). The analysis revealed 
that all the compounds tested inhibited the expression of CWP1.  
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Next we performed a dose-response analysis to determine the potency of the FR235222-mediated 
inhibition of G. lamblia encystation. Flow cytometry quantification revealed that FR235222 was effective 
in inhibiting CWP1 expression already at low nanomolar concentration (Fig. 5C). 
In addition, we tested whether FR235222 treatment inhibited not only CWP1 expression, but also altered 
the protein’s intracellular distribution, a phenotype we recently described when parasite encystation was 
blocked following inhibition of sphingolipid synthesis (Štefanić et al., submitted). Immunofluorescence 
analysis of encysting parasites showed that both in control cells and in the minor proportion of 
FR235222-treated cells with detectable CWP1 levels, the protein was mainly localized in ESVs with 
typical morphology, indicating that formation of these compartments was not compromised (Fig. 5E).  
To further confirm that the FR235222 inhibition of G. lambia encystation was indeed a specific effect, 
additional known HDAC inhibitors, i.e., apicidin, TSA, scripaid and HC-toxin, were tested. All the 
inhibitors were highly effective in reducing CWP1 expression, as assessed by flow cytometry analysis 
(Fig. 5F) and enumeration of CWP1-expressing parasites by manual counting (Fig. S4). Collectively, our 
data indicate that exposure of encysting cells to HDAC inhibitors severely compromised the encystation 
process by preventing induction of CWP expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: FR235222 treatment does not reduce the expression of constitutive proteins. A. Encysting 
parasites were treated for 24 h with FR235222, as described. Flow cytometry quantification of Sar1, protein 
disulfide isomerase 2 (PDI2) and clathrin (CLH) showed that the protein expression did not decrease upon 
inhibitor treatment. Overlay histograms showing cells unstained (U), treated with solvent (Cntl) or 2 μM 
FR235222 (FR). B, schematic representation of Sar1-HA construct. C. Engineered parasites expressing Sar1-HA 
under control of CWP1 promoter were treated as in (A), stained for recombinant Sar1 using an anti-HA antibody 
and quantified by flow cytometry. Overlay histogram showing cells unstained (U), treated with solvent (Cntl) or 
2 μM FR235222 (FR).  D. The same engineered parasites were additionally probed for endogenous CWP1 
expression. The amount of cells with M1 fluorescence is expressed as percentage of total cell number (TOT). 
Note the decreased expression of both proteins upon inhibitor treatment.  
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FR235222 treatment does not down-regulate the expression of constitutively-expressed proteins. 
Next we asked whether FR235222-mediated down-regulation of protein expression took place at a global 
level or it was specific for encystation-induced protein. We tested this by quantifying the degree of 
regulation of constitutively-expressed proteins. The cellular levels of three unrelated endogenous proteins 
(namely the small GTPase Sar1, the endoplasmic reticulum-resident protein disulfide isomerase 2 (PDI2) 
and clathrin), which are involved in the secretory transport of CWP protein but whose expression is not 
stage-regulated, were monitored in encysting cells treated with FR235222. Flow cytometry quantification 
using antibodies against these three proteins revealed that none of them decreased in presence of the 
inhibitor (Fig. 6A), indicating that HDAC targeting does not result in a general reduction of protein 
expression.  
We next tested whether the elements responsive to FR235222 regulation were located in the non-coding 
flanking regions of CWP1. To do this, 120 nucleotides of CWP1 5’ untranslated region (UTR) flanking 
region containing the CWP1 promoter (Hehl et al., 2000) were cloned in front of recombinant Sar1 fused 
to a N-terminal HA tag as a reporter, followed by 180 nucleotides of 3’sequence flanking the CWP1 
ORF, containing the poly A addition site (Fig. 6B). Transgenic parasites were obtained by stable 
integration of the construct into the parasite genome. Similar to the observed inhibition of endogenous 
CWP1, FR235222 treatment down-regulated the expression of the Sar1-HA reporter in engineered 
parasites (Fig. 6C, D). Drug-mediated inhibition of Sar1-HA expression was also observed in parasites 
transiently transfected with an analogous construct which was maintained episomaly (not shown). These 
results show that the short regions flanking the CWP1 ORF and containing all elements necessary for 
stage-regulated expression of CWP1 were sufficient for preventing CWP1 induction in response to 
FR235222 treatment. 
FR235222 does not inhibit G. lamblia replication. FR235222 treatment was shown to efficiently block 
the replication of Apicomplexan parasites with an EC50 of 10 nM (Bougdour et al., 2009). Interestingly, 
when G. lamblia were incubated with FR235222 up to 2 μM, no reduction of replication was observed in 
encysting parasites and only a modest inhibition in trophozoite cultures (Fig. 7A). This result indicates 
that the increased levels of histone acetylation induced by FR235222 were not caused by toxicity or dying 
parasites. Next we tested the sensitivity of the parasite to other HDAC inhibitors. Neither treatment with 
apicidin, nor with scripaid or HC-toxin up to 2 μM affected parasite replication (data not shown). In 
contrast, treatment with trichostatin A (TSA) severely inhibited replication of both parasite stages at 
nanomolar concentrations; as TSA is a broad range inhibitor of cellular deacetylases (Blagosklonny et al., 
2002), is it conceivable that the block of replication is due to a non-specific activity toward other essential 
proteins.  Taken together, these results show that treatment with HDAC inhibitors which are known to 
affect replication in other species, often did not have the same inhibitory effect on G. lamblia replication.  
Given the close association of Giardia with the hosts’ intestinal epithelial cells, we tested whether 
FR235222 was detrimental for mammalian cells.  Four intestinal and fibroblast cell lines were grown to 
sub-confluence (Fig. 7B) or confluence (not shown), exposed to the drug, and their metabolic activity was 
quantified as a measure of cell viability. At both confluencies, 24 h of treatment with 0.02 μM FR235222 
(a concentration which blocks G. lamblia encystation) did not affect metabolic activity of the intestinal 
cells and only moderately reduced the activity in the fibroblasts. Higher inhibitor concentrations up to 2 
μM induced different responses in different cell types, ranging from no alteration in viability in Caco-2 
cells to 50% inhibition in fibroblasts.  Moreover, inhibitor-mediated toxicity was not induced during co-
culture of intestinal cells with G. lamblia (Fig. S3). These results indicate that FR235222 treatment at 
concentrations inhibitory for G. lamblia encystation did not reduce the viability of mammalian intestinal 
cells. 
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FR235222 treatment of trophozoites does not induce stage conversion. Our findings revealed that 
increasing the levels of histone acetylation with FR235222 treatment during encystation blocked stage 
differentiation in G. lamblia. To further investigate the hypothesis that acetylation must decrease to allow 
differentiation, we evaluated whether pharmacologically increased acetylation in trophozoites would keep 
Figure 7: FR235222 treatment of trophozoites does not induce parasite encystation. A. Trophozoites 
(T) and encysting parasites (E) were treated for 24 h with 2 μM of the HDAC inhibitors FR235222 (FR), 
apicidin (API), Trichostatin A (TSA), 0.2 μM TSA or solvent (cntl). Parasite numbers are expressed as 
percentage of untreated samples (cntl). Data are average ± SE (n=9) of a representative experiment done in 
duplicate. B. Viability of mammalian cells treated for 24 h with solvent (cntl) or FR235222 at the indicated 
concentrations was assessed by measuring AlamarBlue reduction (Biosource). Results of a representative 
experiment are presented as percentage of control ± standard errors (n = 3). C. Trophozoites were treated for 
24 h with FR235222 and levels of AcK (left panel) and acetylated tubulin (right panel) were quantified by 
flow cytometry. Overlay histograms showing cells unstained (U), treated with solvent (Cntl) or 2 μM 
FR235222 (FR). D. Trophozoites were treated for 24 h with 2 μM FR235222 (FR), apicidin (API), 
Trichostatin A (TSA), or solvent (cntl) and probed for CWP1. Overlay histogram of the treated cells is 
shown. U, unstained cells. Note the absence of CWP1 induction upon drug treatment. E. Cells were treated 
for 24 h with 2 μM FR235222 (FR), Trichostatin A (TSA), 0.2 μM TSA or solvent (cntl) and analyzed by 
immunofluorescence. Number of parasites expressing CWP1 was expressed as percentage of the total 
number of parasites, assessed by nuclear staining, ± standard errors (n = 6). 
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the cells at the trophozoite stage or induce parasite differentiation. FR235222 incubation increased histone 
acetylation in trophozoites (Fig. 7C, left panel), although not as potently as in encysting cells (Fig. 4A). 
Importantly, the degree of tubulin acetylation did not change in the presence of the drug (Fig. 7C, right 
panel), indicating that FR235222 was effective in specifically modulating the histone acetylation levels in 
both life stages of the parasite. To test whether HDAC inhibition in trophozoites induced parasite stage 
differentiation, we quantified the expression of the encystation-induced protein CWP1 in presence of the 
HDACi FR235222, TSA or apicidin. Flow cytometry analysis (Fig. 7D) and enumeration of CWP1-
expressing parasites by manual counting (Fig. 7E and S4) did not reveal any increase in CWP1 expression 
in presence of the inhibitors tested compared with control cells. In addition, no giardial 14-3-3 re-
localization to the parasite nuclei was detected in the presence of FR235222 (Fig. S5), as is typically 
observed during parasite encystation (Lalle et al., 2006). Collectively, these data indicate that treatment of 
trophozoites with HDAC inhibitors did not promote but rather decreased the rate of spontaneous 
encystation. 
FR235222 alters gene expression in encysting cells and trophozoites. As changes in histone 
acetylation are known to modulate gene transcription, we used a genome-wide approach to investigate 
whether FR235222 treatment modified the expression of a specific range of genes or induced a general 
modulation of the expression profile in G. lamblia. Transcriptomes of both encysting cells and 
trophozoites cultured in presence or absence of the inhibitor were compared by microarray analysis. 
cDNA was labeled with either Cy5-dUTP (FR235222-treated) or Cy3-dUTP (control), hybridized to a G. 
lamblia microarray, and genes whose expression varied by a minimum of two fold following inhibitor 
treatment were considered significantly regulated (p- value <0.01).  
Overall, 88 genes in encysting cells and 118 genes in trophozoites were found to be differentially 
regulated by FR235222 (Fig. S6), corresponding to ~2% of the 4969 currently predicted Giardia genes, 
and to ~1% of the total 9747 genes, including putative deprecated ones. The majority of the genes were 
up-regulated in both the parasite stages, indicating that HDAC inhibition acted primarily by promoting 
gene transcription of a selected set of genes. However in encysting cells treated with FR235222, induction 
of five genes crucial for parasite encystation was blocked, namely the DNA-binding transcription factor 
Myb2 (Huang et al., 2008; Sun et al., 2002), the three structural proteins forming the protective cyst wall 
(CWP1-3) and glucosamine-6-phosphate deaminase (GNP, also known as G6PI-B), which is involved in 
the biosynthesis of the cyst wall polysaccharide (Knodler et al., 1999) (Fig. 8A). These data also confirms 
that the lack of CWP1 induction in encysting parasites treated with FR235222 is due to reduced mRNA 
levels.  
FR235222 up-regulates the expression of identical genes in the two life stages of the parasite. We 
then compared the transcriptomes of encysting cells and trophozoites to test whether the transcriptional 
response to inhibitor treatment was similar in the two stages of the G. lamblia life cycle. Using Gene 
Ontology predictions of the Giardia Genome database, we grouped the FR235222-regulated genes into 
functional classes. Fig. 8C shows the striking similarity of the gene classes modulated in encysting cells 
and trophozoites. The family of high cysteine membrane proteins (Davids et al., 2006) was a highly 
represented class,  which also showed the highest level of up-regulation. Other highly represented classes 
were kinases of the NEK family, proteins annotated as 21.1 and proteins involved in metabolic functions. 
While many of the regulated genes had gene annotations in the Giardia Genome database, a considerable 
number of the genes indentified in both experimental conditions (38% in encysting cells and 49% in 
trophozoites) were hypothetical proteins of unknown function.  
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The set of genes modulated by FR235222 not only belonged to similar gene classes but also overlapped 
considerably in the two experimental conditions (Fig. 8B, D). Of the 64 genes up-regulated in encysting 
cells, 57 were also found to be up-regulated in trophozoites, while of the 24 down-regulated genes, 9 were 
in common with the trophozoite gene list. No correlation was found in stage-specific gene regulation: in  
Figure 8: FR235222 treatment modulates gene expression. RNA extracted from encysting cells and 
trophozoites treated for 15 h with 2 μM FR235222 or solvent were used for dual channel microarray analysis. The 
comparison of the transcription profiles of treated versus untreated samples are shown. A. Drug treatment of 
encysting cells down-regulated the expression of known encystation-specific genes. Names and Giardia DB 
accession numbers are the following: Myb1-like protein, Myb2, (GL50803_8722); cyst wall protein 1, CWP1, 
(GL50803_5638); cyst wall protein 2, CWP2, (GL50803_5435); cyst wall protein 3, CWP3, (GL50803_2421); 
glucosamine-6-phosphate deaminase, GNP, (GL50803_8245). B. Venn diagram of genes regulated by FR235222 
in encysting cells (E) and trophozoites (T). No prominent overlap of genes regulated by FR235222 was observed 
in the opposite direction: only two genes down-regulated in encysting cells were up-regulated in trophozoites and 
none of the genes up-regulated in encysting cells was down-regulated in trophozoites. C. Functional classes 
defined by Gene Ontology (GO) terms of the FR235222 regulated genes in encysting cells (E) and trophozoites 
(T). D. Pattern of gene up- and down-regulated following FR235222 treatment of encysting cells (E) and 
trophozoites (T). 
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encysting cells only two of the down-regulated genes were up-regulated in trophozoites, and none of the 
up-regulated gene was down-regulated in trophozoites. Interestingly, all of the high cysteine membrane 
proteins identified in our array were up-regulated in both encysting cells and trophozoites (with one 
exception in the trophozoites). Similarly, all the NEK kinases and all but one of the 21.1 proteins were 
up-regulated in both parasite stages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to determine whether the genomic environment plays a role in the expression of FR235222-
regulated genes, we asked whether regulated genes were clustered. All regulated genes were distributed 
on 17 genomic scaffolds and a positive correlation was found between the number of regulated genes and 
the number of genes present on a given scaffold (Fig. S7A). Analysis of the gene position in the genomic 
Figure 9: Confirmation of microarray data. A. RNA extracted from trophozoites and encysting cells treated 
for 15 h with 2 μM FR235222 or solvent were tested by reverse transcriptase (RT)-PCR for the transcription of 
regulated and not regulated gene products. Primer pairs binding to the tubulin (TUB) promoter were used as 
negative control. The obtained amplification products confirmed the gene regulation observed by microarray 
analysis. +, up-regulated; -, down-regulated; NR, not regulated; NT, not transcribed. Right panel, densitometric 
quantification of the relative amount of the gene products upon FR235222 treatment expressed as percentage of 
untreated control (cntl). B. The gene product GL50803_17120, whose expression was up-regulated by 2 μM 
FR235222 in both encysting cells and trophozoites, was HA-tagged and episomaly expressed under control of its 
endogenous promoter. Encysting parasites were treated with 2 μM FR235222 (FR) or solvent (cntl) and the 
expression of the recombinant protein monitored by immunofluorescence (left panel) and flow cytometry (right 
panel) analyses. Note the increased expression of the protein upon drug treatment. DAPI, nuclear staining. U, 
unstained cells. 
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scaffolds revealed that the regulated genes were not distributed in tight clusters containing multiple 
consecutive genes (Fig S7B); in addition, regulated genes belonging to the same gene classes were not 
located in the same genomic location, indicating that physical proximity is not required for FR235222-
induced transcriptional co-regulation. However, statistical approaches based on graphical and numerical 
computations revealed small groups of potentially co-regulated genes which were distributed non-
randomly in scaffolds CH991762 and CH991763 in encysting cells, and in scaffold CH991763 in 
trophozoites (Fig. S7C, S8). The biological significance of these findings remains to be determined. 
Validation of gene expression regulation. To confirm the expression patterns observed by microarray 
analysis, we performed RT-PCR of selected genes using RNA extracted from FR235222-treated 
trophozoites and encysting cells. Specifically, in the trophozoite sample we analyzed two genes whose 
expression was up-regulated upon FR235222 treatment (GL50803_114930 and GL50803_112153), while 
in the encysting cell sample we assessed the abundance of CWP1 transcript, whose expression was down-
regulated upon inhibitor treatment. Analyses of genes which were not regulated by the inhibitor 
(GL50803_ 117204 and GL50803_ 9558) or not transcribed (tubulin promoter sequence(Elmendorf et al., 
2001)) were used as a loading and as a negative control, respectively. In each case, the abundance of 
transcripts detected by RT-PCR confirmed the microarray data (Fig.9A). Importantly, PCR reactions 
using the original, non retro-transcribed RNA as template did not give any detectable products, 
confirming the absence of contamination with genomic DNA (not shown).  
In addition, FR235222-induced up-regulation of gene expression was further confirmed at the protein 
level. A N-terminal HA epitope tagged variant of the gene product, GL50803_17120, whose expression 
increased in both encysting cells and trophozoites upon inhibitor treatment, was expressed in 
trophozoites. As seen in the RT-PCR results, immunofluorescence and flow cytometry analyses 
substantiated the increased expression in presence of the inhibitor (Fig. 9B). Collectively, these results 
unambiguously validate the microarray data both at the transcriptional and translational level. 
DISCUSSION 
G. lamblia encystation is critical for both parasite survival outside the host and disease transmission. 
Despite the considerable amount of information available on G. lamblia encystation at the cellular level, 
the molecular underpinnings of its regulation remain limited. In the present study, we investigated the role 
of epigenetic chromatin modification in the parasite stage differentiation. We found that exposure of 
parasites to the HDAC inhibitor FR235222 increased the levels of histone acetylation, altered gene 
transcription and inhibited G. lamblia encystation, thus providing the first evidence that epigenetic 
mechanisms control stage differentiation in this parasite. Notably, FR235222 treatment effectively 
inhibited CWP1 expression at low nanomolar concentrations, suggesting that the observed phenotype is a 
consequence of specific inhibition of giardial HDAC. In addition, the fact that only 1-2% of predicted 
genes are affected and that clear functional categories are identified, argues against a random off-target 
effect. 
A highly reduced histone deacetylation machinery is present in G. lamblia. G. lamblia has a compact 
genome organization and few identified regulatory elements, consistent with significant reductive 
evolution (Morrison et al., 2007). Thus, this protist is considered an interesting model for investigating 
minimized cellular systems.  Analysis of the parasite genome revealed the occurrence of genes coding for 
putative chromatin modifying proteins, including histone acetylases, deacetylases and methylases, 
suggesting that mechanisms for epigenetic regulation of gene expression are present in this parasite. 
Interestingly, demethylases seem to be absent in G. lamblia, Trichomonas, Entameba histolytica and 
microsporidians, indicating that demetylase activity is dispensable for these parasites or carried out by 
unrelated enzymes (Iyer et al., 2008). 
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Consistent with its reduced cellular machinery, only one classical HDAC homologue is annotated in the 
G. lamblia genome (GL50803_3281) and its nuclear localization further support a deacetylase activity on 
histone proteins. The presence of a single HDAC is in striking contrast with the size of the HDAC 
repertoire found not only in metazoan but also in unicellular protozoa, including the apicomplexan T. 
gondii with 5 putative HDACs. It is worth mentioning that a single representative of HDAC I was 
identified so far in another enteric parasite, Entamoeba hystolitica, suggesting that simplified mechanisms 
for regulating histone acetylation are operational in basal organisms (Ramakrishnan et al., 2004). 
Sequence alignments, 3-D modeling and prediction of inhibitor binding mode highlighted the high degree 
of giardial HDAC conservation, in particular at the catalytic site. Moreover, compared with the five T. 
gondii HDACs, giardial HDAC showed the highest degree of similarity with HDAC3, the target of 
FR235222, further arguing for a specific interaction of the inhibitor with the giardial enzyme.  
Of note, the sequence of giardial HDAC contains a 4 amino acid insertion (position 283-286) not found in 
other species. While amino acid insertions appear to be common in G. lamblia proteins, as exemplified by 
giardial histone acetyl transferase (Morrison et al., 2007), their size is typically larger (20 amino acids on 
average). The significance of the extra amino acids in the giardial HDAC is unknown.  
Histone acetylation regulates stage-specific gene expression during G. lamblia encystation. We 
obtained three lines of evidence indicating that epigenetic mechanisms are involved in regulating 
expression of encystation-specific genes.  Firstly, we observed that the level of histone acetylation 
decreased during encystation, which is consistent with the parasites differentiating to a dormant stage. 
Based on this, we can formulate the hypothesis that the high acetylation levels effectively makes the 
parasite refractory to entering differentiation after going through the S-G2 transition of the cell cycle 
(Bernander et al., 2001). Secondly, we tested this hypothesis by actively increasing the acetylation levels 
during encystation. This reduced the synthesis of a relatively small subset of gene products and 
specifically blocked induction of all known encystation-specific genes. This reveals an as yet unknown 
level of stage-specific control of encystation-specific genes in addition to the regulation by transcription 
factors. Importantly, we showed that short flanking regions of encystation-specific proteins are sufficient 
for the FR235222-mediated inhibition of gene expression, indicating that no distant regulatory elements 
are required for modulation of these genes. Thirdly, we demonstrated that histone hyperacetylation altered 
gene transcription; while the majority of FR235222-responsive genes were up-regulated, the mRNA of 
encystation-specific genes were down-regulated. Taken together, our data indicate that chromatin 
acetylation states plays a key role in the regulation of parasite differentiation by controlling the level of 
gene transcription, possibly by altering the accessibility of the promoter region to Myb2 and other cis-
acting factors implicated in regulation of encystation-specific genes. 
Although we unambiguously showed that increased histone acetylation repressed the transcription of 
encystation-specific genes, this repression challenges the classical view where histone hyperacetylation is 
associated with increased gene transcription. Interestingly, inhibition of stage differentiation in response 
to selected HDAC inhibitors, TSA and HC-toxin, but not apicidin, has also been reported in Entamoeba 
parasites, but the molecular mechanism still remains to be investigated (Byers et al., 2005). 
One plausible explanation is that the repression of encystation-specific gene expression in G. lamblia is 
indirect and occurs via the action of a repressor, which is in turn positively regulated by the increased 
histone acetylation. The identification of negative cis-active elements in the CWP2 promoter (Davis-
Hayman et al., 2003) further supports the presence of a repressor mechanism to maintain low levels of 
encystation-specific proteins during vegetative growth. Block of up-regulation of the trans-activator 
transcription factor Myb2 in presence of FR235222 suggests that the putative repressor may act upstream 
of Myb2 activation. 
In other protozoa such as Toxoplasma gondii and  Entamoeba histolytica it has been proposed that HDAC 
regulation of specific genetic loci is stage-specific, and HDAC inhibition during encystation may de-
repress trophozoite-specific genes in E. histolytica, thus arresting parasite differentiation (Ehrenkaufer et 
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al., 2007; Saksouk et al., 2005). However our findings suggest in several ways that G. lamblia may 
possess a simpler HDAC regulation, namely, (i) only one classical HDAC is found in the parasite 
genome, arguing against the presence of stage-specific differential HDAC expression; (ii) using the 
HDAC inhibitor FR235222, we found increased acetylation in both trophozoites and encysting cells, 
suggesting that giardial HDAC is indeed operational in both parasite stages; (iii) contrary to what was 
observed in T. gondii and E. histolytica (Bougdour et al., 2009; Ehrenkaufer et al., 2007), HDACi 
treatment of trophozoites does not trigger parasite stage conversion, suggesting that a trophozoite-specific 
HDAC engaged in the repression of encystation-specific genes is not present in G. lamblia. On the other 
hand, we showed that the levels of histone acetylation decreased in encysting cells compared with 
trophozoites. While we cannot exclude that this decrease is due to a reduced activity of histone 
acetyltransferases, inhibition of HDAC was sufficient to reverse the phenomenon and to block 
encystation. Hence it is likely that G. lamblia does not rely on several stage-specific HDACs but rather on 
a single HDAC whose activity is differentially modulated in the parasite life stages, possibly by binding 
with different stage-specific partners via its C-terminal domain (Pflum et al., 2001). In this context, the 
regulation of histone acetylases and deacetylases in the different stages of G. lamblia is worthy of careful 
characterization. 
Finally, in light of ever increasing indications that HDACs also function as activators of transcription in 
yeast (Kurdistani and Grunstein, 2003), we cannot dismiss the possibility that the FR235222-mediated 
inhibition of encystation-specific gene expression may be a direct consequence of the blocked HDAC 
activity. Future analyses to determine the acetylation pattern of encystation-specific genes will help to 
further our understanding of the epigenetic regulation mechanisms that control stage differentiation in this 
parasite. 
Whole genome transcriptome regulation upon HDAC inhibition. Our microarray data revealed that 
FR235222 treatment changed gene expression in both encysting cells and trophozoites. The observed 
gene regulation is likely to result from a selective inhibition of giardial HDAC and not due to drug-
induced lethality, as treated parasites were able to replicate normally in presence of the inhibitor. In 
addition, analysis of microarray evidence available in the Giardia Genome Database revealed that all but 
three genes regulated by FR235222 treatment were not regulated during stress induction (not shown), 
indicating that the gene changes of mRNA levels induced by FR235222 do not result from an inhibitor-
induced stress response. Finally, the percentage of genes whose expression was changed by FR235222 
was quite small (~2%) and of a similar range to what reported for the treatment  with the HDACi TCA in 
mammalian cells (Heller et al., 2008) and E. histolytica (Ehrenkaufer et al., 2007). 
Analysis of the modulated genes revealed that, in marked contrast with other cyst-forming parasites T. 
gondii and E. histolytica, treatment of G. lamblia trophozoites with HDACi did not induce the expression 
of encystation-specific genes, suggesting that repression of such genes during the vegetative trophozoite 
stage is not likely to be maintained solely by HDAC activity. 
Further comparison of gene expression in encysting cells and trophozoites showed that the genes sensitive 
to FR235222 were strikingly similar in the two stages of the parasite life cycle. This overlap in expression 
profile emphasizes that the developmental program is accomplished with only very few changes in the 
global expression pattern. Besides hypothetical proteins, the major class of up-regulated genes were high 
cysteine membrane proteins (HCMp), a recently described family (Davids et al., 2006) whose function in 
G. lamblia remains enigmatic. While we found that the expression of 26% of the known HCMp genes is 
modulated by FR235222, only ~1% of the previously mentioned VSP family, also composed of cysteine 
rich proteins, was affected. The result was quite surprising, as histone acetylation of the upstream region 
of VSP was proposed to positively regulate the expression of the single VSP variant present on the cell 
surface at any given time, and thus acting as a master regulator of antigenic variation in G. lamblia 
(Kulakova et al., 2006). The fact that inducing histone hyperacetylation did not result in a general 
increase in VSP expression suggests that the epigenetic histone modification by the acetylation mark may 
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not be sufficient to promote VSP transcription, and that additional mechanisms are required to regulate 
the expression of these proteins. Alternatively, the use of different G. lamblia isolates (WB, prototype of 
Assemblage A in our study, and GS, prototype of Assemblage B in (Kulakova et al., 2006)) might also 
account for some differences in gene regulation, as the two isolates present different phenotypes in vitro 
and in vivo (Franzen et al., 2009; Monis et al., 2009). 
The other two protein families whose expression was modulated by FR235222 were cytoskeletal proteins 
21.1 and members of the NIMA-related protein kinases (NEK) (Morrison et al., 2007). The latter are 
widely represented in eukaryotes, but their role remains poorly characterized. Interestingly, the NEK 
family shows a significant expansion in G. lamblia, where it constitutes the majority of the parasite 
kinome (Morrison et al., 2007). The significance of this expansion is currently unknown. 
Finally, genes of the proteins and protein families significantly affected by FR235222 treatment were 
scattered in different scaffolds of the parasite genome, indicating that HDAC inhibition can modulate the 
expression of functionally related genes independent of their genomic location. It is worth noting that 
statistical approaches identified three examples of non-randomly distributed gene sets in both encysting 
cell and trophozoite transcriptomes. Interestingly, the cluster found in trophozoites contained the CWP1 
gene surrounded by four up-regulated genes. As CWP1 mRNA was found to be slightly up-regulated in 
our trophozoite array without detecting parasite stage differentiation, it is possible that the CWP1 
genomic surrounding may have influenced CWP1 transcription without activation of the complete 
encystation program.  
In conclusion, we showed for the first time that HDAC inhibition increased histone acetylation and 
induced transcriptional changes in G. lamblia, substantiating the presence of an evolutionarily conserved 
mechanism for epigenetic regulation of gene expression in this early divergent parasite. In addition, we 
provided evidence that the HDAC repertoire is highly reduced and the phenotypic and transcriptional 
responses following HDAC inhibition are simpler in G. lamblia than in other cyst-forming parasites, 
indicative of the minimized cellular processes typical of this parasite. Lastly, we discovered that HDAC 
inhibition, while not affecting parasite replication, potently blocked G. lamblia encystation and that short 
flanking regions of encystation-specific proteins were sufficient for the drug-mediated repression of gene 
expression.   Collectively, these results reveal that the transcriptional changes during stage-differentiation 
are under the control of epigenetic regulation, and further illuminate the poorly understood mechanisms 
of gene regulation in this parasite. Additionally, our findings clearly demonstrate that HDAC activity is a 
promising target for pharmacological agents aiming to effectively block the production of G. lamblia 
cysts and thus reduce disease transmission. 
EXPERIMENTAL PROCEDURES  
Biochemical reagents. Unless otherwise stated, all chemicals were purchased from Sigma and cell culture 
reagents from Gibco-BRL. Inhibitor stock solutions were prepared at the following concentrations: 179 
mM FR235222, 1.6 mM apicidin, 1 mM Trichostatin A (TSA), 2.29 mM HC-toxin, 3.06 mM scripaid. 
Inhibitors were freshly diluted to the concentrations required for the individual experiment.   
Parasite and tissue culture. Trophozoites of the Giardia lamblia strain WBC6 (ATCC catalog number 
50803) were grown axenically as described (Sonda et al., 2008). Harvested parasites were counted using 
the improved Neubauer chamber. New subcultures were obtained by inoculating 5x104 trophozoites from 
confluent cultures into new 11 mL culture tubes. Two-step encystation was induced as described 
previously (Gillin et al., 1989) by cultivating the cells for 44 h in medium without bile (pre-encysting 
medium) and subsequently in medium with higher pH and porcine bile (encysting medium). 
Drug treatment of trophozoites was performed by incubating sub-confluent cultures for 24 h with the 
inhibitors at the concentrations indicated in the figure legend of the individual experiments. Drug 
treatment of encysting cells was performed in two steps: 8 h drug incubation in pre-encysting medium and 
III Manuscripts                                                                                                            Manuscript 3 
 
 
 
79
additional 16 h incubation in encysting medium. Viability of cysts following drug treatment was tested by 
trypan blue exclusion (Aley et al., 1994). 
Mammalian cells used in this study were: Caco-2 (human colon adenocarcinoma, ATCC HTB 37), 
Intestine 407 (human embryonic jejunoileum, ATCC CCL-6), primary lung fibroblasts isolated from 6- to 
8-week old mice kindly provided by E. Gulbins (University of Duisburg-Essen, Essen, Germany) and 
mouse embryonic fibroblasts (MEF) kindly provided by A. Schinkel (The Netherlands Cancer Institute, 
Amsterdam, The Nederlands). Cells were routinely cultured in Dulbecco’s modified Eagle medium 
(DMEM) or Minimum Essential Media supplemented with non essential amino acids and sodium 
pyruvate, in case of primary fibroblasts. All media were supplemented with 10% fetal calf serum, 2 mM 
glutamine, 50 U of penicillin/mL, and 50 µg of streptomycin/mL. Cultures were maintained at 37°C with 
5% CO2 in tissue culture flasks and trypsinized at least once a week. 
Expression vector construction and transfection. The plasmid for episomal expression of hemagglutinin 
(HA)-tagged GlHDAC (GL50803_3281) under control of CWP1 promoter was based on the expression 
cassette C1-CWP (Hehl et al., 2000).  The plasmid for stable expression of HA-tagged Sar1 under control 
of CWP1 promoter was engineered as described (Stefanic et al., 2009).  The plasmid for the episomal 
expression of HA-tagged GL50803_17120 was based on the expression cassette C1-CWP where the 
CWP1 promoter was replaced by the endogenous promoter. Oligonucleotides (5'-3' orientation) used for 
the construct were the following: for GL50803_3281, PstI-s 
CGCTGCAGATGCCGCCTTCAAAACCCTC and HA-PacI-as CGTTAATTAACTACGC 
GTAGTCTGGGACATCGTATGGGTAGTTCTCATCTAACCCCGCTTC; for GL50803_17120, XbaI-s 
CGTCTAGACTACTATGGATGAAGCCGAG and HA-NsiI-as 
CGATGCATCGCGTAGTCTGGGACATCGTATGGGTAAATCGTGATGTTGTTAGTTAAAC 
encoding the HA epitope tag for the amplification of 200 bp upstream the starting codon containing the 
endogenous promoter followed by the protein leader sequence; 17120-NsiI-s 
CGATGCATGGTGTCCGCGAAGGAAAATATG and 17120-PacI-as 
CGTTAATTAACTAGCTATAAATGGCTGCAATG for the amplification of the GL50803_17120 
coding sequence. 15 μg of plasmid vector DNA was electroporated (350V, 960µF, 800Ω) into 
trophozoites. For stable genome integration, the plasmid DNA was linearized using SwaI restriction 
enzyme before electroporation. Linearized plasmid targets the G. lamblia triose phosphate isomerase 
locus (GL50803_93938) and integration occurs by homologous recombination under selective pressure 
with the antibiotic puromycin (Jimenez-Garcia et al., 2008).  
Gene expression analysis. Trophozoites were treated for 15 h with 2 μM FR235222 or solvent; encysting 
cells were similarly treated in two steps: 8 h drug incubation in pre-encysting medium and additional 7 h 
incubation in encysting medium. RNA was isolated using an RNAeasy kit (Qiagen, Stanford, CA) 
following the “Animal Cells Spin” protocol. Residual genomic DNA was removed with DNase 1 
digestion according to the manufacturer’s protocol. The integrity of the RNA was analyzed in a 
Bioanalyser (Agilent Technologies Inc., Palo Alto, CA) with “Eukaryote Total RNA Nano Series II” 
settings. 
For dual channel microarray analysis, extracted total RNA was processed using the Amino Allyl 
MessageAmp™II a RNA Amplification Kit (Ambion, Austin, TX) and labelled with N-
hydroxysuccinimidyl ester-derivatized reactive dyes Cy™3 or Cy™5, according to the manufacturer’s 
protocol. After purification, 2 g each of Cy3 or Cy5 labelled aRNA were denatured, added to 
SlideHyb™ Buffer I (Ambion), and hybridized to G. lamblia microarrays version 2 (TIGR) in a Tecan 
HybStation at the Functional Genomics Centre Zurich, Switzerland. The arrays are aminosilane surface 
coated glass slides with 9115 oligonucleotides (70mers) designed to cover the whole G. lamblia WBC6 
strain genome. 
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Prior to hybridization, slides were hydrated and blocked with 150 μl BSA-Buffer (0.1mg/ml BSA, 
0.1%SDS in 3xSSC-Buffer) for 1h at 42°C. After washing, samples were injected and hybridized for 16 h 
at 42°C. Slides were scanned in an Agilent Scanner G2565AA, using laser lines 543 nm and 633 nm for 
excitation of Cy3 and Cy5, respectively. Spatial scanning resolution was 10 μm, single pass. The scanner 
output files were quantified using the Genespotter Software (MicroDiscovery GmbH, Berlin, Germany) 
with default settings and 2.5 μm radius. The median spot intensities were evaluated with the Web 
application MAGMA (Rehrauer et al., 2007) and normalized using the print-tip-wise loess correction of 
the limma package (Smith, 2005). Potential gene-specific dye-effects were estimated from self-self 
hybridizations. Differential expression of genes during FR235222 treatment is reported as the log2 of the 
drug-induced fold-change compared with control treated samples, as well as the p-value for differential 
expression as estimated by the empirical Bayes model implemented in limma.  All reactions were 
performed in triplicate. 
Semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR). 300 ng of the isolated RNA 
described above were mixed with 10 μM k-anchorV primer and cDNA was synthesized using the 
Quiagen Omniscript Kit (Qiagen, Stanford, CA) according to the manufacturer’s protocol. Fifty-fold 
dilutions of cDNA were used as template for PCR amplification using 0.4 μM each of gene-specific 
forward primers and a k-adaptor reverse primer. PCR products were separated on 1.5% agarose gels, 
visualized with ethidium bromide, and images recorded in a MultiImage™ Light Cabinet with 
AlphaEase®FC software (Alpha Innotech, San Leonardo, CA, USA). Primers used in the study are: k-
anchorV, CCGGAATTCGGTACCTCTAGA(T18)V; k-adaptor, CCGGAATTCGGTACCTCTAGA; 
Tubulin, ATTTAGAATTCAAATCAGCAAATTC; 114930, GCCAGGGCCTCATCGAAC; 117204, 
ATACGTGGGGGTGGAGAAC; 112135, CGTCCTCTGCTACTCCTTTG; 9558, 
CGGACCATTACTTCTACGTACT; CWP1, CTGGTACATGAGTGACAACGCT. 
Fluorescence microscopy and flow cytometry analysis. For immunolabeling, harvested cells were washed 
twice in ice-cold PBS, and fixed 3% formaldehyde solution in PBS. Fixed cells were and blocked, with or 
without previous permeabilization with 0.2% Triton X-100 in PBS for 20 min, and incubated with 
primary antibodies for 1 h. The primary antibodies used in this study were: anti-acetyl lysine rabbit 
antiserum (Abcam, Cambridge, MA), 1:500 dilution; anti-acetylated tubulin (Sigma), 1:500 dilution; 
Cy3-conjugated anti-cyst wall protein 1 (CWP1) mouse monoclonal antibody (Waterborne, New Orleans, 
LA), 1:60 dilution; anti-clathrin heavy chain (CLH) mouse antiserum (Marti et al., 2003), 1:2000 dilution; 
anti-protein disulfide isomerase 2 (PDI2) mouse antiserum, 1:1000 dilution; anti-Sar1 mouse antiserum 
(Stefanic et al., 2009), 1:300 dilution; Alexa488-conjugated anti-HA mouse monoclonal antibody (Roche 
Diagnostics GmbH, Manheim, Germany) 1:30 dilution; anti-giardial 14-3-3 (Lalle et al., 2006) 1:50 
dilution, kindly provided by M. Lalle (Istituto Superiore di Sanita’, Rome, Italy). Fluorophore-conjugated 
secondary antibodies were purchased from Invitrogen (Basel, Switzerland.) and used at 1: 200 dilution. 
Microscopy analyses were performed on a Leica DM IRBE fluorescence microscope (Leica 
Microsystems,Wetzlar, Germany) using the appropriate settings. Single cell quantification of fluorescence 
was performed using a FACSCalibur flow cytometer (Becton & Dickinson, Basel, Switzerland).  
Mammalian cells metabolic assay. The metabolic activity of mammalian cells was tested by using the 
AlamarBlue® assay (Biosource, Camarillo, CA). Briefly, mammalian cells were grown to confluence or 
semi-confluence in 96-well plates, incubated for 24 h with FR235222 at the concentrations indicated in 
the figure legend, and processed according to the manufacturer instructions. For co-culture experiments, 
cells were seeded in 96-well plates at in 96-well plates at 3x104 cells/well and incubated for 24 h to 
confluence. Harvested G.lamblia trophozoites were added to the cell monolayers at 6x104 parasites/well, 
followed by 24 h incubation with 2 μM FR235222 and viability assay. 
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Western blot analysis of nuclear proteins.  Encysting cells were treated with 2 μM FR235222 as 
described before. Nuclear extracts were prepared by mild detergent lysis as described (Bougdour et al., 
2009). Briefly, 6x107 cells were collected, washed in ice-cold PBS and resuspended in 700 μL lysis buffer 
(10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol (DTT), 0.5 % NP-40, 1 mM PMSF 
and protease inhibitor cocktail). The nuclear pellet was collected by centrifugation at 10000×g for 10 min 
at 4°C and acid extracted for 2 h by adding 200μL each of 5 M MgCl2 and 0.8 M HCl. Insoluble material 
was removed by centrifuging at 13000×g for 10 min at 4°C and soluble proteins containing basic histones 
were precipitated with 25% TCA. Precipitated proteins were washed twice with ice-cold acetone and 
resuspended in 100μL H2O. Aliquots corresponding to 16 μg of proteins were analyzed by SDS-PAGE on 
a 15% gel followed by Coomassie blue staining and probed, following western blotting, using the 
previously described anti-acetyl lysine rabbit antiserum (Abcam) at 1:2000 dilution. Immunoreactive 
bands were visualized with horseradish peroxidase-conjugated secondary antibodies and enhanced 
chemiluminescence (ECL). 
Determination of protein concentration. Protein content was determined using the Bio-Rad Protein Assay 
according to the instructions provided by the manufacturer. Bovine serum albumin was used for the 
standard curve. 
Mass spectrometry identification of histones. Trophozoites were treated with 2 μM FR235222 for 24 h, 
harvested, washed in ice-cold PBS. 3x107 cells were then resuspended in 500 μL lysis buffer (10 mM 
HEPES, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol (DTT), 0.5 % NP-40, 1 mM PMSF and 
protease inhibitor cocktail) , incubated for 30 min at 4°C and the nuclear pellet was collected by 
centrifugation at 10000×g for 10 min at 4°C. The pellet was resuspended in 5 mL IP buffer (10 mM 
HEPES, 10% glycerol, 5 mM EDTA, 1 % NP-40, 1 mM PMSF), sonicated and incubated with 5 μL anti-
acetyl lysine rabbit antiserum overnight at 4°C, followed by addition of protein-A conjugated beads. After 
incubation at 4°C under rotary agitation for 5 h, the beads were washed, resuspended in 30 μL sample 
buffer, boiled and treated with 3.3 μL iodoacetamide (0.5 M in 1 M Tris-HCl pH 8.0) for 15 min at room 
temperature. Proteins were separated on a 15 % gel, stained using the mass spectrometry-compatible 
SilverQuestTM silver staining Kit (Invitrogen) and the excised bands analyzed by peptide mass fingerprint 
using LC/MS/MS. 
Protein structure prediction. The SWISS-MODEL web service (Arnold et al., 2006; Guex and Peitsch, 
1997; Schwede et al., 2003) was used to build 3-D models of GlHDAC and HsHDAC8. Docking of 
FR235222 in the catalytic site of GlHDAC was performed using the program WITNOTP (Armin 
Widmer, Novartis Pharma, Basel).  Alignments were performed with Multalin 
(http://bioinfo.genopoletoulouse.prd.fr/multalin/) and sequence comparisons were performed using 
Blast2. 
Bioinformatic analyses. For visual identification of cluster candidates, we defined for each scaffold a 
metric Mf based on a potential function f analogous to the gravitational potential of mass points. In 
addition to a constant threshold, we used a linear combination μpot+λ·spot+, based on mean μpot and 
conditional standard deviation spot+ of all potential fields generated by all permutations of gene 
distributions. The metric Mf was used to calculate the cluster hierarchy on all levels by complete linkage. 
All clusters were ranked according to the calculated probability pcluster , based on hypergeometric 
distributions. For the identification of statistically evident clusters, we defined approximate permutation 
tests based on the Null-hypothesis H0 of random and uniform distribution of regulated genes within the 
scaffolds, and the three following test statistics: mean deviation X1 and standard deviation X2 of the 
number of not-regulated genes between two regulated genes, and maximum number of consecutive short 
intervals (≤ k) of non-regulated genes X3,k to account for the cluster size. The distributions of these test 
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statistics were approximated by Monte Carlo sampling 100‘000 random permutations for each scaffold. 
The functions used in this study were: f(x) x≠xi  :=∑(i=1,...,n) 1/(x-xi), f(xi):=c<<0; Mf(x,y)  :=maxz ∈[x,y](|f(x)-
f(z)|); fb(x) bx≠1  :=∑(i=1,...,d) bi/(x-i), fb(x) bx=1 :=c<<0; μpot (x)  := (∑p ∈ P fp(x) )/|P|; (spot+)2 := (∑Q={p|p ∈ P ∧ 
fp(x)>0} (fp(x)- μpot (x))2)/|Q|; pCluster Ca,b,r := Pr{Yb-a-2,n,d=r-2}⋅Pr{Y2,2,n-(b-a-2)=2}, where d = number of genes of 
a scaffold, n = number of regulated genes in a scaffold, x1<x2<…<xn, 1 ≤ xi ≤ d the positions (consecutive  
numbers) of the regulated genes, b = (b1, b2, … , bd) , bi = if(i ≠xi, 0, 1), P = set of all permutations of b, 
Ym,s,t   a hypergeometric random variable as m  draws without replacement from a population of t genes, 
thereof s regulated, Ca,b,r  a cluster {a=x1<...<b=xr} with r elements.  
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Figure S1: Mass spectrometry analysis of histones. Trophozoites were treated with 2 
μM FR235222 for 24 h and histones immunoprecipitated as described in the experimental 
procedures section. Protein were separated by SDS-PAGE, silver stained (left panel) or 
probed with anti-acetylated lysine antibody (right panel). Asterisks indicate the bands 
excised and analysed by LC/MS/MS. TOT, total extract; SN, supernatant after nuclear 
pellet isolation; M, mock IP; αAcK, IP with anti-acetyl lysine rabbit antiserum. 
Figure S2: Time course of FR235222 inhibition of encystation. The effect of 2 μM FR235222 
on encystation was monitored by adding the inhibitor in pre-encysting medium at 0, 1, 3, 7 h 
before inducing encystation for 16 h in presence of 2 μM FR235222. Parasites were stained for 
CWP1 and analyzed by flow cytometry. Left panel, overlay histogram showing cells unstained 
(U), solvent treated (Cntl) and pre-treated for 7 h with 2 μM FR235222 (FR).  Right panel, the 
amount of cells with M1 fluorescence is expressed as percentage of total cell number (TOT). 
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Figure S3: Viability of FR235222 treated 
intestinal cells co-cultured with G. lamblia. 
Caco-2 and CCL-6 cells were cultured with or 
without G. lamblia trophozoites of the WBC6 
strain (WB) for 24 h in presence of solvent 
(cntl) or FR235222 at concentrations not 
affecting the viability of the cells (2 and 0.02 
μM, respectively). Viability was assessed by 
measuring AlamarBlue reduction (Biosource). 
Results of a representative experiment are 
presented as percentage of control treated 
cells cultured in absence of G. lamblia (± 
standard errors, n = 3). WB bars, G. lamblia 
trophozoites cultured without intestinal cells. 
Figure S5: FR235222 treatment of 
trophozoites does not induce nuclear 
translocation of 14-3-3. Trophozoites 
were treated for 24 h with 2 μM 
FR235222 (FR) or solvent (cntl), stained 
with anti-giardial 14-3-3 antibody and 
analyzed by immunofluorescence. DAPI, 
nuclear staining. Scale bar: 3 μm. 
Figure S4: CWP1 expression upon 
FR235222 treatment. Trophozoites (T) and 
encysting cells (E) were treated for 24 h with 
2 μM FR235222 (FR), apicidin (API), or 
solvent (cntl) and analyzed by 
immunofluorescence. Number of parasites 
expressing CWP1 was expressed as 
percentage of the total number of parasites 
(TOT), assessed by nuclear staining, ± 
standard errors (n = 6). 
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Figure S6: List of FR235222 regulated genes. Microarray analysis was performed on encysting cells (E) and 
trophozoites (T) treated with 2 μM FR235222, as described in the Experimental procedures section. Genes 
whose regulation reached the significance threshold are shown. Orange, up-regulation; blue, down-regulation. 
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Figure S7: Analysis of regulated gene location in genomic scaffolds. Microarray analysis was 
performed on encysting cells (E) and trophozoites (T) treated with 2 μM FR235222, as described in the 
Experimental procedures section. A. Correlation between the number of regulated genes and the number 
of genes present in the indicated genomic scaffolds. B. Distribution of regulated genes over 9 genomic 
scaffolds. Scaffolds containing less than three regulated genes were not included in the analysis. C. 
Potential plots for regulated genes with threshold μpot+λ·spot+ with λ=1. Asterisks indicate the scaffolds 
with non-randomly distributed co-regulated genes (tested on a significance level α=0.05). 
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Figure S8: Cluster analysis of regulated genes. Microarray analysis was performed on encysting cells 
(E) and trophozoites (T) treated with 2 μM FR235222, as described in the Experimental procedures 
section. A. Expression profiles of scaffolds CH991762 and CH991763 containing non-randomly 
distributed co-regulated genes. Yellow, trophozoite profiles; Green, encysting cell profiles. B. 
Dendrograms of regulated genes in scaffolds CH991762 and CH991763 based on the potential-induced 
metric Mf. Cluster candidates are boxed in red (tested on a significance level α=0.05). 
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1 The role of P-glycoprotein in host-parasite interaction 
 
P-gp is an exceptional membrane transporter because of its ability to carry a large 
variety of compounds across the plasma membrane. This ability to transport a broad 
range of substrates makes P-gp a key mediator of multidrug resistance, a phenomenon 
which is found in a variety of cell types, from pathogenic prokaryotic microorganisms 
to human cancer cells. P-gp is often over-expressed in multidrug resistant cells upon 
therapeutic treatment. In addition, the protein is also expressed at basal levels in non-
resistant cells, but its role in the biology of normal cells has not been completely 
elucidated. Proposed functions for P-gp include a broad range of important cellular 
processes range from roles in immunological processes to membrane lipid 
remodelling. In this context, there is a great interest to understand the physiological 
functions of P-gp in absence of drug pressure.  
In my studies I investigated whether P-gp has a role in host-pathogen interaction. 
As a model pathogen we used the human intracellular parasite T. gondii, which causes 
toxoplasmosis, a potentially life-threatening disease in immunocompomized 
individuals. Our project had two goals: 
1) To define the role of host cell P-gp in host-parasite interaction. To this end, we 
compared three cell lines of mouse embryonic fibroblasts expressing different levels 
of P-gp, namely wild type (WT), P-gp knockout (P-gp KO) and P-gp KO 
complemented with human P-gp (P-gp KO/P-gp). Using these host cells, we analysed 
the role of host P-gp in parasite replication and cholesterol transport, processes that 
are crucial for successful T. gondii propagation and survival. 
2) To characterise P-gp in the parasite and elucidate its function in host-parasite 
interaction. We pharmacologically inhibited T. gondii P-gp (TgP-gp) with the specific 
P-gp inhibitor GF120918 (GF) and we used P-gp KO as host cells to avoid the effects 
derived from host P-gp inhibition. Using this model system, we analysed the role of 
TgP-gp in parasite invasion, replication and lipid metabolism. 
 In my thesis work I show for the first time that both host cell and parasite P-gp 
play an important role in host-parasite interaction.  
  
1.1 HOST P-gp 
 
 Host P-gp is essential for T. gondii replication. 
Parasite replication inside a host cell is a crucial element in T. gondii 
pathogenesis, as it results in host cell lysis. Previous studies showed that parasite 
replication could be inhibited by P-gp modulators (1,2). However, given the 
ubiquitous presence of P-gp, the contribution of host versus parasite P-gp in the 
observed inhibition could not be resolved. To overcome this limitation, we used three 
cell types with different P-gp expression to exclusively analyse the role of host P-gp 
during T. gondii infection. Our analyses revealed a positive correlation between the 
levels of P-gp expression in the host cell and intracellular parasite burden, proving the 
essential role of host P-gp in T. gondii replication. 
P-gp is localized mainly in the plasma membrane, which is the first barrier that 
pathogens need to cross to infect the host cell and a role of host P-gp in host cell 
invasion has been shown recently for the bacterial pathogen Listeria monocytogenes 
(3). We therefore analysed whether host cell P-gp is required for T. gondii invasion. 
Our results showed that parasite invasion was not affected in absence of host P-gp, 
indicating that the decreased parasite burden in P-gp KO cells did not derive from 
reduced parasite invasion.  
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Host P-gp is required for cholesterol transport from the host to the parasite. 
Our analysis showed that T. gondii replication significantly decreased in the 
absence of host P-gp. In order to elucidate the molecular mechanism of decreased 
parasite replication we focused our analysis on cholesterol transport from the host cell 
to the parasite, a key process to guarantee T. gondii replication due to cholesterol 
auxotrophy in the parasite (4). To scavenge host cholesterol, the parasite forms a 
unique system of tubular structures (H.O.S.T.), which sequester cholesterol-
containing endo-lysosomes from the host cytoplasm into the parasitophorous vacuole 
(PV) (5). Importantly, interference with cholesterol trafficking, including cholesterol 
translocation from lysosomes, blocks the delivery of cholesterol to the PV and 
significantly reduces parasite replication (4). 
Previous studies using drug-selected cell lines over-expressing P-gp suggested 
that P-gp may play a role in modulating the intracellular trafficking of cholesterol 
(6,7). Thus, we hypothesized that host P-gp is involved in the transport of host 
cholesterol to the parasite and that its absence will limit the cholesterol delivery to the 
PV and consequently reduce parasite replication. To test this hypothesis we compared 
the transport of host cholesterol to the PV in host cells expressing different levels of 
the protein. By using biochemistry and microscopy-based approaches, we found that 
the transport of host cholesterol to the parasite correlated with the levels of P-gp 
expression in host cells. In addition, we confirmed that the limiting factor for parasite 
replication in P-gp KO cells was indeed limiting availability of host cholesterol. 
Importantly, we observed that P-gp KO host cells accumulated free cholesterol in the 
endo-lysosomes associated to the PV, suggesting that cholesterol mobilization from 
endo-lysosomes to the PV is reduced in absence of host P-gp. 
To further understand how P-gp modulates cholesterol transport to the PV, we 
localized the protein in T. gondii infected host cells. Host P-gp was present 
predominantly in the plasma membrane; however, it was also associated with the PV. 
This localization in the PV proximity suggests two possible options: i) P-gp is present 
in organelles closely associated with the PV or/and ii) P-gp localizes in the 
parasitophorous vacuole membrane (PVM). We favour the first option as P-gp was 
shown to partially localize in early endosomes and lysosomes (8), organelles which 
are also associated with the PV. On the other hand, it is possible that host P-gp is 
incorporated in the PVM, as this membrane derives from the invagination of the host 
plasma membrane, where P-gp is located. However, the PVM is devoid of most of 
host-derived transmembrane proteins (9). Thus a direct incorporation of host P-gp in 
the PVM seems less likely but cannot be excluded as host-derived, raft-associated 
transmembrane proteins were found to be inserted within the PVM (10). 
Based on the data presented here, we propose that host P-gp localizes in endo-
lysosomes associates with the PV and contributes to the mobilization the cholesterol 
from these compartments to the parasite, an essential process for T. gondii replication. 
 
P-gp modulates cholesterol trafficking from endo-lysosomes to the plasma 
membrane in fibroblasts.  
We showed that host P-gp is required for cholesterol transport from the host endo-
lysosomes to the parasite. This observation suggests that P-gp may promote 
cholesterol transport not only to the PV but also to other cellular locations. So far, the 
studies addressing the role of P-gp in cholesterol trafficking produced different 
results. P-gp was proposed to redistribute cholesterol in the plasma membrane via 
flipping it from the inner to the outer leaflet, thus making it more accessible to 
cholesterol acceptors (11). In addition, P-gp over-expression was also shown to 
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increase the uptake of cholesterol-containing micelles (12) and to modulate 
cholesterol biosynthesis (13). Moreover, P-gp over-expression was reported to 
increase cholesterol esterification (6,14). However, another study concluded that P-gp 
expression does not play a major role in cholesterol homeostasis (15). A limiting 
factor in these previous studies investigating the role of P-gp in cholesterol 
homeostasis was the use of unspecific P-gp inhibitors or drug-selected multidrug 
resistant cell lines, as both approaches have the potential of drug-induced side effects.   
For these studies we were able to use host cells deficient for and complemented 
with P-gp, which allowed us to avoid possible off-target effects of drug treatment. To 
analyze P-gp’s involvement in cholesterol homeostasis, we quantified several 
parameters of cholesterol trafficking, including exogenous cholesterol trafficking to 
the ER followed by esterification, cholesterol content in the plasma membrane and 
cholesterol efflux to extracellular acceptors. We found that free and esterified 
cholesterol accumulated in endo-lysosomes and intracellular lipid droplets, 
respectively, while free cholesterol levels decreased in the plasma membrane of P-gp 
KO cells. Importantly, these perturbations of cholesterol trafficking observed in 
absence of host P-gp were reversed upon P-gp complementation.  
Based on our data, we propose that P-gp mediates cholesterol trafficking from 
endo-lysosomes to the plasma membrane but not from plasma membrane to ER, 
where cholesterol esterification takes place. These changes in cholesterol trafficking 
in the absence of P-gp did not reduce the viability or proliferation of the P-gp KO 
cells, suggesting the presence of possible compensatory mechanisms. However, the 
cholesterol auxotrophy of T. gondii made the parasite very sensitive to these changes, 
which resulted in inhibition of replication. Thus, the infection of these cells by T. 
gondii really made the effects of the perturbed host cholesterol trafficking resulting 
from P-gp absence visible and, therefore, T. gondii could be regarded as a bio-
indicator of altered cholesterol homeostasis in the host cell.   
 
1.2 PARASITE P-gp  
  
 Inhibition of T. gondii P-gp strongly decreases parasite replication. 
In the first part of our project we showed that host P-gp is essential for parasite 
replication because it is required for cholesterol transport from the host to the parasite 
(16). Based on this essential role of host P-gp, we analysed if also T. gondii P-gp 
(TgP-gp) played a role in parasite replication. Indeed, we found that parasite 
replication was strongly reduced when we inhibited TgP-gp using the P-gp specific 
inhibitor GF on the host cell background of P-gp KO cells. Given that host P-gp plays 
a role in cholesterol transport, we hypothesized that TgP-gp may also be involved in 
the transport of either parasite-derived lipids and/or host-derived lipids scavenged by 
T. gondii, including long-chain fatty acids and phospholipids (17). In support of a P-
gp mediated transport of cellular lipids, P-gp was shown to flip not only short-chain 
fluorescent analogues of different phospho- and sphingolipids but also the natural 
lipid platelet-activating factors (PAFs) (18-20). In addition, P-gp flipping activity in 
both directions across the plasma membrane was further supported by the recently 
resolved crystal structure of the protein, which revealed a substrate-binding internal 
cavity open to both the cytoplasm and the plasma membrane inner leaflet (21). To test 
whether TgP-gp has a role in lipid transport we inhibited P-gp activity in extracellular 
parasites and analysed the lipid synthesis using metabolic labelling. We found that 
inhibition of TgP-gp reduced lipid synthesis and incorporation of the precursor 
palmitic acid. These results suggest that functional TgP-gp is important for palmitic 
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acid transport and subsequent lipid synthesis in T. gondii.  Importantly, using 
immuno-EM we showed that TgP-gp is localized not only in the plasma membrane of 
the parasite but also in the PV tubular network. This network connects the parasite 
with the lumen and the membrane of the PV and it is suggested to function as a 
reticulum to increase the surface area for transfer of nutrients from the host cell 
cytoplasm (22). Thus, it is possible that the flipping activity of TgP-gp contributes to 
the transport of host-derived lipids across the tubular network membranes. However, 
further analyses are required to elucidate the precise mechanism of host lipid uptake 
by the parasite.  
 
 Inhibition of T. gondii P-gp strongly decreases parasite invasion.  
As T. gondii is an obligate intracellular parasite, it has to actively enter the host 
cell to ensure its propagation and survival. Host cell invasion is a complex process 
which includes initial attachment of the parasite to the host, parasite re-orientation to 
position its apical end in contact with the host cell, formation a moving junction 
between the parasite and host cell membranes mediated by secreted parasite proteins, 
including microneme proteins (MICs) (23,24) and, finally, host cell penetration using 
gliding motility (25,26). The invasion process depends on calcium (Ca2+) homeostasis 
regulation but the precise mechanism of this regulation is not defined yet.   
 In our study we showed that treatment with the P-gp inhibitor GF decreased the 
ability of the parasite to invade host cells. The GF-mediated inhibition of parasite 
invasion was likely due to T. gondii P-gp inhibition, as we previously showed that 
host cell P-gp is not involved in the invasion process (16). As the first step of parasite 
invasion is attachment to the host cell, we analysed whether the decreased rate of T. 
gondii invasion upon GF treatment was due to the parasite’s reduced ability to attach 
to the host. We found that treatment with GF decreased parasite attachment to the host 
cell, while, surprisingly, increasing the secretion of the microneme adhesin MIC2 and 
motility. Attachment, micronemal adhesins secretion, and motility are important steps 
in the invasion process. The relationship between these steps is complex and suggests 
the existence of different regulatory pathways (27). For instance, sustained 
microneme secretion inhibits parasite invasion due to the exhaustion of micronemal 
adhesins required for host cell attachment (28). It was also shown that Ca2+ 
homeostasis regulates the different invasion steps (29-31), however, the precise 
mechanisms of Ca2+ regulation has not been characterised yet.    
In our study we showed that P-gp inhibitor treatment uncoupled parasite 
microneme secretion and motility from attachment and invasion. Importantly, we also 
found that TgP-gp localized in T. gondii acidocalcisomes. Acidocalcisomes are the 
largest Ca2+ storage compartments in T. gondii and the most acidic compartments in 
the parasite (32-34). Acidocalcisomes contain the Ca2+-antiporter ATPase TgA1 
which is responsible for Ca2+ uptake in exchange for H+ (33). In addition, 
acidocalcisome membrane includes the proton pumps H+-ATPase and H+-
pyrophosphatase, which contribute to the acidification of these organelles and to the 
regulation of intracellular pH homeostasis (33,35). The modality of Ca2+ release from 
acidocalcisomes is not characterised in detail, but H+ transport to the acidocalcisomes 
is regarded as a key regulator of this process (32).  
Based on our results, we propose that decreased parasite attachment and invasion 
observed during GF treatment were caused by altered regulation of Ca2+ homeostasis 
due to inhibition of TgP-gp in acidocalcisome membranes. In support of a role for 
TgP-gp in Ca2+ homeostasis, possibly via regulation of H+ transport, several studies 
showed that tumour cell lines with over-expressed P-gp contained higher intracellular 
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level of Ca2+ compared with control cells (36-38). Whether the changes in Ca2+ 
homeostasis are mediated directly or indirectly by P-gp is not clarified yet. However, 
it is possible that the protein affects cellular Ca2+ regulation by acting on H+ transport, 
a P-gp- mediated process previously identified using single-cell photometry of human 
P-gp transfectants or analysis of the P-gp bacterial homologue LmrA (39-41). In 
summary, our study revealed that TgP-gp plays an essential role in the Ca2+ -
dependent invasion process and pointed out the interesting possibility that 
acidocalcisome-localized TgP-gp is involved in regulating Ca2+ fluxes in these 
organelles, likely by modulating H+ transport. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Epigenetic regulation of stage conversion in G. lamblia 
 
The intestinal human pathogen G. lamblia, a worldwide cause of diarrhoea, has a 
simple life cycle with two developmental stages: motile, asexually replicating 
trophozoites and infective, environmentally resistant cysts. Stage conversion from 
trophozoites to cysts is essential for survival and transmission of this pathogen. 
Despite the importance of this process, the molecular mechanisms of its regulation 
remain poorly understood.  
Here, we showed for the first time that inhibition of G. lamblia histone 
deacetylase with the potent HDAC inhibitor FR235222 blocked the formation of 
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Proposed model: Host P-gp is localized in endo-lysosomes and is promoting cholesterol trafficking from 
these organelles to the plasma membrane (PM) and to the T. gondii parasitophorous vacuole (PV). P-gp 
mediated cholesterol transport to the PV is crucial for parasite replication. Parasite P-gp is localized in 
the T. gondii PM, PV tubular network (lines inside the PV) and in acidocalcisomes, the main parasite Ca2+ 
storage. This protein is important for T. gondii replication possibly due to its role in parasite lipid 
transport. Parasite P-gp is also important for T. gondii attachment to and invasion of host cells. 
Exclamation marks indicate the processes modulated by P-gp (cholesterol trafficking inside the host cell 
and parasite invasion outside the host cell). Low density lipoprotein (LDL), high density lipoprotein 
(HDL). 
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infective cysts and induced transcriptional changes in both G. lamblia developmental 
stages. 
 
Histone acetylation levels regulate G. lamblia stage conversion   
Histone acetylases (HAT) and histone deacetylases (HDACs) play a major role in 
controlling gene expression by modulating the levels of chromatin acetylation. 
Histone hyperacetylation is usually linked to chromatin decondensation and 
subsequent activation of gene transcription, while histone hypoacetylation is linked to 
chromatin condensation and transcriptional repression (42). We investigated whether 
epigenetic mechanisms dependent on histone acetylation are involved in the stage 
conversion of G. lamblia, a process which is regulated at the transcriptional level and 
results in high levels of transcription of encystation-specific genes during the first 7-9 
h post induction. Our analysis showed that levels of histone acetylation decreased in 
encysting cells compared to trophozoites. Thus we hypothesized that modulation of 
histone acetylation levels is an important element in the regulation of parasite stage 
conversion. To test this hypothesis, we analysed whether increasing the levels of 
histone acetylation by inhibiting HDAC activity with FR235222, could prevent 
parasite encystation. We found that FR235222 treatment of G. lamblia during 
encystation increased the levels of histone acetylation globally, potently prevented the 
expression of encystation–specific genes and blocked the formation of cysts. 
FR235222 treatment of trophozoites increased histone acetylation but did not induce 
stage conversion, further supporting the hypothesis that high acetylation levels 
effectively prevent the parasite to enter differentiation. Collectively, our data reveal 
that modulation of histone acetylation levels by HDAC plays a major role in 
regulating the encystation process in G. lamblia. HDAC-dependent regulation of stage 
conversion has been proposed also in other protozoan parasites such as intracellular T. 
gondii and Entamoeba histolytica, another intestinal extracellular parasite (43,44). 
However, these studies revealed major differences in HDAC-mediated regulation 
amongst different parasites. For instance, G. lamblia contains only one gene 
homologue of the classical HDAC family while T. gondii contains five putative 
HDAC (45). More importantly, functional differences, such as the induction of 
tachyzoite to bradyzoite differentiation by inhibition of HDAC points to a 
polyphyletic origin of mechanisms which control stage-differentiation processes in 
these protozoa.  
 
FR235222 up-regulates the expression of identical genes in the two life stages of 
G. lamblia. 
As changes in the levels of histone acetylation are known to modulate gene 
transcription, we analysed whether the general pattern of gene expression was 
modified in different life stages of G. lamblia upon HDAC inhibition. Using a 
genome-wide microarray analysis we showed that FR235222 treatment changed the 
mRNA profiles in both trophozoites and encysting cells in a very similar manner. An 
important exception was the inhibition of up-regulation of encystation-specific genes. 
At first sight this apparently challenges the classical view of histone hyperacetylation 
associated with increased gene transcription. More likely, however, failure to induce 
encystation-specific genes following HDAC inhibition is indirect. A possible scenario 
is that a repressor which binds to the promoter of encystation-specific genes in 
trophozoites (46) is down-regulated upon induction of encystation as a consequence 
of the observed histone deacetylation after induction of differentiation.   
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All together, our data suggest that control of G. lamblia stage conversion is under 
the control of epigenetic regulation and dependent on chromatin remodeling by 
histone acetylation. In addition, the block of cyst formation observed upon HDAC 
inhibition reveals that HDAC is a promising target for developing novel anti-Giardia 
drugs with the potential to reduce the transmission of the disease.  
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P-glycoprotein (P-gp) has been extensively studied in the context of the 
multidrug-resistance (MDR) phenotype, both in tumour cells and in pathogenic 
organisms, including parasites. Our study using Toxoplasma gondii as a model 
intracellular parasite provided the first evidence that P-gp plays an important role in 
host-parasite interactions which is different from drug resistance. Specifically, we 
discovered that host cell P-gp modulates the intracellular trafficking of cholesterol, 
thus providing new insights into the role of P-gp in cellular lipid metabolism. 
Moreover, we identified P-gp-mediated T. gondii specific processes which are crucial 
for the parasite survival, thus providing new targets for drug development against this 
clinically significant pathogen. 
Finally, our study investigating stage-differentiation of the enteric parasite 
Giardia lamblia revealed that parasite encystation is under the control of epigenetic 
regulation, and further illuminated the poorly understood mechanisms of gene 
regulation in this parasite. Additionally, our findings clearly demonstrate that histone 
deacetylase activity is a promising target for pharmacological agents aiming to 
effectively block the production of G. lamblia cysts and thus reduce disease 
transmission.  
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Our study showed that host cell P-gp mediates cholesterol trafficking from endo-
lysosomes to the plasma membrane and to the Toxoplasma gondii-containing vacuole. 
However the precise mechanism of cholesterol trafficking mediated by P-gp has to be 
further elucidated. To this aim, it is important to analyse intracellular P-gp distribution 
and trafficking using life-cell microscopy. In addition, it is crucial to determine the 
effect of P-gp on the expression and localization of other proteins that are known to 
be involved in cholesterol transport not only in host cells but also in the parasite. 
Moreover, we showed that T. gondii homologue of P-gp is localized in the 
parasitophorous vacuole network which was suggested to mediate transport of host 
derived nutrients possibly also lipids to the parasite, thus it would be interesting to 
analyse whether T. gondii P-gp is also involved in cholesterol trafficking. 
 Moreover, our study showed that treatment with the P-gp-specific inhibitor GF 
strongly decreased T. gondii replication, adhesion and invasion of host cells. Our data 
on T. gondii P-gp functionality, expression and localization strongly argue for a 
crucial role of P-gp in the parasite biology. However, we cannot exclude the presence 
of off-target effects induced by the inhibitor. Thus additional investigations using 
genetic approaches are required to further our understanding of the function of P-gp 
and possibly other ABC transporters in the biology of T. gondii. 
Finally, our study on stage conversion of the enteric parasite Giardia lamblia 
clearly indicated that parasite encystation is under control of epigenetic regulation. 
Specifically, we showed that modulation of histone acetylation levels by histone 
deacetylase activity is a key factor in the regulation of parasite stage conversion. 
However the precise molecular mechanism of this regulation remains to be elucidated. 
Important experiments to address this question include the extensive characterization 
and regulation of giardial histone acetylation modifying enzymes, and the analysis of 
acetylation marks in individual promoters using chromatin immunoprecipitation. 
Finally, future experiment will focus on identifying additional effector molecules, in 
particular putative repressor(s) which most likely contribute to down-regulate the 
expression encystation-specific genes during vegetative stage. 
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